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“The books of the great scientists are gathering dust on the shelves of learned libraries. And 
rightly so. The scientist addresses an infinitesimal audience of fellow composers. His message 
is not devoid of universality but it’s universality is disemobdied and anonymous. While the 
artist’s communication is linked forever with it’s original form, that of the scientist is 
modified, amplified, fused with the ideas and results of others, and melts into the stream of 
knowledge and ideas which forms our culture. The scientist has in common with the artist 
only this: that he can find no better retreat from the world than his work and also no stronger 
link with his world than his work.” 
 
Max Delbrück, 1969 (Nobelprize acceptance speech) 
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Chapter 1        Situation and objectives 1
 SITUATION AND OBJECTIVES 
 
 
 
1.1. INTRODUCTION 
 
Peritoneal carcinomatosis (PC) is a frequent clinical phenomenon in the course of 
gastrointestinal and ovarian cancer. It is present in 40 to 80 % of the patients with a fatal 
colorectal cancer (Koppe et al., 2006) and in a majority of the patients diagnosed with ovarian 
cancer (Tan et al., 2006). Peritoneal spread is responsible for a low quality of life and a high 
morbidity and mortality (McQuellon et al., 2001). Standard treatment for PC consists of 
systemic 5-fluorouracil-based chemotherapy and offers a median survival of 5.2 to 12.6 
months (Koppe et al., 2006). This treatment is often merely palliative. Peritoneal spread is 
mostly confined to the peritoneal cavity, which makes it very interesting for locoregional 
treatment. In recent years, cytoreductive surgery combined with hyperthermic intraperitoneal 
chemotherapy has been introduced as an alternative treatment, which is already showing 
promising results (Verwaal et al., 2008). The rationale for intraperitoneal chemotherapy is 
based on the peritoneal-plasma barrier which allows higher concentrations of the cytotoxic 
drug to be administered with a limited systemic toxicity (Witkamp et al., 2001). Based on the 
linear correlation between dose and effect for most chemotherapeutic drugs, it can be 
expected that the antitumour activity will increase. Intraperitoneal chemotherapy is often 
combined with hyperthermia based on the synergism between hyperthermia and cytostatic 
agents (Sugarbaker, 2007). Hyperthermia can also enhance drug penetration in the tumour 
(Witkamp et al., 2001). Paclitaxel, which is considered as one of the most important drugs of 
1 
the chemotherapeutic arsenal, is an interesting molecule for intraperitoneal therapy. The 
absorption of paclitaxel from the peritoneum is limited due to its large molecular weight. Its 
predominantly hepatic metabolisation will further decrease the systemic exposure for the 
patient. The use of paclitaxel is however hampered by its poor aqueous solubility (0.34 µg/ml 
or 0.4 µM, Sharma et al., 1995) and the currently used vehicle (Cremophor EL®/ethanol, 
50/50 (v/v) ratio) to solubilise paclitaxel is associated with severe hypersensitivity reactions 
and leaching of plasticisers from PVC infusion sets normally used in hospitals (Gelderblom et 
al., 2001). One of the possible alternatives for dissolving paclitaxel in water are β-
cyclodextrins. These cyclic oligosaccharides consist of 7 glucopyranose units. Their 3D 
structure is characterized by a hydrophobic cavity and a hydrophilic exterior which enhances 
the aqueous solubility of hydrophobic drugs via the formation of inclusion complexes. Two 
reports in literature have demonstrated the feasibility of making paclitaxel/β-cyclodextrin 
complexes without loss of activity for paclitaxel. However, they either used large amounts of 
ethanol (Szente el al., 1999) or toxic organic solvents (methanol and tert-butyl alcohol) during 
production of the complexes (Sharma et al., 1995).  
 
1.2. OBJECTIVES 
 
The objective of this study was to develop a safe paclitaxel formulation suitable for 
hyperthermic intraperitoneal chemotherapy (HIPEC). To achieve this objective the following 
topics were addressed in the research project: 
- Formulation and in-vitro characterisation of a co-solvent-free and tensioactive-
free paclitaxel formulation using chemically modified β-cyclodextrins to design stable 
water soluble inclusion complexes of paclitaxel. 
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- In vitro evaluation of the cytotoxicity of the paclitaxel inclusion complexes 
against colon cancer cell lines. The efficiency of this novel paclitaxel formulation was 
compared to the commercially available Taxol® formulation. In addition the toxicity 
of the formulation excipients of both formulations was also evaluated.  
- In vivo evaluation of the maximum tolerated dose, general toxicity and 
bioavailability following HIPEC with the paclitaxel/cyclodextrin inclusion complexes 
and Taxol® in a rat model for intraperitoneal cancer originating from a colorectal 
cancer. 
- In vivo evaluation of the tumour growth delay via magnetic resonance imaging 
(MRI) and positron emission tomography (PET) following HIPEC with the 
paclitaxel/cyclodextrin inclusion complexes and Taxol® in a rat model for 
intraperitoneal cancer originating from a colorectal cancer. 
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 INTRODUCTION 
 
 
 
“Progression of gastrointestinal or ovarian cancer to the peritoneal surfaces remains a 
dreaded clinical condition. It remains a perplexing challenge with pitfalls in both diagnosis 
and treatment that continue to vex the oncologist. Recently, pharmacologic studies, an 
aggressive surgical approach, and concentration of patients in peritoneal surface malignancy 
treatment centers have begun to generate a small optimism regarding the management of these 
patients.” 
Paul H. Sugarbaker, Washington Cancer Institute 
In “Peritoneal Carcinomatosis: a multidisciplinary approach (Springer, Berlin, 2006)” 
 
As the treatment of peritoneal cancer is based on a multidisciplinary approach, the 
different domains covered in this research project will be briefly introduced in this chapter. 
  
2.1. PACLITAXEL 
 
2.1.1. History 
 
The first report about paclitaxel dates back to the beginning of 1900’s when a British 
official in the Indian subcontinent had noted that parts of Taxus baccata were used to treat 
cancer.  
2 
Some 60 years later, in 1962, a program of the National Cancer Institute (USA) 
evaluating domestic plants for their anticancer activity revealed that crude extracts of the 
Pacific (or Western) yew (Taxus Brevifolia, Fig. 1) showed cytotoxic activity against several 
tumours. It took another 10 years before the active compound paclitaxel was isolated and fully 
characterized by Wani et al. (1971). In 1979, Horwitz and colleagues elucidated the unique 
mechanism of paclitaxel (Schiff et al., 1979), discovering that paclitaxel promoted the 
polymerization of tubulin. This disturbance of the dynamic balance causes cells to go into 
apoptosis.  
 
 
Fig. 1: Taxus Brevifolia 
 
Initially, a major problem was the scarcity of the crude plant material and 
consequently of paclitaxel, but finally a semi-synthetic process using 10-deacetylbaccatin III 
as precursor allowed to produce sufficient amounts of paclitaxel and the first phase I trials 
were initiated in 1983. Its poor water solubility further hampered the development of a 
commercially viable formulation, until a collaboration between the National Cancer Institute 
and Bristol-Myers-Squibb® resulted in a formulation (Taxol®) where paclitaxel was dissolved 
in a 50/50 (v/v) mixture of Cremophor EL® and ethanol. This concentrate (6 mg/ml) is diluted 
to the appropriate concentration and administered via an infusion set to the patient. Finally, in 
1992 and 1994 the Food and Drug Administration (FDA) approved Taxol ® for the treatment 
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of ovarian and breast cancer, respectively. Since then the interest in paclitaxel and other 
taxanes has only increased. They are considered as the most important additions to the 
chemotherapeutic arsenal in the late 20th century. 
 
2.1.2. Chemistry and metabolisation 
 
Paclitaxel, together with docetaxel are the most important representatives of the 
taxanes. These molecules have a taxane ring in common, which is in fact a diterpene carbon 
skeleton (Fig. 2). Paclitaxel is most stable in a pH range of 4 to 8 (Huizing et al., 1995). In 
alkaline medium it degrades rapidly due to hydrolysis of the ester function (Volk et al., 1997).  
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Fig. 2: Chemical structure of paclitaxel 
 
Whereas early phase I studies suggested that the pharmacokinetic behaviour was linear 
and could be described by a simple two-compartment model (Wiernik et al., 1987), later 
studies identified nonlinear pharmacokinetics, with peak plasma concentrations and drug 
exposure increasing disproportionally at higher doses. In plasma, paclitaxel is highly protein-
bound and has a large volume of distribution. It is metabolized in the liver and eliminated via 
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the biliary tract. Renal clearance and urine excretion are minimal (Rowinsky and Donehower, 
1995). Sparreboom and colleagues suggested that the non-linear pharmacokinetic behaviour 
of Taxol® is due to Cremophor EL®, a non-ionic tensioactive excipient used for the 
solubilisation of paclitaxel (Gelderblom et al., 2002). Because paclitaxel has a higher affinity 
for Cremophor EL® than for plasma and human serum albumin, the free paclitaxel fraction in 
blood will be affected when higher amounts of Cremophor EL® are administered 
(Sparreboom et al., 1999). 
 
2.1.3. Method of action and indications  
 
At the Albert Einstein College of Medicine, paclitaxel’s unique mechanism of action 
was discovered in 1979 (Schiff et al., 1979). They found that paclitaxel binds to the 
microtubule rather than to the tubulin dimers. The dynamic equilibrium between microtubules 
and tubulin dimers is important to eukaryotic cells and is essential for mitosis, maintenance of 
cell shape, intracellular transport, cell signalling and division. Microtubuli are formed due to 
the polymerization of α1- and β1-tubulin, under the influence of guanosine triphosphate 
(GTP) and microtubule-associated proteins (MAPs) (Fig. 3). The taxane binding site of β-
tubulin in the microtubule is the cellular target for paclitaxel (Downing et al., 1999). 
Paclitaxel is able to shift the equilibrium between microtubuli and tubulin to the assembly of 
microtubuli (even in the absence of GTP and MAPs). Paclitaxel forms very stable and 
dysfunctional microtubules and is, consequently, known as a microtubule-stabilizing agent. 
Hereby, paclitaxel blocks the normal microtubule dynamics during mitosis. This causes the 
cell to go into cell arrest and apoptosis. Cells treated with paclitaxel typically accumulate in 
the G2 and M phase of the cell cycle. Other antimicrotubule drugs (i.e. vincristine,  
vinblastine, colchicine and podophyllotoxin) induce the disassembly of microtubules. Because 
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cancer cells have a much faster cell division than non-cancerous cells, they are more affected 
by this microtubule stabilizing effect of paclitaxel. 
 
 
Fig. 3: Binding of paclitaxel to the interior surface of the microtubule at the taxane-binding 
site (McGrogan et al., 2008) 
 
Taxanes are used in monotherapy (ovarian, breast and non-small-cell lung cancer) as 
well as in combination therapy (combined with cisplatin for ovarian cancer, combined with 
doxorubicin for breast cancer and combined with cisplatin or carboplatin for non-small-cell 
lung cancer). Paclitaxel is regulatory approved for the treatment of patients with ovarian 
cancer after failure of first-line or subsequent chemotherapy. In addition, combined with a 
platinum compound it is indicated for first-line therapy of ovarian cancer in patients with 
suboptimally debulked stage III or IV ovarian cancer. Recently, it also received approval for 
the treatment of first-line metastatic breast cancer when used in combination with gemicitabin 
(yielding response rates between 25 and 69 % (Paridaens et al., 2000)), for second-line 
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treatment of Kaposi’s sarcoma and in combination with cisplatin as a primary treatment of 
non-small-cell lung cancer (Rowinsky and Calvo, 2006). Further clinical trials are exploring 
other possible indications. 
Resistance to paclitaxel has been reported due to mutations in α en β tubulin, differing 
β-tubulin isotype compositions, P-glycoprotein (P-gp) overexpression or increased 
microtubule dynamics associated with altered MAP expression (McGrogan et al., 2008).  
Side-effects of taxane therapy include myelosuppression, neuropathy, myalgia, fatigue, 
alopecia, diarrhoea, mucosal toxicity and skin and nail changes. Hypersensitivity reactions are 
frequently encountered during administration of Taxol® (i.e. a paclitaxel formulation using an 
ethanol/Cremopher EL® (50/50, v/v) mixture as solvent for paclitaxel) and are treated via 
premedication with steroids and histamine antagonists. 
 
2.1.4. Formulation 
 
Due to its chemical structure, paclitaxel has a very low aqueous solubility (0.4 µM or 
0.34 µg/ml, Sharma et al., 1995) making the development of an intravenous formulation 
challenging. Bristol Myers and Squibb® (BMS) developed, in collaboration with the National 
Cancer Institute (USA), the current Taxol® formulation. This formulation for intravenous (IV) 
administration contains 6 mg paclitaxel per ml, dissolved in a 50/50 (v/v) mixture of 
polyoxyethylated castor oil (Cremophor EL®) and ethanol. This concentrate is administrated 
via infusion after dilution in either 5 % dextrose or 0.9 % sodium chloride to a concentration 
of 0.3-1.2 mg/ml. Typically doses of 135-175 mg paclitaxel per m² body surface are IV 
administered over 3 or 24 hrs. 
Cremophor EL® is implicated as the potential cause of anaphylactic reactions in 
humans and is believed to be the cause of the hypersensitivity reactions often encountered 
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after Taxol® administration (Hennenfent and Govindan, 2006). In approximately 40 % of the 
patients minor reactions like rash and flushing are observed despite premedication and almost 
3 % of the patients have potentially life-threatening adverse effects (Rowinsky et al., 1993; 
ten Tije et al., 2003). As Cremophor EL® also extracts diethylhexylphtalate (DEHP) used as 
plasticizer in polyvinylchloride (PVC) containers, contact between Taxol® and PVC should be 
avoided. Due to these problems encountered by the use of Cremophor EL®, a lot of research 
efforts are focused on alternative approaches to formulate paclitaxel. 
 
2.1.5. Alternative formulation strategies 
 
The aim of developing an alternative paclitaxel formulation is to eliminate the 
drawbacks of the current formulation and to achieve reduced toxicity, easier administration, 
greater patient convenience and maximization of paclitaxel activity. Next to reformulation of 
paclitaxel, taxane analogues are also being developed. An example of this is docetaxel, which 
has been developed by Sanofi-Aventis® in an attempt to find a more water soluble paclitaxel 
analogue. Other microtubule polymerizing agents have been synthesized and are currently in 
early clinical development (Ferlini et al., 2008). This approach will not be discussed in detail 
as it is beyond the scope of this research project.  
In an excellent review Singla et al. (2002) defined several reformulation strategies for 
paclitaxel: co-solvency, emulsification, micellisation, liposome formation, non-liposomal 
drug carrier systems, cyclodextrins and local drug delivery. In the meanwhile, some of these 
alternatives have been tested in clinical trials or have been approved. In this introductory 
chapter only those alternatives for Taxol® are discussed which are already in an advanced 
stage of development.  
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Co-solvency 
One approach to replace Cremophor EL® in the Taxol® formulation is the use of other 
co-solvents. Commonly used co-solvents for the dissolution of hydrophobic drugs include 
ethanol, dimethylsulphoxide, polyethylene glycol, polysorbate and propylene glycol (Adams 
et al., 1993). A 75 % (v/v) polyethylene glycol 400 solution in water was able to dissolve 16 
mg/ml of paclitaxel but upon dilution for infusion, precipitation was observed (Adams et al., 
1993). The vehicle used for Taxotere® consists of ethanol and polysorbate 80 to dissolve 
docetaxel (Bissery et al., 1991). A serious drawback of the co-solvency formulation approach 
is the frequent precipitation upon dilution when the drug is administered (Singla et al., 2002).  
 
Emulsions 
Emulsions and microemulsions of the oil in water (O/W) type have received a lot of 
attention (Tarr et al., 1987; Wheeler et al., 1994; Date and Nagarsenker, 2008; Nornoo and 
Chow, 2008). Tocosol® is a Cremophor EL®-free, vitamin E-based paclitaxel emulsion, which 
uses α-tocopherol PEG succinate as surfactant. Preclinical data showed that its maximum 
tolerated dose (MTD) was three times higher compared to Taxol®. Phase I and II trials 
indicated that Tocosol® was well tolerated and had promising antitumoral activity against 
bladder, non-small-cell lung cancer and ovarian cancer (Hennenfent and Govindan, 2006; 
Rowinsky and Calvo, 2006).  
 
Micellisation 
During micellisation a hydrophobic drug is physically entrapped in a biodegradable 
drug carrier micelle. Two representatives of this approach are Genexol PM® and Pacliex®.  
Genexol PM® is a polymeric-micellar paclitaxel formulation consisting of a 
biodegradable block copolymer which includes monomethoxy poly(ethylene glycol)-block-
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poly(D,L-lactide). Phase I data revealed an MTD of 390 mg paclitaxel/m² following 3 hrs 
intravenous infusion every 3 weeks, whereas paclitaxel doses are typically between 135 – 175 
mg/m² administered during 3 to 24 hrs intravenous infusion. In a multicenter phase II trial, it 
showed significant efficacy in patients with metastatic breast cancer. Further trials are being 
conducted (Lee et al., 2008).  
Pacliex® is a mixed micelles preparation consisting of paclitaxel and a surfactant 
system based on an equimolar mixture of two isoforms of an amphiphilic synthetic derivative 
of retinoic acid. The in vitro and in vivo cytotoxicity of Pacliex® was similar to Taxol® 
(Hassan et al., 2005) 
 
Liposomes 
Liposomes are interesting carrier systems with the ability to encapsulate both 
lipophilic and hydrophilic drugs as they consist of one or more aqueous compartments 
contained within a lipid membrane bilayer. Because of the presence of both lipophilic and 
hydrophilic compartments they can accommodate therapeutic agents with diverse 
physicochemical properties. However, the disadvantages associated with liposomes are a low 
entrapment efficiency, limited drug stability, drug leakage and poor storage stability. 
Liposomal-encapsulated paclitaxel with promising antitumor activity in mice models has 
already been described (Cabanes et al., 1998). Phase I clinical trials determined an MTD of 
175 mg/m² (which is similar to Taxol®). Although neuropathy, myalgia and alopecia were not 
observed, premedication (anti-histamins and steroids) was required to suppress liposome 
infusion reactions (Treat et al., 2001). 
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Non-liposomal drug carrier systems 
Non-liposomal drug carrier systems are formulated as biodegradable polymeric micro- 
or nanocapsules, whereby nanospheres are especially interesting as they allow intraveneous 
and intramuscular administration. One example is the Paclimer® delivery system, which is a 
biopolymer-based formulation designed for site-specific and controlled delivery of paclitaxel. 
It has been evaluated in preclinical studies for its activity against prostate, ovarian and non-
small-cell lung cancer (Harper et al., 1999; Lapidus et al., 2004; Armstrong et al., 2006) but it 
remains unknown if this will result into clinical therapeutic benefits.  
 
Cyclodextrins 
Cyclodextrins have also been used in combination with paclitaxel, but as this 
formulation strategy is the focus of this research project, cyclodextrins are discussed in detail 
in a separate part of the introduction.  
 
Local drug delivery 
Local drug delivery of paclitaxel consists of the implantation of drug releasing stents 
or biodegradable devices loaded with paclitaxel. These devices create a high local 
concentration of paclitaxel in an attempt to eradicate residual cancer cells. 
 
Macromolecular drug carrier conjugates 
The conjugation of paclitaxel with macromolecular drug carriers is already applied in 
several commercially available formulations: Xyotax®, Abraxane® and Taxoprexin®. Because 
of their large size, these conjugates will preferably extravasate through the permeable 
pathological vasculature and thereby accumulate in malignant tissue. This process is known as 
the enhanced permeability and retention (EPR) effect and reduces the systemic toxicity of 
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anticancer drugs. After administration of these formulations conversion from an inactive 
prodrug to active paclitaxel occurs predominantly in the cell, thus reducing systemic toxicity 
and allowing a higher concentration to be administered. 
Xyotax® (Opaxio®) contains a poly-L-glutamate paclitaxel conjugate as paclitaxel is 
covalently bound at the 2´hydroxyl group to the carboxylate of L-glutamic acid. Conjugated 
paclitaxel is inactive but inside the cell paclitaxel is released. Although the results of different 
phase III clinical trials in patients with non-small-cell lung cancer were disappointing (Cella 
et al., 2005; Langer et al., 2005; O’Brien et al., 2005), analysis of the data unexpectedly 
indicated a significantly higher survival rate for women in comparison to men. Hence, new 
trials were started to evaluate its efficacy against non-small-cell lung cancer in women.  
Abraxane® consists of paclitaxel bound to human serum albumine. It is a nanoparticle 
colloidal suspension prepared by high-pressure homogenization of paclitaxel in the presence 
of human serum albumin. In contrast to Taxol®, it is characterised by an almost linear 
pharmacokinetic behaviour and a rapid distribution into tissue. It is approved by FDA for 
metastatic breast cancer in patients who have failed first line treatment. Approval was 
supported by the absence of hypersensitivity reactions in patients receiving no premedication 
(Ferlini et al., 2008).  
In Taxoprexin® paclitaxel is bound to docosahexaenoic acid. The conjugation with a 
fatty acid is based on the observation that tumours have a higher fatty acid uptake, which 
could enhance the drug targeting. As this formulation still contains Cremophor EL® (albeit in 
a reduced concentration) premedication is still mandatory. It has been evaluated for the 
treatment of different cancers (non-small-cell lung cancer, melanoma, advanced gastric and 
oesophageal adenocarcinoma), the best results being obtained for melanoma treatment 
(Hennenfent and Govindan, 2006).  
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2.2. PERITONEAL CARCINOMATOSIS 
 
2.2.1. Peritoneum and Peritoneal Cancer 
 
The peritoneum (Fig. 4) is a serous membrane that lines the peritoneal cavity and is 
composed of a layer of mesothelium and a thin layer of connective tissue. Its total area is 
about the same as the skin surface. There are two types of peritoneum: the visceral 
peritoneum which covers the intra-abdominal organs and mesenteries, and the parietal 
peritoneum which lines the abdominal wall, pelvis, anterior surfaces of retroperitoneal organs 
and inferior surface of the diaphragm. The space between the visceral and parietal peritoneum 
is filled with peritoneal fluid. This fluid, together with the peritoneum, reduces the friction 
and hereby improves the free movement of the abdominal viscera. Other functions of the 
peritoneum include resisting or localizing infection and the storage of fat. The flow of the 
peritoneal fluid is directed from the pelvis to the paracolic gutters and driven by the breathing 
rate (Raptopoulos and Gourtsoyiannis, 2001).  
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Fig. 4: Abdominal cavity showing peritoneum (blue) 
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The peritoneum forms a barrier between the abdominal cavity and the blood stream. 
Therefore, it is also referred to as the peritoneal-plasma barrier and it consists of peritoneal 
fluid, mesothelium, basal membrane, interstitium with bundles of collagen fibrils, blood 
vessels and lymphatic vessels. Drugs with a molecular weight of less than 2000 Da can be 
absorbed by diffusion through the parietal and visceral peritoneum, while larger molecules are 
absorbed by the lymphatic drainage at the diaphragmatic peritoneum (Sugarbaker, 1996). This 
peritoneal-plasma barrier reduces the amount of drug that is absorbed in the blood, allowing 
higher concentrations to be administered in the abdominal cavity. Another advantage of 
intraperitoneal administration of drugs is that a part of the peritoneum is drained with the 
portal vein system. Hence drugs absorbed via this vein system are immediately transported to 
the liver for metabolisation, reducing systemic exposure.   
In general, peritoneal carcinomatosis (PC) (Fig. 5) is considered as independent 
metastatic deposits on the visceral and parietal peritoneum, originating from a primary organ 
of origin in the abdominal cavity. PC is a nice example of the “seed and soil” hypothesis of 
Paget, which states that the metastatic capability of tumour cells (“the seed”) is related to 
finding a good environment (‘the soil’) for implantation.  
In general, the course of PC includes the following steps: release and transport of 
cancer cells, adhesion to the mesothelial layer and the invasion of the peritoneum and 
subperitoneal tissue (Ceelen et al., 2006). The etiology of PC is diverse. One possible cause is 
the shedding of free cells from serosal penetration of the primary tumour. Other possible 
causes are leakage of malignant cells from venous blood backflow or transected lymphatic 
vessels and direct dissemination as a result of surgical trauma. 
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Fig. 5: Peritoneal cancer and its histological environment (de Bree et al., 2002) 
 
PC is a common evolution in the course of digestive and ovarian cancers (Table 1). 
For instance, the peritoneal surface is an important failure site for patients with colorectal 
cancer. Recurrent disease on the peritoneal surface is involved in up to 44 % of patients with 
recurrent colorectal cancer and in 40 to 80 % of patients with a fatal colorectal cancer (Koppe 
et al., 2006). For gastric, ovarian and appendiceal cancer 50, 75 and 31 % of the patients, 
respectively, have peritoneal disease at exploration (Stewart et al., 2005).  
 
Primary tumor Incidence in US 
and Europe 
(cases/year) 
% of patients with 
peritoneal 
disease at 
exploration 
Median survival 
after diagnosis of 
carcinomatosis 
(months) 
Colorectal cancer 
Gastric cancer 
Ovarian cancer 
Peritoneal mesothelioma 
Appendiceal cancer 
130,000 
22,000 
27,000 
1500 
500 
10-15 
50 
75 
100 
31 
5.2 
3.1 
36 
12-17 
NA 
 
Table 1: Common indications for intraperitoneal hyperthermic chemoperfusion (NA, not 
available) (Stewart et al., 2005) 
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2.2.2. Treatment of peritoneal cancer 
 
Based on the data described above, it is clear that PC is a rather common phenomenon 
with important clinical consequences and poor prognosis. Therefore, PC merits attention to 
find new and improved treatment modalities to help these patients. This introduction about the 
treatment modalities for PC will focus on PC from non-gynaecologic origin and specifically 
from colorectal origin. Until recently, PC was considered a terminal condition and the only 
treatment strategy for PC consisted of conventional systemic chemotherapy, possibly in 
combination with cytoreductive surgery of macroscopic tumour nodules. In this case systemic 
chemotherapy is considered as palliative and provides only a limited improvement of survival. 
The median survival after systemic 5-fluorouracil-based chemotherapy for patients with PC of 
colorectal origin varied from 5.2 to 12.6 months (Chu et al., 1989; Verwaal et al., 2003).  
Aggressive cytoreductive surgery followed by (hyperthermic) intraperitoneal 
chemotherapy is a novel therapeutic approach for patients where the peritoneum is the only 
site of metastasis. To date, this technique is used in approximately 30 medical centers 
worldwide (Koppe et al., 2006). Several factors are determining the prognosis after 
intraperitoneal chemotherapy as survival is correlated with gender, age, clinical performance 
status, PC stage and completeness of resection. Obviously, patients without residual 
macroscopic tumours after resection have a higher survival rate as the follow-up study of 
Verwaal et al. (2008) indicated a 5-year survival in 45 % of patients with complete tumour 
resection. Another important parameter to implement a treatment is the quality of life (QOL) 
after surgery. Typically for hyperthermic intraperitoneal chemotherapy (HIPEC), QOL is 
reduced in the first 3 months after surgery but afterwards QOL improved and 1 year post-
operation 58 % of the patients had a normal patient performance status rating (McQuellon et 
al., 2001). Due to the aggressiveness of the treatment, there are high morbidity, mortality (9.3 
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% according to Elias et al., 2001) and failure rates. Therefore, it is important to select only 
those patients who will benefit the most from HIPEC. 
In 2007, the consensus statement about cytoreductive surgery and hyperthermic 
intraperitoneal chemotherapy in the management of peritoneal surface malignancies of 
colonic origin was issued (Fig. 6), providing a tool to select the patients (Esquivel et al., 
2007). 
 
 
Fig. 6:  Consensus scheme for the management of peritoneal cancer from colonic origin 
(Esquivel et al., 2008) 
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Although there is consensus in the selection of patients, there are still significant 
differences in the HIPEC procedure used by the different medical centers: open versus closed 
circulation (to allow recirculation of the perfusion fluid), open versus closed abdominal 
cavity. Other variables include the choice of drug, perfusion duration, temperature of 
perfusion liquid and post-operative administration of intraperitoneal chemotherapy. The 
consensus statement stated that for patients with PC of colonic origin HIPEC should be 
performed with mitomycin C (15 -35 mg/m²) at a temperature of 39-42 °C for 60-120 min. 
Whether an open or closed technique and post-operative chemotherapy of 5-fluorouracil (5-
FU) is used is the choice of the surgeon. 
 
2.2.3. Rationale for hyperthermic intraperitoneal chemotherapy 
 
In 1980, HIPEC (Fig. 7) was applied for the first time in a clinical setting by Spratt et 
al. for the treatment of a patient with pseudomyxoma peritonei. Since then, the interest for this 
novel treatment of PC has only grown. HIPEC is an interesting approach for this type of 
cancer as peritoneal spread is mostly confined to the abdominal cavity. Therefore, regional 
therapy via HIPEC could improve the cure rate of PC patients as the cancer cells are in direct 
contact with the cytotoxic drug. Another interesting advantage of antitumour therapy via 
HIPEC is the peritoneal plasma barrier. This barrier reduces the movement of large molecular 
drugs from the peritoneal cavity to the systemic compartment. For these high molecular 
weight drugs, the peritoneal-plasma partitioning is inverse to the square root of their 
molecular weight (Stewart et al., 2005). This offers an advantage to high molecular weight 
anticancer drugs such as paclitaxel. As diffusion of these molecules across the peritoneal 
membrane is controlled by the peritoneal plasma barrier higher doses can be administered 
intraperitoneally (IP) compared to intravenous (IV) administration which is beneficial as in 
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some cases the effective IV dose exceeds the toxic IV dose. Hence, the peritoneal-plasma 
barrier offers an important pharmacokinetic advantage to IP therapy: high drug concentrations 
are in direct contact with the tumour cells and a reduced systemic toxicity. This advantage is 
expressed by the ratio between the IP and IV drug concentrations.  
In addition to a high molecular weight a drug with optimal properties for HIPEC 
should be metabolised by the liver in order to limit the drug concentration in the systemic 
blood flow since part of the peritoneal blood flow is connected with the portal blood flow. As 
an IP/IV concentration ratio of 1000 has been reported for paclitaxel (Markman, 2003), as the 
IP clearance of paclitaxel is low (resulting in prolonged biological relevant IV concentrations) 
and as paclitaxel is predominantly metabolised in the liver, this drug is a promising candidate 
for application via HIPEC. Also, the non-vesicant properties of paclitaxel are advantageous 
for IP delivery of drugs.  
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Fig. 7: Schematic representation of HIPEC 
Chapter 2         Introduction 23
A last important criterion for drugs suitable for HIPEC is the enhancement of their 
effectiveness by (mild) hyperthermia. The use of hyperthermia dates back to ancient times: 
“Where drugs do not cure, iron does; where iron does not cure, heat does; where real heat 
does not cure, cure is impossible” (Hippocrates, 470-377 BC). In modern medicine, 
hyperthermia alone has shown in vitro cytotoxic activity (Crile, 1963), due to its effect on 
DNA repair, induction of apoptosis and inhibition of angiogenesis (Witkamp et al., 2001). 
Increasing the temperature also enhances drug penetration into the tumour due to membrane 
protein denaturation. The inactivation of tumour cells starts at 40-41 °C and is time and 
temperature dependent (Ceelen et al., 2000). Hyperthermia has also shown to improve the 
cytotoxic activity of various drugs such as mitomycin C, doxorubicin, cisplatin and 
oxaliplatin (Glehen et al., 2004). Most medical centers use HIPEC temperatures between 41 
and 43 °C because the synergism between drug and heat is at its maximum in this temperature 
range and because at temperatures higher than 43 °C bowel toxicity increases (Urano et al., 
1999). Although paclitaxel is heat stable, and paclitaxel and heat have a common target as 
heat also disrupts the microtubule system, the results about the cytotoxic effect when 
combining heat and paclitaxel have been less consistent and in vitro as well as in vivo studies 
have been inconclusive. These conflicting results will be discussed in detail in Chapter 5. 
Possible drawbacks of IP chemotherapy are limited penetration in the tumour tissue 
and surface exposure. The surface exposure can be enhanced by increasing the intraperitoneal 
fluid distribution. Therefore, peritoneal expansion is often applied to optimise the surface 
exposure in the open abdomen technique (Fig. 8). The open technique can be performed via 
the coliseum technique developed by Sugarbaker et al. (1999), where a retractor ring, attached 
to the skin of the abdomen, is placed in the laparotomy wound. This ring is covered with a 
plastic sheet, which has a small opening allowing the surgeon to stir the abdominal organs in 
order to better distribute heat and drug. Yonemura introduced a peritoneal access device to be 
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fitted into the laparotomy wound (Yonemura et al., 1991) (Fig. 8). Disadvantages of these 
open techniques are heat loss and more importantly leakage, creating a hazardous situation for 
the operating personnel. Next to the open abdominal IP techniques, Fujimoto and Koga 
independently developed a technique with a temporary closure of the abdomen (Fujimoto et 
al., 1988; Koga et al., 1988). This closed technique (Fig. 8) not only prevents drug leakage 
and heat loss, but also increases the pressure which may improve drug penetration (Tsiftis et 
al., 1999). Another difference between perfusion techniques is the use of open or closed 
perfusion models: the closed model recirculates the perfusate, whereas the open model 
continuously uses new perfusate. Closed perfusion offers easier control of the system whereas 
there is no risk of recirculation of tumour cells when using the open system. 
 
 
Fig. 8: HIPEC with 3 different peritoneal expansion techniques: A. use of an peritoneal cavity 
expander, B. Coliseum technique and C. closed abdomen (Witkamp et al., 2001) 
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2.3. CYCLODEXTRINS 
 
As previously mentioned, the aqueous solubility of paclitaxel is very low (0.4 µM or 
0.34 mg/ml) and several strategies have been investigated to formulate a suitable carrier for 
this drug molecule in order to prepare an aqueous formulation suitable for IV or IP 
administration. One of these options is the use of cyclodextrins to improve the solubility of 
paclitaxel. Therefore, cyclodextrins will be discussed in detail as this formulation strategy was 
used in this research project.  
 
2.3.1. Structure and properties 
 
Cyclodextrins (CDs) are cyclic oligosaccharides, consisting of α-1,4 linked 
glucopyranose units. They are produced via degradation of starch (mostly corn) using 
glucosyltransferase. Apart from their pharmaceutical use, they are being used in agriculture, 
food industry, fragrances and others. They were first described by Villiers in 1891 and in 
1953 Freudenberg et al. were the first to be granted a patent on the use of CDs in drug 
formulations. The nomenclature of CDs depends on the amount of glucose residues 
(minimum 6 residues). The most commonly used are α, β, γ-CDs consisting of 6, 7 and 8 
glucose residues, respectively. Their 3D structure (Fig. 9) has a conical shape with primary 
hydroxyl groups at the top of the cone and secondary hydroxyl groups located at the bottom. 
The interest in CD for pharmaceutical applications is based on its dual properties: they are 
water soluble because of their hydrophilic exterior, but they have a hydrophobic interior 
cavity. This allows them to form water soluble complexes with less soluble molecules via 
incorporation of hydrophobic moieties in the hydrophobic interior cavity (thus improving the 
solubility and bioavailability of the complexed drug). Hence their extensive use to solubilise 
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and stabilise poorly soluble drugs (Szeltli, 1994; Loftsson and Brewster, 1996). β-CDs are the 
most interesting for pharmaceutical applications as its cavity is large enough to interact with 
aromatic rings. Increasing the glucose residues does not necessarily enlarge the cavity as the 
cavity collapses and twists to form a helix shape when the amount of glucose units further 
increases. 
 
 
Fig. 9: 3D-structure of β-cyclodextrin 
 
2.3.2. β-Cyclodextrins and their derivatives 
 
Despite their higher number of hydroxyl groups in comparison with α-CD the 
solubility of β-CDs is lower compared to α-CDs. This is due to the formation of internal 
hydrogen bonds between the secondary hydroxyl groups. Breaking these hydrogen bonds by 
substituting the hydroxyl groups with other chemical groups increases the solubility of β-CD. 
In addition substituted CDs are more amorphous, enhancing the water solubility. Substitution 
also modifies the shape of the cone, altering the complexation capability.  
Chemical modification results from the introduction of new functional groups at the 2-
, 3- and 6-hydroxyl groups. For β-CD there are 21 possible substitution positions and 221-1 
different combinations possible. Therefore, the European Pharmacopoeia and the United 
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States Pharmacopoeia specify a range of molar substitution (the number substituents per 
anhydroglucose unit ) as the most important characterisation criterion. Manufacturers also use 
the total degree of substitution (TDS) as characterisation parameter. This is the average 
number of substituents per cyclodextrin molecule (for β-CD the maximum TDS is 21). 
Hydroxypropyl-β-CD (HP-β−CD) and sulphobutylether-β-CD are FDA approved for 
human use (Davis and Brewster, 2004), HP-β−CD being the most commonly used CD for 
oral, buccal, intravenous, rectal and ophthalmic applications. The best example is Sporanox® 
(itraconazole), which was developed by Janssen Pharmaceutica. Both the oral and intravenous 
solutions of Sporanox® are formulated with HP-β−CD, producing solutions of 10 mg/ml for a 
molecule that has an aqueous solubility at neutral pH of 1 ng/ml. Other molecules include 
cisapride (Propulsid®) and mitomycin (Mitozytrex®) (Loftsson and Duchêne, 2007). 
Randomly-methylated-β-CD (RAME-β-CD), has been used to formulate chloramphenicol 
(Clorocil®) and β-oestradiol (Aerodiol®) (Loftsson and Duchêne, 2007). The most recent 
chemically modified β−CD to come to the market is sulphobutyl-ether-β-CD (SBEβCD) 
(Captisol®, Cydex). It has been used by Pfizer to formulate an antifungal agent (voriconazole, 
Vfend®) and an antipsychotic agent (ziprasidone, Geodon®) (Loftsson and Duchêne, 2007).  
At present, CDs are further investigated for future applications. This not only includes 
new applications of existing CDs but also comprises the development of new cyclodextrin 
derivatives. Today, CDs are mainly used for low-molecular drugs but new applications for 
CDs could improve the formulation and drug delivery of proteins, peptides and 
oligonucleotides.  
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2.3.3. β-Cyclodextrins and paclitaxel 
 
As discussed previously, β-CDs are the most interesting CDs for pharmaceutical 
application as they are capable of including aromatic groups in their hydrophobic cavities. 
This makes them also an interesting option for the solubilisation of paclitaxel via the 
formation of water soluble complexes. Theoretically one paclitaxel molecule can interact with 
3 cyclodextrins molecules based on the accessible aromatic groups in its molecular structure 
(Fig. 2). A variety of chemically modified β-CDs has already been investigated for their 
solubilising capacity towards paclitaxel (Sharma et al., 1995; Szente, 1999).  
Sharma et al. (1995) extensively investigated β- and γ-CDs for complex formation 
with paclitaxel, using 2 similar methods to form the complexes. Paclitaxel was either 
dissolved in methanol or in tert-butyl alcohol. After the addition of the appropriate amount of 
CD the solution was lyophilized. The lyophilized powder was reconstituted in distilled water 
to evaluate the water solubility of the Pac inclusion complexes: 2,6-dimethylated-β-
cyclodextrin (DIME-β-CD) induced the largest increase of paclitaxel solubility (about 3 
orders of magnitude), whereas Pac solubility only increased 2 orders of magnitude in 
combination with HP-β-CD. 50 % DIME-β-CD solutions containing less than 14 mM 
paclitaxel showed no precipitation upon dilution in buffer. The Pac/CD formulations also 
retained their cytotoxic activity. The authors however concluded that the importance of CDs 
for IV paclitaxel administration was marginal because the required amount of CDs for 
solubilisation was close to the maximum tolerated dose of the CDs (Sharma et al., 1995).  
Szente et al.(1999) confirmed the superior complexing activity of methylated-β-CDs 
for paclitaxel. These β-CDs (at a concentration of 200 mg/ml) were also used to prepare an 
aqueous ethanol solution of paclitaxel (4 mg/ml). These solutions were stable for 6 months 
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without drug precipitation and showed no precipitation upon dilution. Furthermore, these 
solutions had a similar cytotoxic activity compared to Taxol®.  
Based on the promising literature data about the interaction of paclitxel and β-CDs this 
type of CD was used in this research project to formulate a water soluble, co-solvent-free and 
tensioactive free paclitaxel formulation. 
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 FORMULATION AND PHYSICAL STABILITY OF 
PACLITAXEL/β-CYCLODEXTRIN COMPLEXES 
 
 
3.1. ABSTRACT 
Due to its low aqueous solubility paclitaxel (Pac) is currently formulated in a 
Cremophor EL®/ethanol mixture. However, the vehicle of this formulation causes several 
side-effects. Our objective was to formulate a tensioactive-free and co-solvent-free paclitaxel 
solution, which can be used for a hyperthermic intraperitoneal chemoperfusion procedure 
(HIPEC). The potential of chemically modified β-cyclodextrins (β-CDs) to form complexes 
with paclitaxel was investigated as a means to increase the aqueous solubility of paclitaxel. 
Methylated β-CDs (randomly-methylated and 2,6-dimethylated) showed the best ability to 
solubilise paclitaxel compared to sulphobutyl-ether- and hydroxypropyl-β-CD. The minimal 
ratio of paclitaxel versus randomly-methylated-β-cyclodextrin (RAME-β-CD) yielding 100 % 
inclusion efficiency was 1/20 (mol/mol). Pac/RAME-β-CD inclusion complexes prepared via 
freeze drying were stable for at least 6 months when stored at 4 °C. A 5 mg/ml paclitaxel 
solution was formulated using Pac/RAME-β-CD-complexes. Upon dilution of these solutions, 
no precipitation was seen. After 24 hrs storage at room temperature or 2 hrs at HIPEC 
conditions (41 °C) the 1/40 (mol/mol) ratio showed the highest stability at paclitaxel 
concentrations of 0.1 and 0.5 mg/ml. When hydroxypropyl methylcellulose (HPMC) was 
added to the reconstitution medium, the stability significantly increased, offering the 
opportunity to reduce the amount of RAME-β-CDs in the formulation. 
 
 
3 
3.2. INTRODUCTION 
Taxol®, containing paclitaxel as a microtubule stabilizing agent, was approved by the 
FDA for the treatment of breast and ovarian cancer in 1992 and 1994, respectively 
(Panchagnula, 1998). Unlike most antineoplastic agents, paclitaxel does not depolymerize the 
microtubules, but it promotes the polymerization of tubulin. The formed microtubules are 
extremely stable and inhibit the normal microtubule dynamics, which are essential for the cell 
cycle, thus causing cell death (Rowinsky and Donehower, 1995).  
Since paclitaxel has a low aqueous solubility (0.4 µM or 0.34 µg/ml, Sharma et al., 
1995), the drug is currently formulated in a 1:1 (v/v) Cremophor EL®/ethanol mixture, 
available as Taxol®. Amongst multiple problems caused by this vehicle, in particular by 
Cremophor EL®, the most important side effects include hypersensitivity reactions, 
nephrotoxicity and neurotoxicity (Singla et al., 2002). Furthermore, the leaching of the 
plasticizer diethylhexylphthalate (DEHP) from polyvinylchloride (PVC) infusion sets into the 
Cremophor EL®/ethanol formulation should be considered as a another severe problem. 
Therefore, much research is performed to reformulate paclitaxel using the following 
approaches: co-solvency, emulsification, micellisation, liposome formation, non-liposomal 
lipid carriers (microspheres, nanocapsules), cyclodextrins and local drug delivery devices 
(Singla et al., 2002). 
β-Cyclodextrins (β-CDs) are cyclic oligosaccharides which consist of 7 covalently 
linked glucopyranose units. β-CDs have a cone-like structure, combining a hydrophilic 
exterior with a hydrophobic interior which can encapsulate hydrophobic drug molecules or 
parts of these molecules. The resulting inclusion complexes increase the aqueous solubility of 
the drug. β-CDs are chemically modified to enhance their solubility and their complexing 
activity.  
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Hyperthermic intraperitoneal chemoperfusion (HIPEC) after debulking surgery is a 
novel strategy in the treatment or prevention of peritoneal carcinomatosis. Using this 
technique the peritoneum is perfused with a solution (40-43 °C) containing a cytostatic agent. 
The rationale for this treatment lies in the combination of the tumoricidal properties of 
intraperitoneal hyperthermia (Shiu and Fortner, 1980) and various chemotherapeutic drugs. In 
addition, hyperthermia is known to enhance the antitumoral effect of several cytostatic drugs: 
doxorubicin (Jacquet et al., 1998), gemcitabine (Pestieau et al., 1998), cisplatin (Bartlett et al., 
1997), tumor necrosis factor (Bartlett et al., 1997), mitomycin C (Storm, 1989). By applying 
the drug locally, there is a pharmacokinetic advantage as the clearance of the drug from the 
peritoneal cavity is delayed and also higher concentrations of the cytotoxic drug can be 
applied. Randomized clinical trials are available to support HIPEC in the treatment and 
prevention of peritoneal carcinomatosis following resection of pathological gastric cancer 
(Ceelen et al., 2000). Phase I data showed a ≥ 1,000-fold exposure to paclitaxel in the 
peritoneal cavity compared with the systemic compartment (Markman, 1995). The dose-
limiting toxicity of intraperitoneal administered paclitaxel was found to be abdominal pain 
which could be due to the drug, the vehicle (ethanol/Cremophor EL®-mixture in case of 
Taxol®) or both. The latter seems the most plausible, as in recent years it has become clear 
that Cremophor EL® is not an inert vehicle, but exerts a range of biological effects, some of 
which have important clinical implications (Gelderblom et al., 2001). 
The purpose of this study was to formulate a co-solvent- and tensioactive-free 
paclitaxel solution, based on chemically modified β-CDs, which can be used for a HIPEC 
procedure.  
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3.3. MATERIALS AND METHODS 
 
3.3.1. Materials 
 
Randomly-methylated-β-cyclodextrin (RAME-β-CD) with a total degree of 
substitution (TDS) of 13 and 2,6- dimethyl-β-cyclodextrin (DIME-β-CD) with a TDS of 14 
were purchased from Cyclolab (Budapest, Hungary). The following cyclodextrins were 
donated: sulphobutyl-ether-β-cyclodextrin (SBE-β-CD), TDS 6.5 (Captisol®, Cydex, 
Overland Park, USA); hydroxypropyl-β-cyclodextrin (HP-β-CD), TDS 3 (Encapsin®, 
Johnson & Johnson, Beerse, Belgium); hydroxypropyl-β-cyclodextrin (HP-β-CD), TDS 4.5 
(Kleptose HPB®, Roquette, Lestrem, France); hydroxypropyl-β-cyclodextrin (HP-β-CD), 
TDS 5.2 (Cavitron 82005®, Cerestar, Vilvoorde, Belgium); hydroxypropyl-β-cyclodextrin 
(HP-β-CD), TDS 6.1 (Cavitron 82006®, Cerestar). Hydroxypropyl methylcellulose (HPMC) 
(Metolose® 60SH-4000, Shin-Etsu, Tokyo, Japan) was also donated. Paclitaxel was purchased 
from Acros Organics (Geel, Belgium).  
 
3.3.2.Preparation of the inclusion complexes 
 
First the required amount of paclitaxel was dissolved in absolute ethanol (Merck, 
Overijse, Belgium), in a ratio of 1 to 60 (w/w). β-Cyclodextrins were added to the solution to 
obtain Pac/β-cyclodextrin ratios varying from 1/60 to 1/20 (mol/mol) and the solution was 
placed in an ultrasonic bath (Sonis 3 GT, Iskra-Pio, Šentjernej, Slovenia) for 5 min. Next, 
phosphate buffered saline (PBS) (10 PBS tablets (Sigma, Bornem, Belgium) in 2 l 
demineralised water) was added in a ratio of 1/2 (w/w) versus the CD-fraction. Next, the 
solution was placed in an ultrasonic bath for 1 min and afterwards stirred with a magnetic 
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stirrer for 5 min. After evaporating most of the co-solvent from the solution under reduced 
pressure by a rotavap, the solution was freeze dried for 24 hrs at -50 °C and at 1 mbar, after 
being frozen at -70 °C using solid carbondioxide. After freeze drying, a white amorphous 
powder (Alcaro et al., 2002) was obtained. 
 
3.3.3. Paclitaxel determination  
 
The analysis method was based on a method described by Lee et al. (1999). The 
HPLC-system consisted of a pump (L-6000, Merck-Hitachi, Tokyo, Japan), an integrator (D-
2000, Merck-Hitachi, Tokyo, Japan), an injector (Vici, Valco Instruments, Houston, USA) 
with a loop of 25 µL and a UV/VIS detector (UV 2000, Spectra-systems, Darmstadt, 
Germany). Detection was performed at a wavelength of 227 nm. Chromatographic separation 
was achieved with a guard column (Lichrospher® 100-RP-18, 4*4 mm (5µm), Merck, 
Darmstadt, Germany) and an analytical column (Lichrospher® 100-RP-18, 125*4 mm (5µm), 
Merck, Darmstadt, Germany). Before use, the mobile phase consisting of acetonitrile 
(Biosolve, Valkenswaard, The Netherlands) and 0.1% (v/v) phosphoric acid in water (Acros 
Organics, Geel, Belgium) (42:58, v/v) was degassed by ultrasonication under vacuum. A 
calibration curve was validated (inter- and intravariability and precision) for a concentration 
ranging from 1 to 100 µg paclitaxel/ml. 
 
3.3.4. Determination of inclusion efficiency 
 
In order to evaluate the inclusion procedure and to measure the amount of paclitaxel 
that was complexed with β-cyclodextrins, an amount of freeze dried material, equivalent to 1 
mg paclitaxel, was dispersed either in 10 ml PBS or in 10 ml mobile phase used for HPLC-
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analysis. The concentration of dissolved paclitaxel in both samples was determined with the 
HPLC-method. The mobile phase dissolved free as well as complexed paclitaxel, whereas 
only complexed paclitaxel dissolved in PBS (aqueous solubility of paclitaxel: 0.34 µg/ml). 
Therefore, the concentration in the mobile phase was regarded as the 100% value and the 
concentration in PBS was expressed relative to the concentration in the mobile phase to 
calculate the inclusion efficiency. Thus, any increase in aqueous solubility was considered to 
be due to the interaction and formation of complexes between paclitaxel and β-CDs. 
 
3.3.5. Characterisation of Pac/RAME-β-CD complex 
 
3.3.5.1. Thermal analysis 
Thermal analysis of the samples was performed via differential scanning calorimetry 
(2920 Modulated DSC, TA Instruments, Leatherhead, UK). Samples (approximately 10 mg) 
were heated in sealed aluminum pans at 10 °C/min to 400 °C under N2 purge. Both 
complexes and physical mixtures of paclitaxel and RAME-β-CDs (molar ratios ranging from 
1/20 to 1/60) were analysed.  
ead.  
 
3.3.5.2. 1H-NMR 
1H NMR spectra of complexes in 1/20 and 1/40 (mol/mol) ratios were obtained in 
D2O solution at 25 °C at 700 MHz using a Bruker AVANCE II spectrometer equipped with a 
5mm TXI Z-gradient probe h
 
3.3.6. Physical stability testing 
 
The short term physical stability of paclitaxel complexes in PBS was tested at room 
temperature (25 °C, during 24 h) and at HIPEC temperature (41 °C, during 2 h) for 0.1 and 
0.5 mg/ml paclitaxel solutions with or without HPMC. In the experiments where HPMC was 
used, the polymer was added to the reconstitution medium in a concentration of 0.1% (w/v). 
The solutions were stored in sealed glass vials (pharmaceutical grade) exposed to daylight. 
Long term physical stability of a 5 mg/ml solution, stored in the dark, was tested at 4° C for 2 
weeks. For all tests, samples, taken at set intervals, were filtered through a 0.22 µm filter 
(Spartan 30/0.2 RC (Schleicher & Schuell, Dassel, Germany)) and analysed by HPLC 
(following appropriate dilution using PBS). When precipitation was observed in the 5 mg/ml 
paclitaxel solution, the samples were centrifuged at 450g for 10 min and aliquots of the 
supernatans were analysed by HPLC after filtration using a 0.2 µm filter (Spartan 30/0.2 RC).  
 
3.3.7. Analysis of the freeze dried product 
 
The water and ethanol content of the starting material and the freeze dried products 
was determined. The products (200 mg) were analysed for their water content using a Karl 
Fisher titrator (Mettler Toledo DL 35, Beerse, Belgium), while their ethanol concentration 
was determined using a head-space gas chromatography flame ionization detection (GC-FID) 
method. About 20 mg material was dissolved in 0.5 ml H2O, next 0.5 ml H2O (HPLC grade) 
and 0.5 ml of an internal standard solution (t-butanol in H2O, 40mg/100 ml) was added before 
injection into the GC-FID system. 
 
3.3.8. Statistical Analysis 
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Results were analysed with SPSS 14.0 statistical software. For the 24 hrs stability 
experiment the effect of the ratio was evaluated using a one-way ANOVA and a Scheffé post 
hoc test. The stability data at HIPEC conditions were evaluated using a two-way ANOVA 
with pairwise comparisons within each factor, using a Bonferroni correction. For all results 
the homogeneity of variances was analysed with the Levene’s test and the normality of the 
residuals was checked for by a Kolmogorov-Smirnov test.   
 
3.4. RESULTS AND DISCUSSION 
 
3.4.1. Solubilisation of paclitaxel 
 
3.4.1.1. Selection of the chemically modified β-cyclodextrins 
In this research project, different chemically modified β-cyclodextrins were evaluated 
in order to obtain a tensioactive- and co-solvent-free paclitaxel formulation based on these β-
cyclodextrins. By reformulating the commercially available Taxol® solution, it was the 
intention to reduce the dose-limiting toxicity of Cremophor EL® by replacing it with β-
cyclodextrins, being fully aware that these compounds could also exert toxic effects, 
especially renal toxicity. This will be closely monitored during future in vitro and in vivo 
experiments.  
RAME-β-CD, DIME-β-CD, SBE-β-CD and the different HP-β-CDs were investigated 
for their paclitaxel solubilising effect. In a first screening experiment at a fixed cyclodextrin 
concentration (1/80 ratio, w/w) the highest amount of paclitaxel in PBS was recovered using 
methylated-β-cyclodextrins (approximately 90 % inclusion efficiency). SBE-β-CD and HP-β-
CD had a very low affinity for paclitaxel and induced only a small increase of paclitaxel 
solubility (about 2% inclusion efficiency). The degree of substitution of HP-β-CD had a 
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minor effect on paclitaxel inclusion. These results confirmed previous literature reports: 
methylated-β-cyclodextrins provided a better enhancement of the aqueous solubility of 
paclitaxel compared to HP-β-CD (Sharma et al., 1995; Szente et al., 1999). 
As both methylated-β-cyclodextrins produced similar results, RAME-β-CD was 
chosen for futher research because of economical reasons (lower cost). Using the inclusion 
procedure via freeze drying the amount of RAME-β-CD could be reduced to a molar ratio of 
1/20 and still complete inclusion of paclitaxel was obtained. After reconstitution in PBS, all 
ratios (1/20 to 1/60, mol/mol) yielded visually clear solutions at a concentration of 1 mg/ml 
paclitaxel. At a lower ratio (<1/20), not all paclitaxel molecules (about 60 % inclusion 
efficiency) were complexed by RAME-β-CD and no visually clear solutions could be 
obtained. The water content of the freeze dried powder varied between 1.4 and 2.2 %, 
whereas the original RAME-β-CD material had an average water content of 5.4 %. Due to the 
large volumes perfused through the peritoneal cavity during HIPEC and because ethanol is 
known to enhance the sedative effects of anaesthetics it is imperative that the ethanol content 
(used as a co-solvent during production of the freeze dried material) is kept to a minimum. 
The ethanol content of the freeze dried material varied between 2.5 and 3.7 %. At these low 
concentrations, no problems are expected during HIPEC. 
 
3.4.1.2. Characterization of Pac/RAME-β-CD complex 
Differential Scanning Calorimetry (DSC) was used to identify the complexes in the 
freeze dried powder. In contrast to a physical mixture of paclitaxel and RAME-β-CD, no 
endothermal melting peak of paclitaxel (at 225 °C) was observed in the freeze dried material, 
indicating that inclusion complexes have been formed during processing (Fig. 1). This was 
most obvious at the lowest molecular ratio (1/20) as at higher ratios (> 1/40 molar ratio) the 
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sensitivity for the paclitaxel signal was rather low due to the large amount of cyclodextrins in 
the formulation. 
 
A 
B 
C 
D 
Fig 1.: DSC thermograms of Pac (A), RAME-β-CD (B), a physical mixture (C) of Pac and 
RAME-β-CD and an inclusion complex (1/20 molar ratio) (D) of Pac and RAME-β-
CD. The frame indicates the zone of interest for evaluation of complex formation 
between Pac and RAME-β-CD. 
 
1H NMR spectroscopy was used to further support complex formation. Given the very 
low solubility of paclitaxel in D2O, the fact that a set of clearly visible resonances, distinctive 
for the phenylgroups present in paclitaxel (between 7.5 and 8.5 ppm), was observed when 
evaluating the freeze dried powder can only be explained by complexation between drug and 
CD as uncomplexed paclitaxel (pure and in a physical mixture) did not produce a spectrum 
(Fig. 2). 
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 Paclitaxel 
Fig. 2.: 700 MHz 1H NMR spectrum of the 1/20 (mol/mol) inclusion complex. Clearly 
distinguishable paclitaxel resonances, from the phenylgroups, appear between 7.5 and 
8.5 ppm. 
 
3.4.2. Determination of physical stability 
To test the physical stability of paclitaxel solutions, the freeze dried material was 
reconstituted with PBS. Stability is expressed as the concentration of paclitaxel dissolved in 
the solution at the time of sampling compared to the concentration obtained immediately after 
reconstitution. As it is the objective of this study to formulate an alternative for Taxol®, which 
is available in a concentrated solution of 6 mg paclitaxel/ml, a maximum concentration of 5 
mg/ml was chosen for the Pac/RAME-β-CD-formulation. This concentration could be 
obtained at all ratios, but using lower molar ratios (< 1/40) precipitation occurred within 48 
hrs. The higher ratios (≥ 1/40) remained stable for 2 weeks: after storage at 4 °C and out of 
the light, they contained ≥ 95 % of paclitaxel. The improved physical stability of solutions 
containing higher amounts of RAME-β-CD is in accordance with data reported in literature 
(Szente et al., 1999): cyclodextrins not only enhanced solubility, but also the physical stability 
of solutions containing paclitaxel. Precipitation upon dilution can be a major problem when 
drugs with a poor aqueous solubility are administered intravenously via an infusion set. 
Throughout all experiments precipitation upon dilution did not occur with this 
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paclitaxel/RAME-β-CD formulation at all molar ratios. These observations are in good 
agreement with Sharma et al. (Sharma et al., 1995), who reported no precipitation upon 
dilution of paclitaxel solutions which have a concentration below 12 mg/ml in 50% DIME-β-
CD, whereas higher paclitaxel concentrations precipitated when diluted. Concentrations 
above 12 mg/ml are of no interest for a HIPEC procedure as lower concentrations are 
administered due to the large volume used during intraperitoneal perfusion. At all molar ratios 
the freeze dried material remained stable for at least 6 months when stored at 4 °C.  
As it is the objective to use this RAME-β-CD/Pac formulation for an experimental 
HIPEC procedure in rats, the stability of these solutions was evaluated at room temperature 
(25 °C, 24 hrs) and at HIPEC conditions (41 °C, 2 hrs). The physical stability results at room 
temperature will be an indication whether the solution should be prepared immediately before 
administration or can be prepared in advance. Two paclitaxel concentrations (0.1 and 0.5 
mg/ml) were selected, taken in consideration the body surface area of a rat (0.03-0.04 m²), the 
intraperitoneal dose (± 170 mg/m²) and the volume used for the HIPEC procedure (± 80 ml).  
The physical stability of a 0.1 mg/ml paclitaxel solution after 24 hrs storage at room 
temperature was poor (Table 1). Only the formulation with a 1/40 molar ratio had a stability 
above 50 % (69.5 ± 20.4 %). A lower ratio significantly reduced the physical stability of the 
complex, whereas a higher ratio did not result in a significant improvement of stability. At a 
paclitaxel concentration of 0.5 mg/ml the physical stability was higher and ranged from 34.4 
to 97.0 % (Table 1). However, due to the large variation on these data, it was impossible to 
perform any statistical analysis, even after transformation. Taken both concentrations into 
consideration the 1/40 molar ratio was the most stable. The reason for this optimum in 
drug/RAME-β-CD ratio remains unclear, but might be due to a molecular interaction of 
paclitaxel (Balasubramanian et al., 1994). Depending on the drug concentration and the 
polarity of the solvent paclitaxel interacts via intermolecular hydrogen bonds, forming a stack 
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of drug molecules in solution. These stacks influence the physical stability because they act as 
nuclei which promote aggregation and finally precipitation of paclitaxel. Since precipitation 
was the primary cause of instability of these Pac/RAME-β-CD solutions, we assume that this 
self-association may be influenced by the β-cyclodextrin concentration in the solution. A 
variable degree of self-association could explain the high variability in paclitaxel stability.  
 
 Without HPMC With HPMC 
 0.1 mg/ml 0.1 mg/ml 
Pac/RAME-β-CD 
ratio (mol/mol) Stability (%)
 Stability (%) 
  1/60 29.2 ± 21.9 97.0 ± 1.1 
  1/52 13.7 ± 5.1 96.9 ± 1.6 
  1/46 43.4 ± 22.0 96.8 ± 0.9 
  1/40 69.6 ± 20.4 96.4 ± 1.0 
  1/33 14.0 ± 8.7 95.5 ± 0.1 
  1/26 5.2 ± 3.6 95.1 ± 0.8 
  1/20 2.9 ± 1.3 94.3 ± 1.1 
 0.5 mg/ml 0.5 mg/ml 
Pac/RAME-β-CD 
ratio (mol/mol) Stability (%) Stability (%)
 
  1/60 95.4 ± 3.5 96.8 ± 14.2 
  1/52 78.8 ± 31.5 99.0 ± 2.3 
  1/46 97.0 ± 1.6 99.0 ± 6.2 
  1/40 94.8 ± 3.6 90.4 ± 10.2 
  1/33 66.3 ± 53.6 93.9 ± 4.7 
  1/26 35.1 ± 55.9 93.7 ± 2.9 
  1/20 34.5 ± 43.5 98.5 ± 4.9 
 
Table 1: Physical stability ± S.D. (n = 3) of Pac/RAME-β-CD solutions, with or without 
HPMCa added, stored for 24 hrs in sealed vials at room temperature (25 °C) Pac: 
paclitaxel; RAME-β-CD: randomly-methylated-β-cyclodextrins; HPMC: 
hydroxypropylmethyl-cellulose (aMetolose® 60SH-4000). 
 
Stability data at HIPEC conditions showed no interaction between molar ratio and 
time, hence both variables were evaluated individually (Fig. 3). At both drug concentrations, 
the physical stability at a 1/20 molar ratio was significantly lower compared to the other 
evaluated ratios (1/40 and 1/60). For all ratios a significant decrease of stability in function of 
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time was measured, but – similar to the stability data at room temperature – the highest drug 
concentrations after 2 hrs at HIPEC conditions were detected for the 1/40 molar ratio.  
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Fig. 3: Physical stability ± S.D. (n = 3) at hyperthermic conditions (41 °C) of aqueous 
paclitaxel solutions (     without and     with HPMCa added to the reconstitution medium) 
formulated using different Pac/RAME-β-CD ratios (mol/mol) a. 1/60; b. 1/40; c. 1/20. a 
Metolose® 60SH-4000. 
 
As it has been reported that HPMC significantly increased the complexation behaviour 
of cylcodextrins (even at a HPMC concentration as low as 0.1%, w/v) (Jug and Becirevic, 
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2004; Loftsson and Frioriksdottir, 1998), it was evaluated if HPMC might improve the 
stability of the complex and reduce the variability of the stability data. Adding 0.1 % (w/v) 
HPMC to the medium used to dissolve the freeze dried Pac/RAME-β-CD powder resulted 
after 24 hrs at room temperature in paclitaxel concentrations higher than 90 % of the initial 
values (Table 1). Even after 10 days no precipitation was seen and more than 70 % of the 
drug was recovered (data not shown). In contrast to the solutions without HPMC, there were 
no significant differences in stability between the different Pac/RAME-β-CD ratios, offering 
the opportunity to lower the amount of cyclodextrins in the formulation. Adding HPMC also 
reduced the variability of the stability data (Table 1). Similar to the stability testing without 
HPMC, an effect of the drug/CD ratio was seen after 2 hrs at HIPEC conditions (Fig. 3), 
independent of the paclitaxel concentration: 1/20 performed significantly worse than 1/40 and 
1/60 (although its stability at a concentration of 0.1 mg/ml was also higher than 90 %).  
Physical stability of the HPMC-containing formulations was time-dependent in case of 
0.1 mg/ml solutions: drug concentrations at each time point which was significantly lower 
compared to initial concentration, but the concentrations between 30 and 120 min were not 
significantly different. Adding HPMC to the formulation significantly improved stability at 41 
°C (except for 0.5 mg/ml solution at a 1/60 ratio), although HPMC could not enterily prevent 
the precipitation of paclitaxel at a 1/20 molar ratio. These experiments showed that it was not 
necessary to add the hydrophilic polymers during the complexation process, but that adding 
the polymer to the reconstitution medium also had a beneficial effect. The exact mechanism 
behind the stabilising effect of HPMC is unknown. However, Ribeiro et al. (2005) proposed a 
mechanism in which the polymer was able to stabilise the binary drug/CD complex by 
hydrogen bonds and van der Waals interactions, thus forming a stable ternary complex. 
Although the preparation method in this study (manufacturing binary drug/CD complexes 
which were dissolved in  reconstitution medium containing HPMC) was different from the 
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method used by Ribeiro et al. (2005) (immediate preparation of ternary complexes) 
interaction between the drug/CD complexes and HPMC is very likely since the Pac/CD 
complexes completely dissolved in the dissolution medium. In addition to the stabilizing 
effect, we believe that the binding of the polymer to the binary complex also prevented 
precipitation since solutions without HPMC formed a precipitate and HPMC-containing 
solutions remained clear (even after 10 days). The limited loss of paclitaxel in solutions with 
HPMC was due to chemical degradation, evidenced by the appearance of additional peaks in 
the HPLC chromatogram. Based on these observations we assume that the interactions 
between the binary complex and the polymer not only stabilised but also prevented the binary 
complexes to aggregate and precipitate because of the steric hindrance caused by the polymer. 
 
3.5. CONCLUSION 
Complexation of paclitaxel and RAME-β-CDs using a freeze-drying procedure 
allowed to formulate tensioactive-free paclitaxel solutions suitable for HIPEC. Both the freeze 
dried product and paclitaxel solutions (0.1, 0.5 and 5 mg/ml) were stable during a sufficient 
period of time. Addition of HPMC to the reconstitution medium significantly improved the 
stability of the Pac/RAME-β-CD formulation, allowing to reduce the amount of RAME-β-CD 
in the formulation. This formulation of Pac/RAME-β-CD will be used for further in vitro and 
in vivo experiments to evaluate its efficiency and toxicity. 
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 IN VITRO CYTOTOXICITY OF PACLITAXEL/ 
β−CYCLODEXTRIN COMPLEXES FOR HIPEC   
 
 
4.1. ABSTRACT 
 
Hyperthermic intraperitoneal chemotherapy (HIPEC) is a promising strategy in the 
treatment of peritoneal carcinomatosis. To perform HIPEC, a tensioactive- and co-solvent-
free paclitaxel formulation consisting of water-soluble paclitaxel/randomly-methylated-β-
cyclodextrin (Pac/RAME-β-CD) complexes was previously developed. Using MTT and SRB 
assays the cytotoxic activity of this formulation versus Taxol®, was evaluated as well as the 
cytotoxicity of the different formulation excipients (RAME-β-CD and Cremophor EL®). The 
possible synergistic effect of heat and paclitaxel-based chemotherapy during HIPEC was also 
evaluated in vitro. The cytotoxicity assays revealed differences in viability of 40 and 50 % 
between Cremophor EL® and RAME-β-CD treated cells for the CaCo-2 human and the 
CC531s rat colon cancer line, respectively, in favour of RAME-β-CD. Despite the higher 
cytotoxicity of Cremophor EL®, Pac/RAME-β-CD complexes and Taxol® were equipotent. 
Using the MTT and SRB assays the average difference in viability between both cell lines 
was below 10 % and IC50 values showed no significant difference. Hyperthermia after drug 
administration (41 °C during 1 hr) had no effect on cell viability. These results indicated that 
it was possible to reformulate paclitaxel with a less cytotoxic vehicle while maintaining the 
cytotoxic activity of the formulation and that there was no synergism between paclitaxel and 
heat for in vitro cytotoxicity. 
 
4
4.2. INTRODUCTION 
 
Peritoneal carcinomatosis (PC) is characterised by metastatic implants on the 
peritoneal surface of patients suffering in most cases from intra-abdominal cancer, i.e. 
stomach, colon, pancreas or ovarium cancer. For example, after colon cancer resection 
approximately 25-35 % of the patients will develop peritoneal carcinomatosis (Minsky et al., 
1988). Due to the ascites, which frequently accompanies peritoneal cancer, the patients have a 
very low quality of life combined with a high morbidity and mortality (McQuellon et al., 
2001). PC remains difficult to cure because even extended surgery can never completely 
remove all cancer cells embedded in the peritoneum. The median survival of these patients is 
approximately one year when treated intravenously with 5-fluorouracil-based chemotherapy 
and palliative surgery (Machover, 1997). Hyperthermic intraperitoneal chemotherapy 
(HIPEC) after debulking surgery is a strategy in the treatment of this type of cancer. This 
treatment does not only allow the use of a higher dosage of the drug because of the 
peritoneum-plasma barrier, it also combines the tumoricidal properties of hyperthermia and 
various chemotherapeutic drugs. Research has shown a synergism between hyperthermia and 
some cytotoxic drugs, including doxorubicin (Jacquet et al., 1998), gemcitabin (Pestieau et 
al., 1998), cisplatin (Bartlett et al., 1998), mitomycin C (Teicher et al., 1981) and 
immunomodulators like TNF (Bartlett et al., 1997). Randomized clinical trials also supported 
the use of HIPEC in the treatment and prevention of PC following resection of pT3 or pT4 
gastric cancer (Ceelen et al., 2000). 
Paclitaxel (Pac), one of the most potent cancer drugs of recent years, is a good 
candidate for HIPEC due to the limited absorption from the peritoneal cavity, its high first-
pass effect in the liver and its activity against ovarian cancer (Witkamp et al., 2001). 
However, a major problem of paclitaxel is its low aqueous solubility. This problem is 
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currently overcome by dissolving paclitaxel in a Cremophor EL®/ethanol-mixture (1/1, v/v) 
which is commercially available as Taxol®. Since the Cremophor EL® fraction in this 
formulation can cause hypersensitivity reactions, patients have to be pre-treated with 
corticosteroids and antihistamines when receiving an intravenous administration of Taxol® 
(Gelderblom et al., 2001; van Zuylen et al., 2001). Considering that high doses of Cremophor 
EL® and ethanol would be administered during a HIPEC procedure (due to the large volume 
of perfusion liquid used (1.5 L/m² body surface area) and the high intraperitoneal paclitaxel 
concentration required), there was a need for a co-solvent- and tensioactive-free paclitaxel 
formulation suitable for HIPEC. Therefore a paclitaxel formulation was developed using 
randomly-methylated-β-cyclodextrins (RAME-β-CD), resulting in a new co-solvent- and 
tensioactive-free formulation consisting of Pac/RAME-β-CD complexes (Bouquet et al., 
2007). The absence of ethanol is noteworthy because paclitaxel/CD complexes were already 
developed, but ethanol was still used in that formulation (Szente et al., 1999).  
The current paper investigates the in vitro efficiency of this newly developed 
formulation versus Taxol® using a human (CaCo-2) and a rat colon (CC531s) cancer cell line. 
In addition, the cytotoxicity of the excipients used in both formulations is compared and the 
possible synergism between paclitaxel and heat during application of HIPEC is determined. 
 
4.3. MATERIALS AND METHODS 
 
4.3.1. Materials 
 
Randomly-methylated-β-cyclodextrin (RAME-β-CD) with a total degree of 
substitution (TDS) of 13 was purchased from Cyclolab (Budapest, Hungary), paclitaxel (Pac) 
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from Acros Organics (Geel, Belgium), Taxol® from Bristol-Myers Squibb (Brussels, 
Belgium) and Cremophor EL® from Alpha Pharma (Waregem, Belgium). 
 
4.3.2. Preparation of the inclusion complexes 
 
The required amount of paclitaxel was dissolved in absolute ethanol (Merck, Overijse, 
Belgium), in a ratio of 1 to 60 (w/w). Randomly-methylated-β-cyclodextrin (RAME-β-CD) 
was added to the solution to obtain Pac/RAME-β-CD ratios of 1/60, 1/40 and 1/20 (mol/mol) 
and the solution was placed in an ultrasonic bath (Sonis 3 GT, Iskra-Pio, Šentjernej, Slovenia) 
for 5 min. Next, phosphate buffered saline (PBS, 0.01M, pH 7.4) (1 PBS tablet (Sigma, 
Bornem, Belgium) in 200 ml demineralised water) was added in a ratio of 1/2 (w/w) versus 
the RAME-β-CD fraction. Next, the solution was placed in an ultrasonic bath for 1 min and 
afterwards stirred with a magnetic stirrer for 5 min. After evaporation of most of the co-
solvent under reduced pressure, the solution was frozen at -70 °C using solid carbon dioxide 
and freeze dried for 24 h at -50 °C and 1 mbar. After freeze drying, a white amorphous 
powder was obtained (Alcaro et al., 2002). 
 
4.3.3. Determination of the administered paclitaxel concentrations 
 
The HPLC-system consisted of a pump (L-6000, Merck-Hitachi, Tokyo, Japan), an 
integrator (D-2000, Merck-Hitachi, Tokyo, Japan), an injector (Vici, Valco Instruments, 
Houston, USA) with a 25 µL loop and a UV/VIS detector (UV 2000, Spectra-systems, 
Darmstadt, Germany). Detection was performed at a wavelength of 227 nm. Chromatographic 
separation was achieved with a guard column (Lichrospher® 100-RP-18, 4*4 mm (5µm), 
Merck, Darmstadt, Germany) and an analytical column (Lichrospher® 100-RP-18, 125*4 mm 
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(5µm), Merck, Darmstadt, Germany). Before use, the mobile phase consisting of acetonitrile 
(Biosolve, Valkenswaard, The Netherlands) and 0.1 % (v/v) phosphoric acid in water (Acros 
Organics, Geel, Belgium) (42:58, v/v) was degassed by ultrasonication under vacuum. A 
calibration curve was validated for a concentration ranging from 1 to 100 µg paclitaxel/ml. 
 
4.3.4. Cell Culture 
 
The human colon adenocarcinoma cell line, CaCo-2, was obtained from the Institut 
National de la Santé et de la Recherche Médicale (Unité 55 Hopital St-Antoine, Paris, 
France). The rat colon cancer cell line, CC531s, was obtained from the Laboratory of 
Experimental Oncology (University Antwerp, Belgium). Both cell lines were maintained in T 
25 culture flasks (Sarstedt, Newton, NC, USA) at 37 °C in a humidified atmosphere 
containing 10 % CO2. Dulbecco’s modified medium (DMEM; Invitrogen, Merelbeke, 
Belgium), supplemented with 10 % foetal bovine serum (FBS; Invitrogen, Merelbeke, 
Belgium), 100 IU/ml penicillin (Invitrogen, Merelbeke, Belgium), 100 µg/ml streptomycin 
(Invitrogen, Merelbeke, Belgium) and 2.5 µg/ml fungizone (Bristol Myers Squibb, Brussels, 
Belgium), was used as growth medium for both cell lines. For subculturing, cells were rinsed 
with Moscona’s solution (8.0 g NaCl; 0.3 g KCl; 0.05 g Na2HPO4.H2O; 0.025 g KH2PO4; 
1.0 g NaHCO3 and 2.0 g dextrose in 950 mL distilled water) and were finally detached with 
trypsin/EDTA (Invitrogen, Merelbeke, Belgium). The viability of the cells was determined by 
their ability to exclude 0.4 % trypan blue dye (Sigma, Bornem, Belgium). All cells were free 
of mycoplasma as tested  via DAPI staining. 
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4.3.5. Cytotoxicity Assays 
 
The cytotoxicity of Taxol® and Pac/RAME-β-CD formulations (1/20, 1/40 and 1/60 
mol/mol ratio or 1/30, 1/60 and 1/90 w/w ratio) was tested at paclitaxel concentrations of 
0.01, 0.1, 1, 5 and 10 µg/ml (corresponding to 0.012, 0.12, 1.17, 5.86 and 11.72 µM, 
respectively). In case of Taxol® these paclitaxel concentrations corresponded to a Cremophor 
EL® concentration ranging from 0.880 to 880 µg/ml. In case of Pac/RAME-β-CD complexes 
the paclitaxel concentration corresponded to cyclodextrin concentrations varying between 0.3 
and 900 µg/ml depending on the molar ratios. The cytotoxicity of RAME-β-CD and 
Cremophor EL was also tested separately (without drug) using 10 concentrations: 0, 0.01, 0.1, 
0.5, 1, 1.5, 2, 2.5, 3, 3.5 mg/ml. 
To evaluate the cytotoxicity, cells were seeded in 96-well plates (Sarstedt, Newton, 
NC, USA) at a concentration of 15x10³ and 60x10³ cells/ml for the CC531s and CaCo-2 cell 
line, respectively. After 24hrs, 20 µl medium was replaced by 20 µl drug (or excipient) 
solution to obtain the required drug (or excipient) concentration. Eight wells per concentration 
were used and all experiments (MTT and SRB) were repeated (n = 2). After drug 
administration, the plates were incubated for 1hr at normothermic (37 °C) or hyperthermic (41 
°C) conditions. Next the cells were incubated for 96 hrs at 37 °C and 10 % CO2. Hereafter, 
the cytotoxicity of the formulations was determined via MTT and SRB assays. 
 
4.3.5.1. MTT assay 
One hundred microlitres medium was replaced by 100 µl MTT-reagent (3-(4,5-
dimethylthiazol-2-yl)-2,5-difenyl-tetrazolium bromide, at a concentration of 1 mg/ml in PBS-
D+). The reagent was mixed and incubated in dark for 2 hrs at 37 °C. Afterwards all medium 
was removed and 200 µl DMSO (Acros Organics, Geel, Belgium) was added to dissolve the 
Chapter 4  In vitro cytotoxicity of paclitaxel/β-cyclodextrin complexes for HIPEC 65
formed formazan. After incubation of the plates for 1 hr at 37 °C and mixing, the optical 
density was measured at 490 nm using an ELISA reader (Molecular Devices, Sunnyvale, 
USA). 
 
4.3.5.2. Sulphorhodamine B (SRB) assay 
The SRB test was initiated by fixing the cells via addition of 50 µl of 50 % 
trichloracetic acid (Sigma, Bornem, Belgium) to the incubation medium and incubating the 
plates for 1 hr at 2 °C. Afterwards, the wells were rinsed five times with water and dried. The 
cells were stained with 200 µl SRB (0.4 % in 1 % acetic acid) (Sigma, Bornem, Belgium) for 
30 min and rinsed 4 times in 1 % glacial acetic acid (Novolab, Geraardsbergen, Belgium). 
After drying the 96 well plate, 200 µl 10 mM Tris buffer (pH 10.5) was added per well to 
release the dye. After mixing, the optical density was measured at 490 nm with an ELISA 
reader (Molecular Devices, Sunnyvale, USA). 
For both assays, cell viability of each well was expressed using the following 
equation: 
Cell viability (%) = (Absorbancetest cell / Absorbancecontrol cells) x 100 
 
4.3.6. Statistical Analysis 
 
For each individual experiment the 50 % inhibitory drug concentration (IC50) was 
determined using probit analysis. To determine the difference in cytotoxicity between RAME-
β-CD and Cremophor EL® the mean cell viability per excipient concentration was determined 
(i.e. average of 8 wells). Next, the mean cell viability of RAME-β-CD at a specific 
concentration was subtracted from the mean cell viability of Cremophor EL® at the same 
concentration. This was done at all 9 concentrations of the formulation excipients (excluding 
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the blank), thus creating a new set of 9 variables. Of this group (n = 9) the overall average and 
its 95 % confidence interval was determined. When the cytotoxicity experiments were 
repeated (n = 2, performed on different days) the average difference in viability of all 
experiments was 6.6 ± 5.1 % and 6.8 ± 6.3 % for the CC531s and CaCo-2 cell line, 
respectively. As this percentage was caused by (biological) variation of the experiment (i.e. 
the MTT and SRB test), a 10 % difference in cytotoxicity was set as cut-off value to 
determine the equivalence in cytotoxicity between RAME-β-CD and Cremophor EL®. When 
the difference of the overall average in cell viability between both excipients was less than 10 
% (absolute value), their cytotoxic activity was considered equipotent. The same protocol was 
followed when comparing normo- versus hyperthermic conditions. In this case the viability at 
normothermic conditions was subtracted from the viability at hyperthermic conditions. The 
equivalence of the cytotoxic activity of the paclitaxel/RAME-β-CD complex and Taxol® 
formulation was analysed using a similar procedure: 5 concentrations (excluding the blank) 
were used to determine the difference in overall cytotoxicity of Taxol® versus paclitaxel/ 
RAME-β-CD complexes. Repeated experiments revealed a biological variation of 6.4 ± 6.1 % 
and 8.1 ± 6.7 % for the CC531s and CaCo-2 cell line, respectively. Hence, a 10 % difference 
was again chosen as cut-off value to determine equipotency of both formulations. All other 
statistical analyses were performed using a one-way ANOVA test (two-sided) and p-values of 
less than 5 % were considered statistically significant. Statistical Program for Social Scientists 
(SPSS 14.0) was used to analyse the results. 
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4.4. RESULTS 
 
4.4.1. Cytotoxicity of Cremophor EL® and RAME-β-CD 
 
In a first series of experiments, the cytotoxicity of the formulation excipients was 
investigated, in a concentration that ranged from 0.01 to 3.5 mg/ml. The viability graphs (Fig. 
1) showed that the cell viability of RAME-β-CD and Cremophor EL® was comparable at the 
lowest concentrations (0.01 and 0.1 mg/ml) but at approximately 0.5 mg/ml a sharp drop in 
viability was observed in case of Cremophor EL®, reaching a minimum viability at 1.5 
mg/ml. At hyper- and normothermic conditions, the viability graphs of RAME-β-CD 
indicated a viability of more than 50 % for both cell lines and both staining methods at the 
highest concentration (3.5 mg/ml) tested (Fig. 1B, 1C and 1D), except for the SRB staining of 
the CaCo-2 cell line with a viability of 50 % at a concentration of 3 mg/ml (Fig. 1A). This 
was confirmed by the determination of the IC50 values.  
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Fig. 1: Viability graphics (determined via SRB and MTT cytotoxic assays) of the CaCo-2 and 
CC531s cell line after addition of different concentrations of Cremophor EL and 
RAME-β-CD at normothermic (37 °C) and hyperthermic (41 °C) conditions (n = 8 
wells per concentration, error bars represent SD).    ▲    Cremophor EL® 37 °C  ■   
Cremophor EL® 41 °C    ▲   RAME-β-CD 37 °C    ■     RAME-β-CD 41 °C. The 
replicate experiments (n = 2) of the SRB and MTT test are presented as individual 
data sets, not as mean value. 
 
Compared to RAME-β-CD, the IC50 values for Cremophor EL® at hyper- and 
normothermic conditions were much lower for both cell lines. The IC50 values of the SRB 
tests for Cremophor EL® were between 0.1 and 0.5 mg/ml for both cell lines. The MTT test 
resulted in IC50 values between 0.5 and 1 mg/ml and between 0.3 and 0.7 mg/ml for the 
CaCo-2 and CC531s cell line, respectively. No statistical analysis was performed between 
RAME-β-CD and Cremophor EL® as the majority of IC50 values for RAME-β-CD were 
above the highest concentration tested and could therefore not be included in the statistical 
test. The large differences in cytotoxicity were further confirmed by determining the 
equivalence of both excipients. Here, the minimum difference in cytotoxicity between both 
excipients at 37 °C for both assays was 50.0 and 42.2 % for the CC531s and CaCo-2 cell line, 
respectively. Hyperthermia for 1 hr at 41 °C did not increase the cytotoxicity of either 
excipient. In case of CaCo-2 cells the largest difference in cytotoxicity between both 
temperatures was -7.4 % for the SRB test, whereas these differences ranged between -2.8 and 
1.2 % for the MTT test. Similar results were found when investigating the effect of heat using 
the CC531s cell line: the absolute differences between RAME-β-CD and Cremophor EL® 
were smaller than 10 % (except for one MTT experiment of RAME-β-CD: 15.7 %). Heat was 
unable to create differences larger than the biological variation of the experiment. 
 
4.4.2. Cytotoxicity of Taxol® and paclitaxel/RAME-β-CD complexes 
 
In a next step the cytotoxic activity of the Pac/RAME-β-CD formulations and Taxol® 
was evaluated. The procedure, which was used to evaluate the cytotoxicity of the formulations 
on the cancer cell lines, was based on the HIPEC procedure intended during in future in vivo 
work. Three molar Pac/RAME-β-CD ratios (1/20, 1/40 and 1/60) were tested because a 
difference in stability as a function of the Pac/RAME-β-CD ratio was revealed in a previous 
study (Bouquet et al., 2007) which might affect the cytotoxicity of these inclusion complexes. 
In addition, the highest ratio (1/90, w/w or 1/60, mol/mol) was included as this ratio is similar 
to the Pac/Cremophor EL® ratio used in Taxol® (1/88, w/w). 
 
4.4.2.1. CC531s cell line 
The viability data of the CC531s cell line revealed small differences in cytotoxic 
activity between Taxol® and the different Pac/RAME-β-CD formulations at 37 °C (Fig. 2A): 
the average difference in viability varied between -5.0 and 2.3 % for the SRB test (Table 1A) 
and between -6.5 and 4.0 % for the MTT test (Table 1B). At 41 °C, the differences in cell 
viability between Taxol® and the Pac/RAME-β-CD complexes remained below 10 % (Table 
1C and 1D). At both temperatures, the different types of formulation were equivalent (Fig. 2A 
and 2B). Heat was unable to significantly increase or decrease the differences in cell viability 
between Taxol® and the Pac/RAME-β-CD complexes (p-value of 0.376 and 0.963 for the 
SRB and MTT test, respectively). This showed that both formulations were similarly affected 
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by heat. The effect of heat was also studied for each formulation individually. For Taxol®, the 
differences in cell viability (Fig. 2C) between the different temperatures (37 vs. 41 °C) were 
small: all below 10 % and on average: -0.9 ± 5.6 % and -1.1 ± 2.9 % for the MTT and SRB 
test, respectively. 
 
 
 
A 
 
 
B 
 
 
C 
 
 
D 
-30 -20 -10 10 
Fig. 2: Mean (n = 5 concentrations and 8 wells per concentration ) and 95 % confidence 
interval of the difference in cell viability (determined via SRB (♦) and MTT (■) 
cytotoxicity assays, n = 2) between Taxol® and Pac/RAME-β-CD at normo- (A) and 
hyperthermic conditions (B) and between normo- and hyperthermic conditions for 
Taxol® (C) and Pac/RAME-β-CD (D) for the CC531s cell line.          1/60 (mol/mol) 
ratio,           1/40 (mol/mol) ratio and           1/20 (mol/mol) ratio. 
 
For Pac/RAME-β-CD (not considering the different ratios) the average difference in 
viability (Fig. 2D) between normothermic and hyperthermic treatment was 0.7 ± 4.7 % and 
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0.8 ± 1.5 % for the MTT and SRB test, respectively. These observations showed that heat did 
not improve the activity of both formulations.  
The IC50 values obtained after evaluation of both types of formulation at 37 °C did 
not show a difference: all values were smaller or equal than the lowest paclitaxel 
concentration (0.01 µg/ml) tested, except for two MTT tests of Taxol® (IC50: 0.03 and 0.05 
µg/ml) and for one MTT test of the complexes (IC50: 0.06 µg/ml). The IC50 values at 41 °C 
were similar to the values obtained at 37 °C: most IC50 values (± 80 %) were smaller than the 
lowest concentration tested (0.01 µg/ml) and could not be taken into account for statistical 
analysis to compare between both temperatures. 
 Cell line Cell 
assay 
Temp. 
(°C) 
Min. mean
Difference 
(%) 
Confidence 
Interval 
(%) 
Max. mean 
Difference 
(%) 
Confidence 
Interval 
(%) 
A SRB - 5.0 [- 14.5; 4.5] 2.3 [- 0.4; 4.9] 
B MTT 37 - 6.5 [- 16.1; 3.2] 4.0 [-16.3; 24.4] 
C SRB - 2.7 [- 10.8; 5.3] 8.6 [- 11.9; 29.1] 
D 
CC531s 
MTT 41 - 4.8 [-13.0; 3.4] - 1.6 [- 8.7; 5.6] 
E SRB - 9.2 [- 21.2; 2.9] 3.3 [0.5; 6.1] 
F MTT 37 - 8.5 [- 11.6; -5.5] 3.3 [- 3.1; 9.7] 
G SRB -10.0 [-14.0; -6.1] 3.7 [-2.2; 9.5] 
H 
CaCo-2 
MTT 41 -7.6 [-20.2; 4.9] 7.1 [-2.5; 16.6] 
 
Table 1: Minimum and maximum mean (n = 5 concentrations and 8 wells per concentration) 
difference in cell viability (determined via MTT and SRB cytotoxicity assays, n = 2) 
between Pac/RAME-β-CD (all three ratios) and Taxol® at 37 and 41 °C. 
 
4.4.2.2. CaCo-2 cell line 
The results (Fig. 3) of the CaCo-2 cell line were similar to the CC531s cell line. All 
Pac/RAME-β-CD formulations were equivalent to Taxol® at both temperatures (Fig 3A and 
3B). The difference in viability at 37 °C ranged between -9.2 and 3.3 % for SRB (Table 1E) 
and between -8.5 and 3.3 % for MTT (Table 1F). The difference in viability at 41 °C for the 
SRB test ranged from -10.0 to 3.7 % (Table 1G) and from -7.6 to 7.1 % for the MTT assay 
(Table 1H). The differences between Taxol® and Pac/RAME-β-CD were not significantly 
different when comparing both temperatures (p-values of 0.885 and 0.383 for SRB and MTT 
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test, respectively). When investigating the influence of temperature on either the activity of 
Taxol® or the Pac/RAME-β-CD formulations, the differences were small. For Taxol® (Fig. 
3C), the SRB test showed an average difference of 2.4 ± 3.5 % and the MTT test a difference 
of -4.0 ± 4.0 %. For the inclusion complexes (Fig. 3D) the average difference was  1.4 ± 7.9 
% and -0.9 ± 5.6 % for the SRB and MTT test, respectively. 
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Fig. 3: Mean (n = 5 concentrations and 8 wells per concentration) and 95 % confidence 
intervals of the difference in cell viability (determined via SRB (♦) and MTT (■) 
cytotoxicity assays, n = 2) between Taxol® and Pac/RAME-β-CD at normo- (A) and 
hyperthermic conditions (B) and between normo- and hyperthermic conditions for 
Taxol® (C) and Pac/RAME-β-CD (D) for the CaCo-2 cell line.         1/60 (mol/mol) 
ratio,           1/40 (mol/mol) ratio and           1/20 (mol/mol) ratio. 
 
The IC50 values of the MTT at 37 °C (Table 2) ranged from 2.76 to 8.59 µg/ml and 
from 3.12 to 10.64 µg/ml for Taxol® and Pac/RAME-β-CD formulations, respectively. There 
was no significant difference between these groups (p = 0.958). At 41 °C, the values for the 
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MTT ranged from 4.77 to 7.72 µg/ml and from 4.29 to 12.90 µg/ml for Taxol® and 
Pac/RAME-β-CD formulations, respectively (Table 2). There was also no significant 
difference (p = 0.179) between these IC50 values. When comparing the data of Taxol® at 37 
°C versus the data at 41 °C to evaluate the influence of heat, no significant difference between 
both groups (p = 0.672) could be detected for MTT. The IC50 values of the MTT test also did 
not differ significantly (p = 0.227) between both temperatures for the Pac/RAME-β-CD 
formulations. 
Formulation Temperature 
(°C) 
Cell assay Minimum IC50 
(µg/ml) 
Maximum IC50 
(µg/ml) 
MTT 2.76 8.59 37 SRB < 0.01 0.57 
MTT 4.77 7.72 
Taxol® 
 41 SRB < 0.01 0.35 
MTT 3.12 10.64 37 SRB 0.03 0.42 
MTT 4.29 12.90 Pac/RAME-β-CD 41 SRB < 0.01 0.58 
 
Table 2: Minimum and maximum IC50 values (determined via MTT and SRB cytotoxic 
assays) of Pac/RAME-β-CD complexes (taking all three ratios into consideration) 
and Taxol® at 37 °C and 41 °C for the CaCo-2 cell line. 
 
Considering the SRB test, the IC50 values were smaller compared to the MTT test 
(some even below the lowest concentration tested, i.e. <0.01 µg/ml). At 37 °C the SRB test 
had a maximum IC50 value of 0.57 and 0.42 µg/ml for Taxol® and the Pac/RAME-β-CD 
formulations, respectively (Table 2). There was no statistical significant difference between 
both formulations (p = 0.450). Similar results were seen at 41 °C: no significant difference 
between both formulations (p = 0.906) with maximum IC50 values of 0.35 and 0.58 µg/ml for 
Taxol® and Pac/RAME-β-CD, respectively. In function of temperature, no significant 
differences between the IC50 values were detected for Taxol® and the Pac/RAME-β-CD 
formulations (p-values of 0.573 and 0.791, respectively). 
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4.5. DISCUSSION 
 
Paclitaxel is an essential cytotoxic agent used in the management of different types of 
cancer. However, the adverse effects observed after administration of Taxol® are a 
considerable drawback for the use of paclitaxel. It has become clear that Cremophor EL® 
(essential in the formulation in order to solubilise paclitaxel) is not a physiological inert 
compound as numerous pharmacokinetic and pharmacodynamic effects of Cemophor EL® 
have been reported in literature (Gelderblom et al., 2001; van Zuylen et al., 2001). Due to 
these adverse effects, the development of new paclitaxel formulations, containing a suitable 
carrier to improve the aqueous solubility, is essential. 
A paclitaxel formulation intended for a HIPEC procedure in the treatment of 
peritoneal cancer of colorectal origin was developed using RAME-β-CD (Bouquet et al., 
2007). The difference with a similar approach, used by Szente et al. (1999), was that our 
formulation did not contain ethanol. Exclusion of ethanol is essential because of the 
synergism with volatile anaesthetics, which may lead to increased fatalities in a future in vivo 
model. RAME-β-CD significantly improved the solubility of paclitaxel and the in vitro 
stability of the formulation was sufficient to achieve suitable paclitaxel concentrations 
(Bouquet et al., 2007). In this study we evaluated the cytotoxicity of this Pac/RAME-β-CD 
formulation and compared the cytotoxic activity of RAME-β-CD versus Cremophor EL®. 
Based on the results of the MTT and SRB assays it is obvious that Cremophor EL® is 
a stronger cytotoxic agent in comparison to RAME-β-CD with average differences in viability 
above 40 %. This was also reflected in the IC50 values. The values for RAME-β-CD were in 
most cases above 3.5 mg/ml (highest concentration tested), whereas the IC50 values for 
Cremophor EL® were all below or equal to 1 mg/ml. This confirmed a study (Szente et al., 
1999) which concluded that methylated-beta-cyclodextrins did not exhibit cytotoxicity on 
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PC3 cancer cell lines in contrast to Cremophor EL®. However, it has been reported that a 
concentration of 1-2 mg/ml methylated-beta-cyclodextrins showed cytotoxic effects on human 
breast and ovarian adenocarcinoma cell lines (Grosse et al., 1998) which is in contrast to our 
data. 
The presented data clearly illustrated that Cremophor EL® is more cytotoxic than 
RAME-β-CD, although in literature there have been conflicting reports about the cytotoxic 
activity of Cremophor EL®. Liebmann et al. (1994) observed that a Cremophor EL® 
concentration of 1.35 mg/ml was able to block a portion of the cells in the G1-phase, making 
it impossible for paclitaxel to exert its effect during mitosis and because of this effect lower 
paclitaxel concentrations (0.043 µg/ml or 50 nM) were as effective as higher concentrations. 
In contrast, Cordes and Plasswilm (1998) reported a cytotoxic effect of the diluent used in 
Taxol® and Fjällskog et al. (1994) discovered that paclitaxel in Cremophor EL®/ethanol was 
more potent against doxorubicin-resistant cell lines than paclitaxel dissolved in ethanol alone, 
suggesting an additional cytotoxic effect of Cremophor EL®. The latter was confirmed by 
Reinecke et al. (1997), who observed a higher cytotoxicity of Taxol® than paclitaxel dissolved 
in DMSO and suggested that this was caused by the additional growth inhibitory effect of 
Cremophor EL®. Although it is difficult to compare our data with other literature reports 
because of differences in cell lines and administered concentrations, our data showed a clear 
cytotoxic effect of Cremophor EL® on both cell lines at a concentration of approximately 1 
mg/ml whereas RAME-β-CD is much less cytotoxic with IC50 values above 3.5 mg/ml. 
Exposure to heat did not affect cytotoxicity. 
When comparing Taxol® versus the Pac/RAME-β-CD complexes, there was no 
relevant difference between both formulations since the differences in viability were below 10 
%. Although the formulation excipients have a large difference in cytoxicity, both types of 
paclitaxel formulations were equipotent, even for the Pac/RAME-β-CD formulation with the 
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lowest ratio (1/20, mol/mol). This shows that the different in vitro stability observed for the 
different molar ratios reported in previous research (Bouquet et al., 2007) did not have a 
negative effect on the cytotoxicity of the inclusion complexes: all three ratios yielded similar 
results in cytotoxicity. For both cell lines, this similarity in cytotoxicity of Taxol® and 
Pac/RAME-β-CD was confirmed by the IC50 values. This is in accordance with other 
researchers who did not observe a loss in activity of paclitaxel formulated in β-cyclodextrins 
(Szente et al., 1999). Our research has proven that although the formulation excipients are 
very different in cytotoxicity, the Pac/RAME-β-CD formulation is as cytotoxic as Taxol®. We 
hope that these promising in vitro results can be confirmed in vivo: producing a paclitaxel 
formulation for intraperitoneal chemotherapy and more specific for HIPEC, that is equipotent 
to Taxol® but less toxic. If this new formulation proves to be effective, it could also be 
evaluated against a peritoneal cancer of other origin, ovarian cancer being the most relevant. 
After investigating the cytotoxicity of the excipients and both formulations, one 
question remained unanswered: does hyperthermia have a beneficial effect on the cytotoxicity 
of the investigated paclitaxel formulations? Because paclitaxel and hyperthermia both act on 
the microtubuli, it is questioned if they have a synergistic or antagonistic effect. Our results 
showed no enhancement of the cytotoxic activity of all investigated paclitaxel formulations at 
higher temperature using the rat CC531s and the human CaCo-2 cell line, indicating no 
synergistic effect of heat nor a loss of activity due to instability of the formulation at higher 
temperatures. Rietbroek et al. also reported a lack of thermal enhancement for paclitaxel and 
docetaxel (Rietbroek et al., 1997). This was confirmed for docetaxel (Dumontet et al., 1998). 
In contrast, Cividalli et al. reported an effect between paclitaxel and hyperthermia in a mouse 
tumour model (Cividalli et al., 1999) and Othman et al. confirmed that there was an 
hyperthermic enhancement of the apoptotic and antiproliferative activity of paclitaxel 
(Othman et al., 2001). More recently, results were published in which no enhancement 
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between hyperthermia and paclitaxel was seen, but there was an enhancement for docetaxel 
(Faheez et al., 2003). A possible explanation for these contradictory results is the numerous 
factors involved in this process. Recent research illustrated that depending on the cell line, the 
applied temperature and the number of days after treatment different results were obtained 
(Michalakis et al., 2007). At present, there is no consensus on hyperthermia and taxanes, but 
our data suggested that there was no thermal enhancement of the cytotoxic activity of 
paclitaxel, independent of the type of formulation, on the CaCo-2 and CC531s cell line. 
 
4.6. CONCLUSION 
A newly developed Pac/RAME-β-CD formulation has shown a similar cytotoxic 
activity as Taxol® against a rat (CC531s) and a human (CaCo-2) colon cancer cell line, as was 
confirmed via two cytotoxicity assays (MMT and SRB). For the Pac/RAME-β-CD 
formulation there was no difference in cytotoxicity between the different ratios of RAME-β-
CD used. Importantly, a clear difference in cytotoxicity between Cremophor EL and RAME-
β-CD was detected; the latter being the less toxic. There was no effect of applying 
hyperthermia (41 °C during 1 hr) on the survival rate of the cells. 
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 PDMP ANALOGUE RESENSITIZES MDR CELLS 
FOR PACLITAXEL/β-CYCLODEXTRIN 
COMPLEX 
 
 
5.1. ABSTRACT 
 
As multi drug resistant (MDR) cells have higher levels of glucosylceramide, the 
addition of ceramide or glucosylceramide synthase (GCS) inhibitors is a possible strategy for 
resensitization of MDR cells. A previously developed paclitaxel/randomly methylated-β-
cyclodextrin (Pac/RAME-β-CD) formulation was evaluated versus Taxol® for its cytotoxic 
potency using MTT and SRB assays. The different formulation excipients (RAME-β-CD and 
Cremophor EL®) were also evaluated. The results showed that Cremophor EL® contributed to 
the cytotoxic activity of Taxol®, whereas Pac/RAME-β-CD produced similar results as 
paclitaxel dissolved in DMSO. Cell viability after exposure to Pac/RAME-β-CD was not 
concentration dependent due to the presence of P-glycoprotein (P-gp) efflux pumps in the 
CC531s cell line which induced the MDR. 
A recently developed D-threo-(1R,2R)-1-phenyl-2-decanoylamino-3-morpholino-1-
propanol (PDMP) analogue and GCS inhibitor (HPPP) was tested for its ability to resensitize 
the MDR cells. Addition of 5 µM HPPP was sufficient to generate a concentration-dependent 
decrease of cell viability after administration of Pac/RAME-β-CD complexes. The addition of 
C6-ceramide at a concentration of 10 µM produced similar results, whereas addition of 
verapamil (P-gp inhibitor) and NB-DNJ (selective GCS inhibitor) showed no effect on the 
cytotoxic activity of Pac/RAME-β-CD. These results indicated that Cremophor EL® 
5 
contributed to the activity of Taxol® and that the addition of HPPP (non-selective GCS 
inhibitor) resensitized MDR cells. This resensitization, however, was not related with the 
inhibition of P-gp pumps. 
 
5.2. INTRODUCTION 
 
Multidrug resistance (MDR) is a major obstacle in the clinical application of various 
cytotoxic drugs. It is characterized by the ability of tumours to exhibit simultaneous resistance 
to structurally and functionally unrelated chemotherapeutic agents. The best known and 
studied mechanism of MDR is the overexpression of a transmembrane protein, P-glycoprotein 
(P-gp) which is encoded by the MDR1 gene (Ueda et al., 1986). P-gp is a member of the 
ATP-dependent membrane transport proteins and causes the efflux of chemotherapeutics 
(including anthracyclines, taxanes, vinca-alkaloids) resulting in a reduced intracellular drug 
concentration and thus reduced antitumour activity (Nobili et al., 2006).  
In 1996, Lavie et al. demonstrated that MDR cells also have higher glucosylceramide 
levels, indicating a correlation between MDR and (glucosyl)ceramide metabolism. Ceramide 
is a lipid second messenger involved in several cell regulating processes, such as 
differentiation, proliferation and apoptosis (Kolesnick et al., 1998). Because of its role in 
apoptosis, this sphingolipid has attracted a lot of attention as a possible target for cancer 
therapy. There is a growing body of evidence that combining paclitaxel and ceramide 
increases the cytotoxic potency of paclitaxel (Myrick et al., 1999; Mehta et al., 2000; Charles 
et al., 2001; Qiu et al., 2006), even in multidrug resistant cells (Devalapally et al., 2007; van 
Vlerken et al., 2007; Desai et al., 2008; Swanton et al., 2008). Hence increasing cellular 
ceramide levels via co-administration of ceramide or via inhibition of ceramide metabolism 
(via addition of glucosylceramide synthase inhibitors) has been proposed as another way to 
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increase the cytotoxic activity of anticancer drugs (Lavie et al., 1997; Lucci et al., 1999; Liu 
et al., 2001). The inhibitors of glucosylceramide synthase (GCS) can be divided into two 
classes: D-threo-(1R,2R)-1-phenyl-2-decanoylamino-3-morpholino-1-propanol (PDMP) and 
N-butyldeoxynojirimycin (NB-DNJ) and their respective analogues. 
Paclitaxel (Pac) is a powerful chemotherapeutic that has a special place in the anti-
cancer therapy because of its unique mechanism which consists of the stabilization of the 
microtubuli. Unfortunately, the clinical application of paclitaxel is hampered by its poor 
solubility in water. Therefore, it is formulated in a Cremophor EL®/ethanol (1/1, v/v) solution, 
which is commercially available as Taxol®. However, this formulation causes several 
problems, the most important being hypersensitivity reactions (Singla et al., 2002), and 
formulation development of paclitaxel has focused on alternative excipients to improve the 
aqueous solubility of paclitaxel, one of these alternatives being cyclodextrins. 
Cyclodextrins are cyclic oligosaccharides, which increase the solubility and 
bioavailability of numerous hydrophobic compounds. In previous research (Bouquet et al., 
2007), randomly-methylated-β-cyclodextrins (RAME-β-CD) have been used to form 
complexes with Pac, which after reconstitution in phosphate buffered saline render a 
paclitaxel solution that can be used in hyperthermic intraperitoneal chemotherapy (HIPEC). 
This formulation showed a similar activity as Taxol® against two colon cancer cell lines 
(CC531s and CaCo-2) during in vitro cytotoxicity tests (Bouquet et al., 2009). In this research 
we have further investigated the activity of our formulation against the CC531s cell line, a rat 
colon cancer cell line. After the detection of a P-gp-positive subpopulation in the CC531s cell 
line, co-administration of Pac and HPPP, a PDMP analogue (Hillaert et al., 2006) was 
investigated as a way to enhance the cytotoxic activity of the Pac/RAME-β-CD formulation. 
 
 
Chapter 5 PDMP analogue resensitizes MDR cells for paclitaxel/β-cyclodextrin complex 86
5.3. MATERIALS AND METHODS 
 
5.3.1. Materials 
 
Randomly-methylated-β-cyclodextrin (RAME-β-CD) with a total degree of 
substitution (TDS) of 13 was purchased from Cyclolab® (Budapest, Hungary), paclitaxel 
(Pac) from Acros Organics (Geel, Belgium), Taxol® from Bristol-Myers Squibb (Brussels, 
Belgium), Cremophor EL® from Alpha Pharma (Waregem, Belgium), R(+)-verapamil.HCL 
(Verapamil) from Sigma-Aldrich (Bornem, Belgium), N-butyldeoxynojirimycin.HCl (NB-
DNJ) from Tebu-Bio (Boechout, Belgium), C6-ceramide from Sigma-Aldrich (Bornem, 
Belgium). N-((E,2R,3R)-3-Hydroxy-5-phenyl-1-(pyrrolidin-1-yl)pent-4-en-2-yl)palmitate 
(C31H52O2N2) (HPPP, Fig. 1) was synthesised at the Laboratory of Medicinal Chemistry, 
Ghent University (Hillaert et al, 2006). 
 
Fig.1:  Molecular structure of HPPP 
 
5.3.2. Preparation of the inclusion complexes 
 
The required amount of paclitaxel was dissolved in absolute ethanol (Merck, Overijse, 
Belgium), in a 1/60 (w/w) ratio. RAME-β-CD was added to the solution to obtain a 
Pac/RAME-β-CD ratio of 1/40 (mol/mol) and the solution was placed in an ultrasonic bath 
(Sonis 3 GT, Iskra-Pio, Šentjernej, Slovenia) for 5 min. Next, phosphate buffered saline (PBS, 
0.01M, pH 7.4) (Sigma, Bornem, Belgium) was added in a 1/2 (w/w) ratio versus the RAME-
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β-CD fraction. This solution was placed in an ultrasonic bath for 1 min and afterwards stirred 
with a magnetic stirrer for 5 min. After evaporation of most of the co-solvent under reduced 
pressure, the solution was frozen at -70°C using solid carbon dioxide and freeze dried for 24 
hrs at -50°C and 1 mbar. After freeze drying, a water-soluble powder was obtained. 
 
5.3.3. Determination of paclitaxel concentration 
 
To determine the Pac concentration in the formulations used during the cytotoxicity 
studies the following HPLC-system was used: a pump (L-6000, Merck-Hitachi, Tokyo, 
Japan), an integrator (D-2000, Merck-Hitachi, Tokyo, Japan), an auto sampler (L-7200, 
Merck-Hitachi, Tokyo, Japan) with a 25 µL loop and a UV/VIS detector (L-4200, Merck-
Hitachi, Tokyo, Japan). Detection was performed at a wavelength of 227 nm. 
Chromatographic separation was achieved with a guard column (Lichrospher® 100-RP-18, 
4*4 mm (5µm), Merck, Darmstadt, Germany) and an analytical column (Lichrospher® 100-
RP-18, 125*4 mm (5µm), Merck, Darmstadt, Germany). The mobile phase consisting of 
acetonitrile (Biosolve, Valkenswaard, The Netherlands) and 0.1% (v/v) phosphoric acid in 
water (Acros Organics, Geel, Belgium) (42:58, v/v) was degassed by ultrasonication under 
vacuum. A calibration curve was validated for a concentration range from 1 to 100 µg 
paclitaxel/ml. 
 
5.3.4. Cell Culture 
 
The rat colon cancer cell line, CC531s, was obtained from the Laboratory of 
Experimental Oncology (University Antwerp, Belgium). The cell line was maintained in T 25 
culture flasks (Sarstedt, Newton, NC, USA) at 37°C in a humidified atmosphere containing 
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10% CO2. Dulbecco’s modified medium (DMEM; Invitrogen, Merelbeke, Belgium), 
supplemented with 10% foetal bovine serum (FBS; Invitrogen, Merelbeke, Belgium), 100 
IU/ml penicillin (Invitrogen, Merelbeke, Belgium), 100 µg/ml streptomycin (Invitrogen, 
Merelbeke, Belgium) and 2.5 µg/ml fungizone (Bristol Myers Squibb, Brussels, Belgium), 
was used as growth medium. All cells were tested free of mycoplasma with DAPI staining. 
 
5.3.5. Cytotoxicity Assays 
 
The cytotoxicity of Taxol® and the Pac/RAME-β-CD formulation (1/40 mol/mol ratio 
or 1/60 w/w ratio) was tested using the following paclitaxel concentrations: 0.1, 1, 5, 10, 20 
µg/ml (corresponding with a range of 0.12 to 23.44 µM). Considering the Pac concentration 
range, this corresponded to a Cremophor EL® concentration ranging from 8.8 to 1760 µg/ml 
and to a RAME-β-CD concentration varying between 6.0 and 1200 µg/ml. The cytotoxicity of 
RAME-β-CD and Cremophor EL was also tested (without Pac) using 10 concentrations: 0, 
0.01, 0.1, 0.5, 1, 1.5, 2, 2.5, 3 and 3.5 mg/ml. When a additional compound (C6-ceramide, 
HPPP, verapamil) was added to test its synergism on cytotoxicity, Pac concentrations of 1, 5, 
10 and 20 µg/ml were used.  
To evaluate the cytotoxicity, cells were seeded in 96-well plates (Sarstedt, Newton, 
NC, USA) at a concentration of 15x10³ CC531s cells/ml. After 72 hrs, 20 µl medium was 
replaced by 20 µl drug (or excipient) solution to obtain the required drug (or excipient) 
concentration. Eight wells per concentration were used and all experiments (MTT and SRB) 
were performed in duplicate. Next, the cells were incubated for 48 hrs at 37°C and 10% CO2. 
The addition of heat was investigated by placing the cells at 41 ° for 1 hr after administration 
before placing them back at 37 °C. 
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Since C6-ceramide and HPPP were dissolved in DMSO before addition to the drug 
solution, each experiment included a DMSO blank which contained the DMSO concentration 
used to dissolve the investigated molecule. No toxicity was detected at all DMSO 
concentrations used. The cytotoxicity was determined via MTT and SRB assays. 
 
5.3.5.1. MTT assay 
One hundred µl medium was replaced by 100 µl MTT-reagent (3-(4,5-
dimethylthiazol-2-yl)-2,5-difenyl-tetrazolium bromide, at a concentration of 1 mg/ml in PBS-
D+). The reagent was mixed and incubated in dark for 2 hrs at 37°C. Afterwards all medium 
was removed and 200 µl DMSO (Acros Organics, Geel, Belgium) was added to dissolve the 
formed formazan. After incubation of the plates for 1 hr at 37°C and mixing, the optical 
density was measured at 490 nm using an ELISA reader (Molecular Devices, Sunnyvale, 
USA).  
 
5.3.5.2. Sulphorhodamine B (SRB) assay 
Cells were fixed by adding 50 µl of 50% trichloracetic acid (Sigma, Bornem, 
Belgium) to the incubation medium and incubating the plates for 1 hr at 2°C. Afterwards, the 
wells were rinsed five times with water and dried. The cells were stained with 200 µl SRB 
(0.4% in 1% acetic acid) (Sigma-Aldrich, Bornem, Belgium) for 30 min and rinsed 4 times in 
1% glacial acetic acid (Novolab, Geraardsbergen, Belgium). After drying the 96 well plate, 
200 µl 10 mM Tris buffer (pH 10.5) was added per well to release the dye. After mixing, the 
optical density was measured at 490 nm with an ELISA reader (Molecular Devices, 
Sunnyvale, USA).  
For both assays, cell viability of each well was expressed using the following 
equation: Cell viability (%) = (Absorbancetest cells / Absorbancecontrol cells) x 100 
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5.3.6. MDR Analysis 
 
MDR analysis was performed as previously described by Swerts et al. (2004). Flow 
cytometric detection of P-gp activity was performed using a rhodamine 123 (rho 123) efflux 
assay. Cells were incubated for 1 hr at 37°C with 200 ng/ml rho123 (Sigma-Aldrich, Bornem, 
Belgium) with or without 10 µM of the P-gp inhibitor R(+)-verapamil.HCL (Sigma-Aldrich, 
Bornem, Belgium). The cells were washed twice and resuspended in medium without rho 123 
in the presence or absence of verapamil. After incubation of 1 hr at 37°C, the intracellular 
rho123 concentration was measured with a flow cytometer (FACSort, BD Biosystems, 
Erembodegem, Belgium). At least 10,000 events were counted and analyzed with the Cell 
Quest software (BD Biosystems, Erembodegem, Belgium). From this data, the retention ratio 
was calculated by dividing the median fluorescence of the cells incubated with verapamil by 
the median fluorescence of the cells incubated without verapamil. A test result was considered 
positive if the cells exhibited rho 123 efflux and if the intracellular rho 123 fluorescence was 
enhanced in the presence of verapamil by at least 10 % (resulting in a rho 123 retention ratio 
(RR) of at least 1.10) (Wuchter et al., 2000). For testing the influence of the different added 
compounds on P-gp activity, the same procedure was followed as described above, only 
verapamil was replaced by the compound under investigation. 
 
5.3.7. Statistical Analysis 
 
For each individual experiment the 50% inhibitory drug concentration (IC50) was 
determined using probit analysis. To determine the difference in cytotoxicity between RAME-
β-CD and Cremophor EL® the mean cell viability per excipient concentration was determined 
(i.e. average of 8 wells). Next, the mean cell viability of RAME-β-CD at a specific 
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concentration was subtracted from the mean cell viability of Cremophor EL® at the same 
concentration. This was done at all 9 concentrations of the formulation excipients (excluding 
the blank), thus creating a new set of 9 variables. Of this group (n=9) the overall average and 
its 95% confidence interval was determined. When the difference of the overall average in 
cell viability between both excipients was less than 10% (absolute value), their cytotoxic 
activity was considered equipotent (similar to the method used by Bouquet et al., 2009). 
 The equivalence of cytotoxic activity between paclitaxel/RAME-β-CD complexes 
and Taxol® was analysed using a similar procedure: 5 concentrations (excluding the blank) 
were used to determine the difference in overall cytotoxicity of Taxol® versus 
paclitaxel/RAME-β-CD complexes, using a 10% difference as cut-off value to determine 
equipotency of both formulations. This evaluation method indicates if both formulations are 
equipotent over a fixed concentration range. Statistical Program for Social Scientists (SPSS 
15.0) was used to analyse the results. 
 
5.4. RESULTS  
 
5.4.1 Comparison of cytotoxicity of Pac/RAME-β-CD and Taxol® 
 
Both the MTT and SRB tests (Fig. 2) indicated a difference in viability of the CC531s 
cells after exposure to Taxol® and Pac/RAME-β-CD, mainly at concentrations above 5 µg/ml.  
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Fig. 2: Viability graphics (determined via SRB and MTT cytotoxic assays) of the CC531s cell 
line after addition of different concentrations of Taxol®, Pac/RAME-β-CD and Pac 
dissolved in DMSO (Pac/DMSO) at 37°C (n = 8 wells per concentration, error bars 
represent standard deviations). The replicate experiments (n=2) of the SRB and MTT 
test are presented as individual data sets.   ■   Pac/RAME-β-CD,   ■   Taxol®,   ■   
Pac/DMSO 
 
Whereas both formulations showed a similar response in the lower concentration 
range (< 5µg/ml), an increasing difference was observed at higher concentrations. At 20 
µg/ml Taxol® reduced the viability to about 10 % whereas the viability after treatment with 
Pac/RAME-β-CD remained above 50 %. This was also reflected in the IC50 values (Table 1).  
 
IC50 (µg/ml) after treatment with Cell assay Conc (µg/ml) Taxol® Pac/RAME-β-CD Pac/DMSO 
4.11 > 20.00 > 20.00 MTT 0.10-20.00 3.85 > 20.00 > 20.00 
1.86 > 20.00 > 20.00 SRB 0.10-20.00 2.03 8.15 > 20.00 
 
Table 1: IC50 values (determined via MTT and SRB cytotoxic assays) of Taxol®, 
Pac/RAME-β-CD and Pac dissolved in DMSO (Pac/DMSO). The cell viability was 
determined at 37 °C using the CC531s cell line. The replicate experiments (n = 2) of 
the SRB and MTT assay are presented as individual data sets. 
 
For the MTT and SRB tests the IC50 values of Taxol® ranged between 1.86 and 4.11 
µg/ml, whereas the IC50 values for Pac/RAME-β-CD were above 20 µg/ml (except for one 
SRB staining: 8.15 µg/ml). Hyperthermia had no influence on these results as the IC50 values 
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of Pac/RAME-β-CD remained above 20 µg/ml (except for one SRB staining: 13.36 µg/ml ) 
and IC50 of Taxol® ranged between 0.37 and 3.52 µg/ml for the MTT and SRB assays (Table 
2).  
 
IC50 (µg/ml) after treatment with Cell assay Conc (µg/ml) Taxol® Pac/RAME-β-CD Pac/DMSO 
3.31 > 20.00 > 20.00 MTT 0.10-20.00 0.37 > 20.00 > 20.00 
3.52 13,36 > 20.00 SRB 0.10-20.00 1.52 > 20.00 > 20.00 
 
Table 2: IC50 values (determined via MTT and SRB cytotoxic assays) of Taxol®, 
Pac/RAME-β-CD and Pac dissolved in DMSO (Pac/DMSO). The cell viability was 
determined at 41 °C using the CC531s cell line. The replicate experiments (n = 2) of 
the SRB and MTT assay are presented as individual data sets. 
 
Pac dissolved in DMSO (Pac/DMSO) was also tested  in the same concentration range 
(0.10 – 20. µg/ml) (Fig 2). This resulted in similar viability graphs as for the Pac/RAME-β-
CD complex and IC50 values of Pac/DMSO were above 20 µg/ml for both cell assays and at 
both temperatures (Table 1, Table 2). In contrast to Taxol®, both Pac/RAME-β-CD and 
Pac/DMSO did not induce a concentration-dependent decrease of viability. Although the 
cytotoxicity of both formulation excipients (RAME-β-CD and Cremophor EL®) was 
previously reported, their effect on the CC531s cell line was also determined using the test 
procedure applied in this study. Here, the previously reported results (Bouquet et al., 2008) 
were confirmed as the IC50 values of RAME-β-CD and Cremophor EL® were > 3.5 mg/ml 
and ≤ 0.5 mg/ml, respectively.  
As the cytotoxicity of Pac/RAME-β-CD was concentration-independent, the CC531s 
cells were examined for P-gp activity with a Rho123 efflux assay. The flowcytometric results 
yielded a retention ratio of 5.44, indicating that the cells were P-gp positive (Fig. 3). To rule 
out the possibility that this resistance against paclitaxel was recently acquired by the CC531s 
cells and therefore unobserved in the previous study, the Pac/RAME-β-CD formulation and 
Taxol® were tested using the same test setup as reported by Bouquet et al. (2009) (i.e. lower 
cell concentration and longer contact period between formulation and cells). These results 
(data not shown) were consistent with those results published by Bouquet et al. (2009): 
Taxol® and Pac/RAME-β-CD were equipotent as a similar cytotoxicity was observed over the 
entire paclitaxel concentration range. 
 
Fig. 3: Flowcytometric assay of Rhodamine 123 efflux in the CC531s cell line.        Cells 
incubated without verapamil,         Cells incubated with verapamil. 
 
5.4.2 Modulation of multidrug resistance  
 
To increase the activity of the Pac/RAME-β-CD formulation in order to obtain a 
similar efficiency compared to Taxol®, the effect of the addition of different compounds to 
Pac/RAME-β-CD was investigated. Taxol® was included as a reference in each experiment 
investigating the effect of a specific compound: its average IC50 values of all MTT and SRB 
tests (n = 32) were 12.59 ± 4.66 and 7.47 ± 3.75 µg/ml, respectively. Increasing 
concentrations of HPPP (0.5, 5 and 50 µM) significantly decreased IC50 values of the 
Pac/RAME-β-CD formulation in a concentration-dependent manner (Table 3). Addition of 5 
µM HPPP significantly reduced the IC50 of the inclusion complex to approximately 9 µg/ml 
(MTT assay), which is similar to the one reported for Taxol®. The cytotoxic effect of HPPP 
alone was limited at 5µM: cell viability was approximately 80 % and IC50 values were 
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between 22.10 and 26.00 µM for the MTT test. However, as increasing the HPPP 
concentration to 50 µM resulted in IC50 values below the lowest paclitaxel concentration 
tested, it is obvious that at this concentration the cytotoxicity of HPPP was predominant. The 
results obtained for the SRB assay confirmed the MTT results (Table 3).  
 
IC50 (µg/ml) determined via  Compound Conc (µM) MTT MTT SRB SRB 
0.00 > 20.00 > 20.00 > 20.00 > 20.00 
0.50 > 20.00 > 20.00 > 20.00 20.00 
5.00 9.00 9.75 1.55 2.81 HPPP 
50.00 < 1.00 < 1.00 < 1.00 < 1.00 
0.00 > 20.00 > 20.00 > 20.00 20.00 
0.50 > 20.00 > 20.00 > 20.00 > 20.00 
5.00 > 20.00 > 20.00 > 20.00 > 20.00 Verapamil 
50.00 > 20.00 > 20.00 > 20.00 19.32 
0.00 > 20.00 > 20.00 > 20.00 > 20.00 
0.50 > 20.00 > 20.00 16.35 > 20.00 
5.00 > 20.00 > 20.00 16.01 > 20.00 NB-DNJ 
50.00 > 20.00 > 20.00 17.83 > 20.00 
0.00 > 20.00 > 20.00 > 20.00 > 20.00 
10.00 < 1.00 9.26 < 1.00 1.64 
30.00 < 1.00 < 1.00 < 1.00 < 1.00 C6-Ceramide 
50.00 < 1.00 < 1.00 < 1.00 < 1.00 
 
Table 3:  IC50 values (determined via MTT and SRB cytotoxic assays) of Pac/RAME-β-CD 
formulation combined with different compounds to evaluate their effect on its 
cytotoxic activity. The cell viability was determined at 37 °C using the CC531s cell 
line in a Pac concentration range of 1.00 -20.00 µg/ml. The replicate experiments (n 
= 2) of the SRB and MTT assay are presented as individual data sets. 
 
Figure 4 shows the average difference in viability between Pac/RAME-β-CD and 
Taxol® over the entire paclitaxel concentration range (1-20 µg/ml). Without HPPP added to 
the Pac/RAME-β-CD formulation or when 0.5 µM HPPP was added, the difference between 
both formulations was above 20 %. However, this was reduced to less than 10 % (indicating 
equipotent formulations) when 5 µM HPPP was used, demonstrating the effect of HPPP to 
enhance the activity of paclitaxel. At a concentration of 50 µM HPPP Pac/RAME-β-CD was 
more cytotoxic than Taxol®, but this was caused by the cytotoxic activity of HPPP itself.  
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Fig. 4: Mean (n = 5 concentrations and 8 wells per concentration) and standard deviation of 
the difference in cell viability (determined via MTT assay, n = 2) between Taxol® and 
Pac/RAME-β-CD. Cell viability at 37°C was tested over a concentration range of 1-20 
µg paclitaxel/ml using a CC531s cell line. Different concentrations (0, 0.5, 5 and 50 
µM) of HPPP      , Verapamil      and NB-DNJ      were combined with Pac/RAME-β-
CD to evaluate their effect on paclitaxel cytotoxicity. The replicate experiments (n = 
2) of the MTT assay are presented as individual data sets. 
 
In addition to HPPP, two other compounds (verapamil and NB-DNJ) were added to 
the Pac/RAME-β-CD formulation. Used at the same concentrations as HPPP, both did not 
increase the cytotoxicity of Pac/RAME-β-CD as neither compound lowered the IC50 values 
of Pac/RAME-β-CD (Table 3): verapamil and NB-DNJ had individual IC50 values above 50 
µM. Even a concentration of 500 µM NB-DNJ (a concentration capable of blocking all GCS 
activity) did not induce an effect. Combining Pac/RAME-β-CD with 0.5 and 5 µM C6-
ceramide showed no effect on cell viability, but at concentrations of 10, 30 and 50 µM 
Pac/RAME-β-CD became more potent compared to Taxol® (Table 3). The IC50 values of C6-
ceramide were about 50 µM for the MTT tests. In general, SRB data confirmed the MTT test 
(Table 3).  
A last series of experiments investigated the influence of the different compounds 
(verapamil, NB-DNJ, HPPP and C6-ceramide) on the activity of the P-gp efflux pump. 
Verapamil and NB-DNJ were tested at the highest concentration (50 µM), whereas HPPP and 
C6-ceramide were tested at a concentration of 5 and 10 µM, respectively. Only verapamil 
resulted in a retention ratio higher than 1.10: 23.07 at a concentration of 50 µM verapamil. 
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5.5. DISCUSSION 
 
Although Bouquet et al. (2009) previously concluded that Taxol® and the Pac/RAME-
β-CD formulation had a similar cytotoxic activity towards colon cancer cell lines of human 
and rat origin, the procedure previously used to evaluate the cytotoxicity of paclitaxel (over a 
concentration range from 0.01 to 10.00 µg/ml) might not be optimal to detect differences 
between potent cytotoxic agents as a low cell concentration (15 x 10³ cells per ml) and a long 
exposure time (96 hrs) of the cells to paclitaxel were used. Therefore this study further 
investigated the activity of Pac/RAME-β-CD complexes and Taxol® against the rat colon 
cancer cell line (CC531s) using a higher cell concentration at the time of administration and a 
shorter time of exposure to the drug (48 hrs). As a result of the different procedure a 
significant difference in cytotixicity between both formulations was detected: the 
concentration-dependent decrease of viability remained after exposure to Taxol®, whereas the 
cytotoxic effect of Pac/RAME-β-CD was not concentration dependent. At the highest 
paclitaxel concentration the viability was above 50% compared to a viability of 10 % for 
Taxol®.  
These observations can be correlated with the IC50 value of Cremophor EL® 
(<0.5mg/ml) and the paclitaxel/Cremophor EL® ratio (1/88, w/w) in Taxol®: at a paclitaxel 
concentration of 10 and 20 µg/ml (corresponding to Cremophor EL® concentrations of 0.9 
and 1.8 mg/ml), Cremophor EL® significantly contributed to the cytotoxic effect of Taxol®. 
As a result, the difference between Taxol® and Pac/RAME-β-CD only became apparent at 
these higher concentrations since RAME-β-CD (the excipient used to formulate the inclusion 
complexes) did not induce cell death based on its IC50 value (≥ 3.5 mg/ml) and the 
Pac/RAME-β-CD ratio (1/60, w/w) in the inclusion complexes. Other researchers also 
suggested that Cremophor EL® contributed to the cytotoxic effect of Taxol® (Fjällskogg et al., 
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1994; Reinecke et al., 2000). In contrast, Engblom et al. (1999) claimed that Cremophor EL® 
had no influence on cell viability, the maximum paclitaxel concentration tested in that study 
however was only 3 nM (equivalent to 0.22 µg/ml Cremophor EL®).  
Our results clearly indicated that the Pac/RAME-β-CD formulation has an antitumour 
effect which only depended on paclitaxel because its effect was similar to Pac dissolved in 
DMSO and RAME-β-CD itself was not cytotoxic at the applied concentrations. The 
concentration-independent effect on viability observed with Pac/RAME-β-CD and 
Pac/DMSO was due to P-gp protein efflux pumps present in the CC531s cells, reducing the 
sensitivity of the cancer cells towards paclitaxel.  
Since the discovery of increased levels of glucosylceramide in multidrug resistant cells 
(Lavie et al., 1996), ceramide and GCS inhibitors have gained attention as potential 
therapeutics in cancer management. Paclitaxel stresses the cell which induces the production 
of ceramide (Radin, 2003), but MDR cells decrease the levels of ceramide by transforming it 
to glucosylceramide by up-regulation of GCS and thus escaping apoptosis (Lavie et al., 1997). 
Combining Pac treatment with ceramide or a GCS inhibitor would increase intracellular 
ceramide levels, causing even MDR cells to go into apoptosis. In light of this view HPPP, a 
GCS inhibitor and PDMP analogue, was added to the Pac/RAME-β-CD solution. Addition of 
a non-cytotoxic concentration of 5 µM increased the cytotoxic potency of the Pac/RAME-β-
CD formulation. Other researchers reported similar results with PDMP (Bieberich et al., 
1999). Our research confirmed that a selective inhibition of GCS with NB-DNJ was not 
effective for improving paclitaxel activity (Bieberich et al., 1999; Veldman et al., 2003; 
Norris-Cervetto et al., 2004), which indicated - as suggested by Norris-Cervetto et al. (2004) - 
that the chemosensitization by PDMP is not solely caused by inhibition of GCS. Other 
researchers have recently shown other possible intracellular interactions of paclitaxel and 
ceramide (Qiu et al., 2006; Swanton et al., 2008). In addition, co-administration of 10 µM C6-
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ceramide to a Pac/RAME-β-CD formulation enhanced the cytotoxic activity of the 
Pac/RAME-β-CD formulation, showing that both exogenous ceramide addition or non-
selective GCS inhibition are effective methods to improve Pac cytotoxicity. 
MDR modulators like verapamil, that inhibit the P-gp efflux pump, have an effect on 
GCS activity and expression (Bleicher et al., 2002). Therefore, it was investigated if GCS 
inhibition by HPPP and NB-DNJ had an effect on the activity of the P-gp efflux pump. 
According to Liu et al. (2001) GCS targeting did not modify P-gp expression or Rho123 
efflux. However, Gouazé et al. (2005) found that blocking of GCS down-regulated P-gp. Our 
results indicated that only verapamil had an effect on the efflux of Rho123 as HPPP, NB-
DNJ, C6-ceramide had no effect on the retention ratio of Rho123. This indicated that HPPP 
did not affect P-gp activity. 
 
5.6. CONCLUSION  
 
The tumoricidal activity of a novel co-solvent-free and tensioactive-free cyclodextrin-
based paclitaxel formulation was only related to paclitaxel as the formulation excipient 
(RAME-β-CD) played no role in the cytotoxicity of the formulation. In contrast, the observed 
effect of Taxol® was in part due to the cytotoxicity of Cremophor EL® which is used to 
solubilise paclitaxel. The cytotoxic activity of the Pac/RAME-β-CD formulation was not 
concentration dependent as the P-gp efflux pumps in the colon cancer cell line induced 
multidrug resistance (MDR). Combining the Pac/RAME-β-CD complexes with HPPP, a 
novel PDMP analogue which inhibits glucosylceramide transferase, resensitized the MDR 
cells for paclitaxel. The mechanism for this higher efficiency in MDR cells is not related to an 
inhibition of the activity of the P-gp efflux pumps, but to its non-selective inhibition of GCS. 
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 IN VIVO TOXICITY AND BIOAVAILIBILITY OF 
TAXOL® AND A PACLITAXEL/β-
CYCLODEXTRIN FORMULATION IN A RAT 
MODEL DURING HIPEC 
 
 
6.1. ABSTRACT 
 
The spread of gastrointestinal or ovarian cancer to the peritoneum is a clinical 
condition associated with a high mortality and high morbidity. In recent years, hyperthermic 
intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery has emerged as a 
promising strategy in the management of peritoneal carcinomatosis (PC). A paclitaxel (Pac) 
formulation using randomly-methylated-β-cyclodextrins (RAME-β-CDs) to form a water 
soluble complex was previously developed for HIPEC application. In the current study, the in 
vivo toxicity and bioavailability of this formulation was compared in an in vivo rat model in 
comparison to Taxol®. The maximum tolerated dose (MTD) of both formulations as well as 
of β-cyclodextrins was determined. Blood parameters (red blood cell and white blood cell 
count, creatinine, ALT and GGT) were evaluated over a 20 day period. The bioavailability of 
both formulations was determined under normo- (37 °C) and hyperthermic (41 °C) 
conditions. 
Following HIPEC, both formulations had a similar MTD: 0.24 mg paclitaxel per ml. 
Red blood cell count decreased to a minimum after 10 days and was not fully recovered after 
20 days for both formulations. White blood cell monitoring showed an inflammatory state 
6 
following therapy with Pac/RAME-β-CD formulation at day 10 and 15. Liver and kidney 
parameters did not change significantly during the 20 day period. Bioavailability data of the 
inclusion complexes showed a 40-fold increase of the area under the curve (AUC) of the 
plasma concentrations for the Pac/RAME-β-CD formulation in comparison to Taxol®. 
Hyperthermia yielded no significant differences in bioavailability data. These results showed 
that both formulations had a similar toxicity profile but differed in bioavailability, establishing 
the bioavailability enhancing effect of cyclodextrins. 
 
6.2. INTRODUCTION 
 
Peritoneal carcinomatosis (PC) is present in 40 to 80 % of the patients with a terminal 
colorectal cancer (Koppe et al., 2006) and in a majority of patients diagnosed with ovarian 
cancer (Tan et al., 2006). Patients with PC have a low quality of life combined with a high 
morbidity and mortality (McQuellon et al., 2001). Systemic 5-fluorouracil-based 
chemotherapy offers a median survival of 5.2 to 12.6 months for patients diagnosed with PC 
(Koppe et al., 2006). In the last decennium, hyperthermic intraperitoneal chemotherapy 
(HIPEC) after debulking surgery was introduced as a curative approach for PC. An 8-year 
follow-up of a randomized trial in patients with PC of colorectal origin has recently shown a 
significant increase in the disease-specific survival from 12.6 to 22.2 months and a 5-year 
survival of 45 % for patients treated with HIPEC following complete cytoreduction (R-1) 
(Verwaal et al., 2008). One of the rationales behind HIPEC is the presence of the peritoneum-
plasma barrier which permits a higher exposure of peritoneal carcinoma nodes to 
chemotherapy: phase I studies have shown up to 1000-fold higher intraperitoneal (IP) levels 
compared to plasma levels after IP administration of paclitaxel (Markman et al., 2003). The 
combination of IP chemotherapy and hyperthermia during HIPEC is based on the synergism 
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of both and the direct cytotoxic effect of hyperthermia at temperatures above 41 - 42 °C 
(Wust et al., 2002). Hyperthermia can also increase drug uptake into the tumour tissue due to 
improved cell permeability (Witkamp et al., 2001).  
Paclitaxel (Pac), which binds and stabilizes the microtubuli, is a promising molecule 
for intraperitoneal chemotherapy. Due to its large molecular weight, absorption from the 
peritoneum is reduced. Another advantage is that Pac is rapidly cleared by the liver (Witkamp 
et al., 2001). However, local toxic effects like abdominal pain and life-threatening 
hypersensitivity reactions of the current Taxol® formulation have limited the use of paclitaxel 
and prompted the need for newer and safer paclitaxel formulations (Markman et al., 2003; 
Gelderblom et al., 2001). In previous research (Bouquet et al., 2007), a co-solvent- and 
tensioactive-free paclitaxel formulation was developed using randomly-methylated-β-
cyclodextrins (RAME-β-CD) to improve the water solubility of paclitaxel. These Pac/RAME-
β-CD complexes were dissolved in phosphate buffered saline solution with 0.1 % 
hydroxypropylmethylcellulose (HPMC) to produce stable solutions which can be used for 
HIPEC applications. In the current study, the Pac/RAME-β-CD formulation and Taxol® were 
used for a HIPEC procedure in rats to determine the maximum tolerated dose (MTD), general 
toxicity and bioavailability.  
 
6.3. MATERIALS AND METHODS 
 
6.3.1. Materials 
 
Randomly-methylated-β-cyclodextrin (RAME-β-CD) with a total degree of 
substitution (TDS) of 13 was purchased from Cyclolab (Budapest, Hungary), paclitaxel (Pac) 
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from Acros Organics (Geel, Belgium), Taxol® from Bristol-Myers Squibb (Brussels, 
Belgium).  
 
6.3.2. Preparation of the inclusion complexes 
 
The required amount of paclitaxel was dissolved in absolute ethanol (Merck, Overijse, 
Belgium), in a ratio of 1 to 60 (w/w). RAME-β-CD was added to the solution in a 1/20 
(mol/mol) Pac/RAME-β-CD ratio and the solution was placed in an ultrasonic bath (Sonis 3 
GT, Iskra-Pio, Šentjernej, Slovenia) for 5 min. Next, phosphate buffered saline (PBS) (Sigma, 
Bornem, Belgium) was added in a ratio of 1/2 (w/w) versus the RAME-β-CD fraction. Next, 
the solution was placed in an ultrasonic bath for 1 min and afterwards stirred with a magnetic 
stirrer for 5 min. After evaporation of most of the co-solvent under reduced pressure, the 
solution was frozen at -70 °C using solid carbon dioxide and freeze dried for 24 hrs at -50 °C 
and 1 mbar. After freeze drying, a powder, suitable for reconstitution, was obtained. The 
reconstitution medium consisted of phosphate buffered saline with 0.1 % 
hydroxypropylmethylcellulose (HPMC) (Metolose® 60SH-4000, Shin-Etsu, Tokyo, Japan). 
 
6.3.3. Determination of the paclitaxel concentration in the perfusate  
 
To ensure that an accurate amount of paclitaxel was delivered during HIPEC the 
compatibility of both formulations with different tubings was evaluated. Taxol® was tested in 
combination with Marprene® (Watson-Marlow, Zwijnaarde, Belgium), Pt-cured silicone 
(Pumpsil®, Watson-Marlow, Zwijnaarde, Belgium) , Tygon® (VWR, Leuven, Belgium) and 
Tygothane® (VWR, Leuven, Belgium), while Pac/RAME-β-CD was only tested in 
combination with Marprene® tubing. The paclitaxel solution (concentration: 0.24 mg/ml) was 
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circulated at 41 °C through the tubing using a roller pump (Watson-Marlow, flow rate: 30 
ml/min). Samples of the perfusate were collected at 0, 15, 30, 45 min. The samples were 
filtered through Spartan 30/0.2 RC filters (Whatman, Brussels, Belgium) and following 
appropriate dilution using PBS analysed by HPLC. The HPLC-system (Merck-Hitachi, 
Tokyo, Japan) consisted of a pump (L-6000,), an integrator (D-2000), an autosampler (L-
7200) with a 25 µL loop and a UV/VIS detector (L-4200). Detection was performed at a 
wavelength of 227 nm. Chromatographic separation was achieved with a guard column 
(Lichrospher® 100-RP-18, 4*4 mm (5µm), Merck, Darmstadt, Germany) and an analytical 
column (Lichrospher® 100-RP-18, 125*4 mm (5µm), Merck, Darmstadt, Germany). The 
mobile phase consisting of acetonitrile (Biosolve, Valkenswaard, The Netherlands) and 0.1% 
(v/v) phosphoric acid in water (Acros Organics, Geel, Belgium) (42:58, v/v) was degassed by 
ultrasonication under vacuum. A calibration curve was validated for a concentration ranging 
from 1 to 100 µg paclitaxel/ml. Stability is expressed in a percentage relative to the initial 
concentration at 0 min.  
 
6.3.4. Determination of paclitaxel plasma concentration 
 
For the determination of Pac plasma concentration during HIPEC, blood samples were 
collected at 0, 5, 10, 20, 40, 60 and 90 min in heparin containing tubes via a catheter in the 
jugular vein. The plasma samples were analysed at the Department of Pharmacy and 
Pharmacology (Netherlands Cancer Institute) according to a validated HPLC-MS/MS method 
(Stokvis et al., 2004). 
Briefly, 13C6-paclitaxel was added to the samples as an internal standard. Paclitaxel 
was extracted from the samples by a liquid-liquid extraction using tert-butyl methyl ether. 
After evaporation of the solvent, the sample was injected onto the analytical column. The 
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analytical column was a Zorbax Extend C18 column (150 x 2.1 mm i.d., particle size 5 µm) 
(Agilent Technologies, Palo Alto, USA), followed by chromatographic analysis using an 
eluent consisting of 10 mM ammonium hydroxide-methanol (30:70, v/v) with a flow rate of 
0.2 ml/min. Positive ionization electrospray tandem mass spectrometry was performed for 
selective and sensitive detection with an API 3000 triple quadrupole MS (Sciex, Tornhill, 
Canada). The resulting multiple reaction monitoring (MRM) chromatograms were used for 
quantification using Analyst 1.2. software (Sciex). The validated range for paclitaxel was 
from 0.25-1000 ng/ml using 200 µl plasma. AUC, Tmax and Cmax were calculated from the 
plasma concentration values with the MW-Pharm 3.0® software (Mediware® 1987-1991, 
Utrecht, The Netherlands). 
 
6.3.5. HIPEC procedure 
 
This experiment was approved by the ethical committee for animal testing of the 
Faculty of Medicine, Ghent University (ECD 03/23). Adult Wag/Rij rats (Harlan, Horst, The 
Netherlands) (body weight ≥ 270 g) were housed under the following conditions: ad libitum 
access to food and water, 12-hour day/night cycle and 24 °C as room temperature. The 
animals were anaesthetized with isoflurane (Forene®, Abbott, Louvain-La-Neuve, Belgium) 
and were subcutaneously injected with buprenorfine hydrochloride (0.3 mg/kg) (Temgesic®, 
Shering-Plough, Brussels, Belgium) except for the bioavailability study where no Temgesic® 
was used. An incision was made in the abdomen. Inlet and outlet tubing (Marprene® and 
Pumpsil® for Pac/RAME-β-CD and Taxol®, respectively) were placed in the peritoneal cavity 
for perfusion with the cytostatic solution during 45 min. The paclitaxel concentration in the 
solution was monitored with the method described above at 0,15, 30 and 45 min. A roller 
pump (Watson-Marlow®, Zwijnaarde, Belgium) circulated the perfusate at flow rate of 30 
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ml/min through a heat exchanger, ensuring a temperature of 37 or 41 °C for normo- and 
hyperthermic conditions, respectively. During perfusion, the body and perfusate temperature 
were closely monitored by thermosensors (ELLAB®, Roedovre, Denmark) and data were 
collected using E-Val® 2.10 software (ELLAB®, Roedovre, Denmark). After HIPEC, the 
solution was removed from the peritoneum and the incision was sutured.  
 
Illustration 1: HIPEC in a ratmodel. 
 
6.3.6. Maximum tolerated dose and toxicity study 
 
The maximum tolerated dose (MTD) of RAME-β-CD and both Pac formulations 
(Taxol® and Pac/RAME-β-CD complex) was defined as the highest non-lethal dose with a 
maximum reduction in body weight of 10% 2 weeks after HIPEC treatment. The test 
procedure was based on the Organisation for Economic Co-operation and Development 
(OECD) guidelines for testing of chemicals. Briefly, to determine MTD the concentration of 
the test substance (RAME-β-CD, Taxol® and Pac/RAME-β-CD) was gradually increased 
using one rat per concentration.  
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The influence of both formulations on blood parameters (i.e. red blood cell (RBC) 
count, white blood cell (WBC) count, creatinine, alanine amino transferase (ALT) and γ-
glutamyl transferase (GGT) concentration) was determined at the Laboratory of Clinical 
Biology (Ghent University Hospital). One ml blood was collected from the tail vein of the rat 
at 0, 5, 10, 15, 20 days post intervention. For RBC and WBC count, blood was collected in 
K2EDTA tubes (Vacutest®, Milian, Geneva). For RBC count 4.0 µL blood was analysed with 
flow cytometry (Sysmex® XE-2100-L, Norderstedt, Germany). WBC count was performed 
with 18 µL blood, pretreated with Stromatotlyser-FB® (Sysmex®, Norderstedt, Germany) for 
RBC lysis. For differentiation of WBC, 18 µL samples were pretreated with Stromatolyser 4-
DL® and Stromatolyser-DS®. Hereafter, all analyses of WBC were performed with 
fluorescent flow cytometry (Sysmex® XE-2100-L, Norderstedt, Germany). 
Creatinine, ALT and GGT concentrations were measured in serum. Creatinine 
determination was done via a colorimetric analysis based on the reaction of creatinine and 
picrine acid in an alkaline solution to form a creatinine-picrine acid complex. The absorption 
was measured with a Cobas 6000® c501 (Roche, Vilvoorde, Belgium) analyser. The ALT 
concentration was linked to its ability to catalyse the following reaction: α-ketoglutarate and 
L-alanine reacted to form L-glutamate and pyruvate. The pyruvate fraction was reduced by 
lactate dehydrogenase to lactate and NAD+. The absorption of the NAD+ was measured in the 
Cobas 6000® c501 analyser and allowed to measure the activity of ALT. The activity of GGT 
was based on its ability to catalyse the formation of 5-amino-2-nitrobenzoate from the 
reaction between L-γ-glutamyl-3-carboxy-4-nitroanilide and glycylglycine. The increase in 
absorption due to the formation of 5-amino-2-nitrobenzoate is measured with a Cobas 6000® 
c501 analyser. 
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6.3.7. Statistical Analysis 
 
Statistical Program for Social Scientists (SPSS 16.0) was used to analyse the results, 
using 0.05 as significance level. A repeated univariate analysis of variances was performed to 
investigate the time effect and the interaction between time and formulation (and temperature) 
on body weight, blood parameters or plasma concentration. Mauchly’s test of sphericity was 
used to test the homogeneity of the covariance matrices. In case this assumption was violated 
the Greenhouse-Geisser correction factor was used. A Bonferroni-corrected post-hoc analysis 
was performed to investigate all possible pairwise comparisons between the repeated 
measures in each treatment group and between the treatment groups at each time point. All 
other statistical analyses were performed using a two-sided one-way ANOVA. 
 
6.4. RESULTS  
 
6.4.1 Compatibility of paclitaxel formulations in different tubings 
 
After 45 min perfusion of the Pac/RAME-β-CD formulation under hyperthermic 
conditions using Marprene® tubing, 89 ± 1 % (n = 3) of the drug remained in the perfusate. In 
contrast, hyperthermic perfusion of Taxol® in Marprene® tubing only resulted in a residual 
paclitaxel fraction of 40 ± 2 % (n = 3). Using Pt-cured silicone (Pumpsil®), Tygon® and 
Tygothane® tubings for perfusion of Taxol® under the conditions encountered during the 
HIPEC procedure (41 °C, 45 min) resulted in a residual paclitaxel concentration equivalent to 
65 ± 7 %, 46 ± 13 % and 52 ± 4 % (n = 3), respectively, compared to the initial paclitaxel 
concentration. Based on these results Marprene® was used during HIPEC for delivery of the 
Pac/RAME-β-CD solution and Pumpsil® for Taxol®.  
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6.4.2. Maximum Tolerated Dose 
The maximum tolerated dose (MTD) of all compounds was determined using the 
HIPEC settings (41 °C, 45 min). MTD of RAME-β-CD (dissoloved in PBS) was set at a 
concentration of 10 mg/ml as no mortality was observed at this concentration and the weight 
loss was less than 10 % 2 weeks post intervention (Table 1). 
 
Compound Concentration (mg/ml) Mortality (%) Weight (%)* 
10.00 0 97 ± 2 % RAME-β-CD 
15.00 50 ND 
15.00 0 98 ± 3 % RAME-β-CD + 0.1 % 
HPMC (w/w) 20.00 50 ND 
Formulation Pac concentration (mg/ml) Mortality (%) Weight (%)* 
0.24 0 100 ± 7 % Taxol® 
0.30 50 ND 
0.24 0 95 ± 2 % Pac/RAME-β-CD  0.30 25 ND 
 
Table 1: Determination of maximum tolerable dose (MTD) of randomly-methylated-β- 
cyclodextrin (RAME-β-CD), RAME-β-CD + 0.1 % hydroxypropylmethylcellulose 
(HPMC), Taxol® and paclitaxel/RAME-β-CD (Pac/RAME-β-CD) complexes (1/20, 
mol/mol) in a hyperthermic peritoneal perfusion procedure in a rat (n = 4).  
* weight of a rat 14 days post treatment, expressed as a percentage of the initial body 
weight, ND: not determined 
 
As Pac/RAME-β-CD complexes are dissolved in PBS supplemented with 0.1 % (w/v) 
HPMC prior to HIPEC, the MTD of RAME-β-CD dissolved in this medium was also 
determined. This experiment indicated that the addition of HPMC allowed to increase the 
RAME-β-CD concentration to 15 mg/ml RAME-β-CD without encountering mortality. At a 
RAME-β-CD concentration of 20 mg/ml 50% mortality (n = 4) was observed (Table 1). No 
significant difference (p = 0.279) was seen between the weight curves of rats treated with a 10 
mg/ml RAME-β-CD solution in PBS or 15 mg/ml RAME-β-CD solution in PBS 
supplemented with 0.1 % HPMC.  
The study to determine the MTD of both Pac-formulations was started at a Pac 
concentration of 0.06 mg/ml and was stepwise increased with increments of 0.06 mg/ml. 
After treatment with Taxol® the mortality was 50 % (n = 4) at a Pac concentration of 0.3 
mg/ml, whereas the mortality after treatment with the Pac/RAME-β-CD complexes at the 
same concentration was 25 % (n = 4) (Table 1). Hence, 0.24 mg/ml was considered the MTD 
for both formulations. At this concentration, there was no significant difference (p = 0.194) 
between both treatments based on the weight curves of the rats.  
 
6.4.3. Blood parameters 
 
For both Pac formulations, the RBC count decreased significantly in function of time 
(p < 0.05) (Fig. 1). There was also a marginal significant difference (p = 0.046) between both 
paclitaxel formulations: pairwise comparison of the different time points only revealed a 
significant difference at day 10 and 15 (p-values < 0.05). The levels of lymfocytes were not 
significantly different over time and between both formulations (p = 0.241 and p = 0.275, 
respectively) (Fig. 1). The neutrocytes showed an interaction between time and the two 
formulations. Therefore, no general conclusions for both formulations could be drawn and 
both formulations were analysed with a Bonferroni post hoc test at each time point. HIPEC 
treatment with Taxol® had no significant effect on the neutrocyte count over the 20-day 
period (all p-values ≥ 0.05), whereas a significant difference was observed in case of 
Pac/RAME-β-CD complexes at day 10 and 15 compared to day 0 (p-values < 0.05). 
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Neutrocytes 
 
  
Fig. 1: White blood cell count (neutrocytes and lymfocytes), red blood cell count and serum 
creatinine concentration (mg/dl) in rats (n = 4) after HIPEC with Pac/RAME-β-CD 
and Taxol® using a paclitaxel concentration of 0.24 mg/ml. day 0; ■ day 5; ■ day 
10; ■ day 15 and ■ day 20. 
 
Serum samples were evaluated for their creatinine, ALT and GGT concentration. 
Creatinine levels showed no significant difference between Pac/RAME-β-CD and Taxol® (p = 
0.906) over the 20 day period. There was also no significant time effect (p = 0.615) for both 
formulations. Since GGT concentrations of about half of the samples of both formulations 
were below the detection limit of 3 U/L, the results of GGT were not statistically analysed. 
There was a marginal significant (p = 0.041) decrease of ALT in time, but more importantly 
no significant difference between the formulations was observed (p = 0.983). 
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6.4.4. Bioavailability study 
 
HIPEC was performed using a paclitaxel concentration of 0.24 mg/ml (previously 
determined as MTD). After 45 min the paclitaxel concentration in the perfusate amounted to 
62 ± 4 % and 61 ± 2 % (n = 3) of the initial concentration when the Pac/RAME-β-CD 
solution was perfused using the in-vivo settings at normo- and hyperthermic conditions, 
respectively. Similar results were obtained after perfusion of Taxol®: 61 ± 7 % and 61 ± 8 % 
(n = 6) for normo- and hyperthermic conditions, respectively.  
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Fig 2: Paclitaxel plasma concentration (ng/ml) in rats (n = 6) after intraperitoneal perfusion 
using different solutions at a paclitaxel concentration of 0.24 mg/ml and at 
normothermic (37 °C) and hyperthermic (41 °C) conditions: Taxol, normothermic, 
Taxol, hyperthermic, ▲Pac/RAME-β-CD, normothermic and ■ Pac/RAME-β-CD, 
hyperthermic. 
 
Plasma concentrations of paclitaxel were monitored during 90 min (i.e. 45 min during 
and 45 min after HIPEC). The average plasma concentrations (Fig. 2) showed large 
differences between Taxol® and Pac/RAME-β-CD and statistical analysis of the individual 
plasma concentrations indicated a significant interaction between three factors (time, 
formulation and temperature) (p-value < 0.05); therefore the simple effect of each factor was 
investigated at a specific level of another factor via a Bonferroni post hoc test. This analysis 
confirmed that at both temperatures (37 and 41 °C) the plasma values of Pac/RAME-β-CD 
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were significantly higher than those of Taxol® (both p-values equal to 0.000). Investigating 
the effect of temperature on both formulations showed that temperature had no significant 
influence (p = 0.993) on Taxol®, whereas there was a marginal significant effect for 
Pac/RAME-β-CD (p = 0.040).  
The pharmacokinetic parameters (AUC0-90min, Cmax, ratio between AUCIP and 
AUCplasma during perfusion) after HIPEC are summarized in Table 2. Intraperitoneal 
perfusion with Pac/RAME-β-CD complexes resulted at both temperatures in a significantly 
higher Cmax and AUC0-90min compared to Taxol® (p-values < 0.05). One-way ANOVA 
showed no significant difference of AUC and Cmax between normo- and hyperthermic 
treatment with Taxol® (p-values of 0.638, 0.617 and 0.341, respectively) and Pac/RAME-β-
CD complexes (p-values of 0.757, 0.076 and 0.073, respectively). Hyperthermia also had no 
significant effect on the ratio of intraperitoneal and plasma AUC’s after administration of both 
formulations (p-values of 0.654 and 0.185 for Taxol® and Pac/RAME-β-CD, respectively). 
 
 
Formulation Temperature 
(°C) 
AUC0-90min 
(mg/ml)*min 
Cmax 
(mg/ml) 
AUC ratio*
Taxol® 37 2.80 ± 0.83 0.05 ± 0.01 10441 ± 4249 
Taxol® 41 3.03 ± 0.82 0.05 ± 0.02 9542 ± 2155 
Pac/RAME-β-CD 37 122 ± 66 1.91 ± 1.00 276 ± 59 
Pac/RAME-β-CD 41 134 ± 72 2.73 ± 0.54 177 ± 181 
 
Table 2: Pharmacokinetic parameters (mean ± standard deviation, n=6) after intraperitoneal 
perfusion for 90 min with paclitaxel solutions (using a paclitaxel concentration of 
0.24 mg/ml) at normothermic (37 °C) and hyperthermic (41 °C) conditions.  
*AUC ratio of intraperitoneal concentration and plasma concentration over a 40 min 
period. 
 
 
 
6.5. DISCUSSION 
 
For IV administration of Taxol® it is recommended to use polyvinylchloride (PVC)-
free infusion sets due to the leaching of diethylhexylphthalate (used as plasticiser for PVC), 
which is primarily caused by Cremophor EL® (Allwood et al., 1996). The low recovery of 
paclitaxel after perfusion of Taxol® in Marprene® tubing was probably also due to an 
interaction of the formulation with the tubing as a white deposit was formed inside the tubing. 
This adsorbed layer did not dissolve in water, but was soluble in DMSO. HPLC analysis 
confirmed the presence of Pac in this DMSO solution. The Pac/RAME-β-CD formulation had 
a better compatibility with Marprene® tubing at normo- and hyperthermic conditions since the 
recovery of paclitaxel was comparable to the in vitro stability data of Pac/RAME-β-CD 
complexes (± 80 %) reported by Bouquet et al. (2007). To ensure that a sufficient dose of 
paclitaxel was delivered during HIPEC perfusion of Taxol®, tubings composed of different 
materials were tested. A Pt-cured silicone tubing (Pumpsil®) yielded the best results. 
Although this was slightly lower than the stability of Pac/RAME-β-CD, the in vivo stability 
of both formulations was similar (as indicated by the paclitaxel concentration in the 
perfusate). The current results stress the importance of selecting the appropriate material to 
deliver Taxol® in a HIPEC setting in order to ensure that the appropriate dose is delivered to 
the patient. 
Before bioavailability testing, the MTD of both paclitaxel formulations after HIPEC 
was determined. In addition the safety of RAME-β-CD was also evaluated as to our 
knowledge, the MTD of RAME-β-CD for HIPEC administration has not been documented. 
As the MTD of a RAME-β-CD solution increased from 10 to 15 mg/ml when 0.1 % (w/w) 
HPMC was added to the aqueos solution, it is obvious that HPMC is not only beneficial for 
the aqueous stability of Pac/RAME-β-CD complexes (Bouquet et al., 2007). The MTD of 
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Taxol® and the Pac/RAME-β-CD formulation in the HIPEC setting was set at a paclitaxel 
concentration of 0.24 mg/ml (equivalent to 0.28 mM). Taking the body surface area (BSA) of 
a rat (BSA (cm²) = 9.1 x g0.66, Baker et al., 1979) and the total perfusate volume (100 ml) into 
account, a maximum dose of approximately 65 mg/m² can be tolerated by the rats when 
HIPEC is performed with these formulations. To our knowledge, this is the first determination 
of the MTD of paclitaxel for HIPEC in rats, but this dose was lower than the dose (175 
mg/m²) administered to humans in a clinical pharmacokinetic trial of HIPEC therapy (de Bree 
et al., 2008). Paclitaxel has also been administered IP in clinical trials via instillation therapy. 
In these trials doses ranged between 20 and 175 mg/m² (de Bree et al., 2006). The 
intraperitoneal MTD determined in rats (0.28 mM) clearly underlined the pharmacokinetic 
advantage of HIPEC as only concentrations in the nanomolar range were obtained after IV 
therapy (de Bree et al., 2006).  
Although specific cyclodextrins (2-hydroxypropyl-β-cyclodextrin and 
sulphobutylether β-cyclodextrin (Rajewski et al., 1995; Gould and Scott, 2005) have been 
investigated extensively and are considered safe for parental use, there have been concerns 
about the safety (nephrotoxicity and hemolysis) of other cyclodextrins used for parental 
delivery (Frank et al., 1976; Irie and Uekama, 1997; Loftsson and Duchêne, 2007). Therefore 
blood parameters were evaluated after IP administration of RAME-β-CD-containing 
paclitaxel formulations as absorption of RAME-β-CD following IP administration could 
hamper its use for HIPEC application. Although no histopathological study of the kidneys 
was done creatinine levels indicated no modification of the kidney function. The initial 
decrease in RBC count (to a minimum value at day 10) observed for both formulations is 
probably linked to the surgical procedure. The normal RBC level however was not restored at 
day 20 for both formulations. The marginal but significant difference in RBC count between 
both formulations can be due to the significantly higher plasma concentrations of paclitaxel 
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after HIPEC with Pac/RAME-β-CD complexes as paclitaxel, like most cytostatic agents, has 
an influence on RBC count The constant serum ALT levels indicated that no liver toxicity 
was encountered.  
Based on the in vitro toxicity data reported by Bouquet et al. (2009) it was surprising 
that Taxol® and Pac/RAME-β-CD had a similar MTD as in vitro experiments had shown that 
Cremophor EL® was more cytotoxic than RAME-β-CD against different colon cancer cell 
lines. The similarity in MTD can be linked to the difference in paclitaxel plasma 
concentration observed after HIPEC therapy using both formulations. It has previously been 
described that Cremophor EL® significantly reduced the bioavailability of paclitaxel after IP 
injection  by the micellar entrapment of the drug (Gelderblom et al., 2002). Even IV, this 
entrapment had an influence on the blood/plasma distribution ratio (Sparreboom et al., 1999). 
A beneficial effect of this slow release of paclitaxel from the micelles is a reduced toxicity, 
but the entrapment of paclitaxel in micelles also suppressed its permeation into tumor tissue 
(Yokogawa et al., 2004). Poor tumor penetration is a possible drawback of IP therapy 
(Dedrick and Flessner, 1997), eliminating the advantage of placing the tumour in direct 
contact with high concentrations of the cytostatic drug. In this respect the inclusion complex 
of paclitaxel has a pharmacokinetic advantage as cyclodextrins are known to enhance the 
solubility and bioavailability of poorly soluble drugs (Davis and Brewster, 2004). Moreover, 
they are known as permeability enhancers (Rajewski and Stella, 1996). The high plasma 
levels observed in this study clearly showed that cyclodextrins enhance the bioavailability and 
permeability of IP administered drugs. In contrast, IP administration of paclitaxel nano- and 
microparticles yielded a similar or slower absorption in comparison to Taxol® (Tsai et al., 
2007). What impact the different bioavailability has on the therapeutic efficiency of both 
formulations will be investigated via a tumor growth delay study.  
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The use of hyperthermia is not only based on the direct cytotoxic effect of heat; it can 
also enhance the efficacy and tumour penetration of cytostatic drugs (Witkamp et al., 2001). 
However, in this study no significant influence of temperature on the bioavailability data was 
observed, indicating that there is no effect of temperature on the permeation of paclitaxel 
through the peritoneum. As previous in vitro toxicity data showed no influence of 
hyperthermia on the cytotoxic activity of Pac/RAME-β-CD and Taxol® (Bouquet et al., 
2009), a possible additive effect of heat on tumour growth delay will have to come from its 
direct cytotoxic action.  
 
6.6. CONCLUSION  
 
Evaluation of the toxicity of Taxol® and Pac/RAME-β-CD complexes during HIPEC 
therapy in a rat model indicated that the maximum tolerated dose of both formulation was 
similar (0.24 mg paclitaxel/ml), despite the different in-vitro toxicity of the excipients used in 
the dosage forms (Cremophor EL® vs. RAME-β-CD). Blood parameters showed 
inflammation in rats treated with Pac/RAME-β-CD in comparison to Taxol®. The 
bioavailability of paclitaxel after HIPEC at normo- and hyperthermic conditions using 
Pac/RAME-β-CD complexes was significantly higher in comparison to Taxol®. Hyperthermia 
had no significant influence on the bioavailability of both formulations. 
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 PREMILINARY EVALUATION OF THE TUMOUR 
GROWTH DELAY IN A RAT MODEL 
FOLLOWING HIPEC WITH TWO PACLITAXEL 
FORMULATIONS 
 
 
7.1. ABSTRACT 
 
Peritoneal carcinomatosis (PC) remains a dreaded clinical syndrome, common to the 
evolution of gastrointestinal and ovarian cancers. In the last years, a new treatment modality 
consisting of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) 
has given new hope to PC patients. For this treatment, a cyclodextrin-based paclitaxel 
formulation was developed and previously evaluated for bioavailability and maximum 
tolerated dose in healthy rats. In the current investigation, the feasibility of a tumour growth 
delay study in rats with a PC of colorectal origin via positron emission tomography (PET) and 
magnetic resonance imaging (MRI) was evaluated. Based on the preliminary results (3 rats 
per treatment group), a study protocol was established. From the limited information available 
in the current data set, some trends were emerging: (a), hyperthermia does not have a 
beneficial effect on the activity of paclitaxel, (b) the cyclodextrin-based formulation 
performed better and was the only formulation so far capable of producing a significant 
decrease in tumour volume 2 days post treatment. Based on these preliminary data a study 
using 6 rats per treatment group will be initiated to generate conclusive results about the effect 
7 
of Taxol® and Pac/RAME-β-CD complexes on tumour growth delay following HIPEC at 
normo- and hyperthermic conditions. 
 
7.2. INTRODUCTION 
 
Peritoneal carcinomatosis (PC) is in most cases a secondary cancer. For example, PC 
is present in up to 80 % of patients with terminal colorectal cancer (Koppe et al., 2006) and 
peritoneal spread is diagnosed in the majority of ovarian cancer patients (Tan et al., 2006). 
Pseudomyxoma peritonei, a specific type of PC (Smeenk et al., 2007), is mostly caused by the 
spread of an appendiceal tumour to the peritoneum. PC is associated with poor prognosis and 
quality of life, and often treatment is limited to palliative care with patients having a median 
survival of 6 months (Chu et al., 1989). 
However, the combination of cytoreductive surgery and hyperthermic intraperitoneal 
chemotherapy (HIPEC) has shown promising results for the treatment of PC (Verwaal et al., 
2003). Recently, an 8-year follow-up study in patients with PC of colorectal origin has 
indicated a significant increase in survival after HIPEC (Verwaal et al., 2008): 5-year survival 
in 45 % of fully resected patients. This treatment procedure in combination with complete 
cytoreduction offers new hope to PC patients.  
HIPEC combines the cytotoxic actions of hyperthermia and chemotherapy, offering a 
synergistic antitumoral effect in some cases (oxaliplatin, mitomycin, doxorubicin and 
cisplatin) (Glehen et al., 2004) and resulting in higher drug concentration at the cancer 
nodules compared to intravenous administration.  
In previous research (Chapter 6), the maximum tolerated dose (MTD), following 
HIPEC, was determined at 0.24 mg/ml or 0.28 mM paclitaxel in a rat in vivo model (Wag/Rij 
rats). This largely exceeded the paclitaxel concentration obtained in humans after IV 
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administration which are in the nanomolar range. A similar observation was made following 
intraperitoneal and intravenous administration of paclitaxel to humans during a Phase I 
clinical trial as the IP concentration was 1000-fold higher than the IV concentration 
(Markman, 2003).  
For the accurate assessment of peritoneal cancers, laparotomy and laparoscopy are still 
considered as the golden standards. However, the invasive nature of these procedures requires 
more animals and increases surgical stress to the animals. Therefore, this study monitors the 
growth of a macroscopic tumour (induced in the peritoneal cavity of rats) in function of time 
using MRI (to obtain anatomical data) and PET (to obtain information about the metabolic 
status of the tumour tissue) for repeated evaluation of the tumour in the same test animals. 
Following the development (Bouquet et al., 2007), in vitro (Bouquet el al., 2009) and in vivo 
toxicity testing and bioavailability study (Chapter 5), the tumour growth delay (TGD) in a rat 
model for colon cancer was determined following (normo- and hyperthermic) intraperitoneal 
administration of different paclitaxel formulations. This chapter describes the preliminary 
evaluation of tumour response following IP administration of paclitaxel using magnetic 
resonance imaging (MRI) and positron emission tomography (PET) to visualize the tumour. 
The information obtained during this study will form the basis of an extensive TGD study. 
 
7.3. MATERIALS AND METHODS 
 
7.3.1. Materials 
 
Randomly-methylated-β-cyclodextrin (RAME-β-CD) with a total degree of 
substitution (TDS) of 13 was purchased from Cyclolab (Budapest, Hungary), paclitaxel (Pac) 
Chapter 7  Preliminary evaluation of the tumour growth delay in a rat model  
   following HIPEC with two paclitaxel formulations. 
131
from Acros Organics (Geel, Belgium), Taxol® from Bristol-Myers Squibb (Brussels, 
Belgium).  
 
7.3.2. Preparation of the inclusion complexes 
 
The required amount of paclitaxel was dissolved in absolute ethanol (Merck, Overijse, 
Belgium), in a ratio of 1 to 60 (w/w). Randomly-methylated-β-cyclodextrin (RAME-β-CD) 
was added to the solution in a 1/20 (mol/mol) Pac/RAME-β-CD ratio and the solution was 
placed in an ultrasonic bath (Sonis 3 GT, Iskra-Pio, Šentjernej, Slovenia) for 5 min. Next, 
phosphate buffered saline (PBS) (Sigma, Bornem, Belgium) was added in a ratio of 1/2 (w/w) 
versus the RAME-β-CD fraction. Next, the solution was placed in an ultrasonic bath for 1 min 
and afterwards stirred with a magnetic stirrer for 5 min. After evaporation of most of the co-
solvent under reduced pressure, the solution was frozen at -70°C using solid carbon dioxide 
and freeze dried for 24 h at -50°C and 1 mbar. After freeze drying, a powder for reconstitution 
was obtained. The reconstitution medium consisted of phosphate buffered saline with 0.1 % 
hydroxypropylmethylcellulose (HPMC) (Metolose® 60SH-4000, Shin-Etsu, Tokyo, Japan). 
 
7.3.3. HIPEC procedure 
 
This study was approved by the ethical committee for animal tests of Faculty of 
Medicine (Ghent University, ECD 03/23). Adult Wag/Rij rats (Harlan, Horst, The 
Netherlands) of at least 270 g body weight were kept under the following conditions: access at 
libitum to food and water, 12-hour day-night cycle and 24°C room temperature. The animals 
were anaesthetized with isoflurane (Forene®, Abbot, Louvain-La-Neuve, Belgium). An 
incision was made in the abdomen and in- and outlet tubings (Marprene® and Pumpsil® 
Chapter 7  Preliminary evaluation of the tumour growth delay in a rat model  
   following HIPEC with two paclitaxel formulations. 
132
(Watson-Marlow, Zwijnaarde, Belgium) for Pac/RAME-β-CD and Taxol® administration, 
respectively) were placed in the peritoneal cavity for perfusion with the cytostatic solution 
during 45 min. A roller pump (Watson-Marlow®, Zwijnaarde, Belgium) circulated the 
perfusate at a flow rate of 30 ml/min through a heat exchanger, ensuring a temperature of 
37°C (normotherm) or 41 °C (hypertherm). During the perfusion body and perfusate 
temperature were closely monitored by thermosensors (ELLAB®, Roedovre, Denmark) and 
data was collected using E-Val® 2.10 software (ELLAB®, Roedovre, Denmark). After the 
HIPEC procedure, the solution was removed from the peritoneum and the incision was 
sutured. 
 
Illustration 1: HIPEC in a ratmodel 
 
The Pac concentration in the perfusion solution used for the HIPEC procedure was 
monitored (at 0, 15, 30 and 45 min) using a validated HPLC-UV/VIS method. All samples 
were filtered through a 0.22 µm filter (Spartan 30/0.2 RC) (Schleicher & Schuell, Dassel, 
Germany) and analysed by HPLC (following appropriate dilution using PBS). The HPLC-
system (Merck-Hitachi, Tokyo, Japan) consisted of a pump (L-6000), an integrator (D-2000), 
an autosampler (L-7200) with a 25 µL loop and a UV/VIS detector (L-4200). Detection was 
performed at a wavelength of 227 nm. Chromatographic separation was achieved with a guard 
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column (Lichrospher® 100-RP-18, 4*4 mm (5µm), Merck, Darmstadt, Germany) and an 
analytical column (Lichrospher® 100-RP-18, 125*4 mm (5µm)). The mobile phase consisting 
of acetonitrile (Biosolve, Valkenswaard, The Netherlands) and 0.1% (v/v) phosphoric acid in 
water (Acros Organics, Geel, Belgium) (42:58, v/v) was degassed by ultrasonication under 
vacuum. A calibration curve was validated for a concentration ranging from 1 to 100 µg 
paclitaxel/ml. 
 
7.3.4. Tumor model 
 
A CC531s rat colon adenocarcinoma cell line was obtained from the Laboratory of 
Experimental Oncology (University Antwerp, Belgium). The cell line was grown in culture 
flasks (Sarstedt, Newton, NC, USA) at 37 °C in a humidified atmospehere with 5 % CO2 
using RPMI 1640 medium, buffered with HEPES (20 mM) (Invitrogen Corporation®, Gibco®, 
Ghent, Belgium) and supplemented with 10 % fetal calf serum, 4 mM L-glutamine, 50 U/ml 
penicillin and 50 µg/ml streptomycin. Confluent cells were detached with trypsin/EDTA 
(Invitrogen, Zwijnaarde, Belgium) and vitality was evaluated with trypan blue (Sigma). Cell 
suspensions with a cell concentration of 2,000,000 cells in 0.2 mL PBS were injected 
subcutaneously in the upper hind leg of Wag/Rij rats to induce a tumour. After 4 weeks, 
tumors of about 1 cm size were prelevated and tissue samples (5 x 5 mm, with 2-3 mm 
thickness) were transplanted on the parietal peritoneum (covering the abdominal muscle) of a 
new rat.  
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7.3.5. Tumour imaging 
 
Tumour characteristics were evaluated using PET and MRI imaging 6, 9 and 14 days 
after implantation of the tumour. HIPEC treatment with paclitaxel was performed 7 days after 
implantation. For both imaging techniques rats were anaesthetized with xylazine (Xyl-M 2 %, 
VMD, Arendonk, Belgium) and ketamine (Ketamine 100, CEVA Santé Animale, Brussel, 
Belgium) using a concentration of 10 mg/kg and 90 mg/kg, respectively. Animals were 
divided into 6 groups which were treated with different HIPEC procedures (normo- vs. 
hypertherm) and different formulations (Taxol® vs. Pac/RAME-β-CD complexes): (a) 
Taxol®-37 °C, (b) Taxol®-41 °C, (c) Pac/RAME-β-CD-37 °C, (d) Pac/RAME-β-CD-41 °C, 
(e) blank control group which received no treatment, (f) HIPEC control group which received 
HIPEC treatment at 41.5°C using phosphate buffered saline as perfusion solution.  
 
7.3.5.1. Determination of tumor activity via PET  
Tumor growth in the peritoneal cavity of rats was monitored by positron emission 
tomography (PET) imaging after the administration of 2-(fluorine-18)-fluoro-2-deoxy-D-
glucose (FDG) using a Philips® PET Allegro (Philips Medical Systems®, Cleveland, USA) 
(Illustration 2). The spatial resolution of this system ranges from 5-6 mm FWHM (Full-Width 
Half-Maximum). The Allegro scanner (Suleman et al, 2004) is a whole-body 3D PET scanner 
using 4x6x20 mm³ gadolinium oxyorthosilicate (GSO) crystals. The physical diameter is 82.0 
cm and the axial field of view is 18 cm without interplane septa. The transaxial field of view 
(FOV) of the system is 576 mm and the axial FOV is 180 mm. The injected acitivity ranged 
from 200 to 700 µCi and all images were appropriately normalized. During PET acquisition, 
the emission time was 15 minutes. To get quantitatively comparable values of the signal 
intensities from different acquisitions, an appropriate decay correction and image analysis was 
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applied, using MATLAB® (Mathworks, MA, USA) as image processing toolbox. The latter 
method consists of creating a virtual slice presenting maximum values along the axis 
perpendicular to the coronal plane (maximum intensity projection). These images were 
filtered using a mean filter of 13 x 13 kernel width. Regions of interest (ROI) around heart 
and the tumor were drawn to calculate the ratio of the maxima within these ROI’s. 
 
7.3.6.2. Determination of tumor volume via MRI 
Complementary anatomical information about the tumour was acquired with a 
Siemens® Trio 3T MRI (Erlangen, Germany) using a T1-weighted 3D FLASH sequence. The 
rats were placed head first and prone in a (wrist) coil to measure the tumor volume. The MRI 
Trio is a clinical whole-body scanner with a bore size of 60 cm. The highest homogeneity is 
0.3 ppm Vrms (Volts root mean square) over 40 DSV (diameter spherical volume). The 
maximum gradient strength is 40 mT/m and has a slew rate of 200 T/m/sec. The wrist coil is a 
circulary polarized no-tune transmit/receive coil normally used for joint examinations of 
wrist, hand and fingers. The aforementioned sequence involved a flip angle of 10°, a 
repetition time (TR) of 13 ms and echo time (TE) of 4.9 ms to obtain a voxel size of 0.19 x 
0.19 x 0.4 mm³. In order to easily locate the tumor, the rat was palpated and a vitamin B12 
pellet was attached to the skin. Tumor volume was defined by creating a volume of interest 
(VOI) consisting of a stack of planar ROI’s (using PMOD software, PMOD Technologies, 
Adliswil, Switserland). 
 
7.3.7. Statistical Analysis 
 
Statistical Program for Social Scientists (SPSS 16.0) was used to analyse the results. 
Data of day 6 were used as reference (100 %) in the PET and MRI study. The different 
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treatment groups were compared with each other on day 9 and day 14 using a one-way-
ANOVA. A significance level of 0.05 was used. Bonferroni post-hoc analysis was performed 
for pairwise comparisons between the treatment groups. Differences between the day 9 and 14 
time points for each treatment group was tested using a paired samples t-test with a 
significance level of 0.05. 
 
7.4. RESULTS  
 
7.4.1 Treatment characteristics 
 
All treatments were well tolerated: no mortalities occurred and 2 weeks post treatment 
all rats had recovered to at least 95 % of their starting weight.  
After a 45 min HIPEC procedure with Taxol®, 77 ± 12 % and 70 ± 9 % (n = 3) of the 
paclitaxel concentration remained in the perfusate at normo- and hyperthermic conditions, 
respectively. Paclitaxel concentrations at the end of the HIPEC procedure with Pac/RAME-β-
CD were 74 ± 5 % and 58 ± 9 % (n=3) of the initial concentration at normo- and hyperthermic 
conditions, respectively. 
 
7.4.2. Tumour Growth Delay 
Tumour data obtained at day 6 (one day prior to treatment) were considered as 
reference values and the measurements at day 9 and 14 post implantation (i.e. 2 and 7 days 
after HIPEC treatment) were expressed as a percentage of these values.  
Tumours were evaluated via MRI and PET on day 9 and 14 as tumour activity in the 
blank control group (i.e. without treatment) decreased at day 21 due to necrosis. PET data 
indicated that the tumour activity had increased to a maximum of 167 ± 22 % (n=3) at day 14 
Chapter 7  Preliminary evaluation of the tumour growth delay in a rat model  
   following HIPEC with two paclitaxel formulations. 
137
but had dropped to 113 ± 37 % after 21 days. The same evolution was seen on MRI: a tumour 
volume of 153 ± 19 % at day 14 and 130 ± 100 % at day 21. The large variation at day 21 was 
due to a tumour that continued to increase in volume in one rat. In general, results of PET and 
MRI confirmed each other, showing a similar evolution of the tumour.  
 
7.4.2.1. PET imaging  
 
 
Fig. 1: Axial view of a rat with peritoneal cancer (black arrow); head and tail of rat are at the 
bottom and top of image, respectively, and the heart is indicated by the white arrow. 
 
At day 9 no significant differences were detected between the average FDG activity 
measured in the different treatment groups (Fig. 1). Although the tumour activity at day 9 
dropped for some formulations below 100 % (i.e. blank HIPEC procedure, Taxol®-37 °C and 
Pac/RAME-β-CD-37 °C) while the activity increased in the other groups, these observations 
were not significant due to the large variability (standard deviations between 20 and 40 %). 
On day 14 the tumour activity in rats without treatment had increased to 167 ± 22 % 
(Fig. 2), but again no significant differences were observed between the 6 groups (p-values ≥ 
0.05).  
None of the 6 treatments showed a significant difference between day 9 and 14 (p-
values ≥ 0.05). On both days there was also no significant difference between normo- and 
hyperthermic administration of both formulations (p-values of 1). 
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Fig. 2: Tumour activity (%), measured via PET imaging, 2 (   ) and 7 (   )  days post treatment 
in rats without paclitaxel treatment (Blank, HIPEC) and in rats having different 
paclitaxel treatments: Taxol®-37 °C, Taxol®-41 °C, Pac/RAME-β-CD-37 °C and 
PAC/RAME-β-CD-41 °C) (n = 3). Blank = no treatment; HIPEC = hyperthermic 
perfusion with saline. 
 
 
7.4.2.2. MRI 
 
Fig.3: Radial MRI image of rat with peritoneal cancer (white arrow) (abdomen at bottom of 
image). 
 
The tumour volume in the blank control group increased to 140 and 153 % on day 9 
and 14, respectively. At day 9, all treatment groups had a reduction in tumour volume but 
only two groups (Pac/RAME-β-CD 37 °C and 41°C) differed significantly from the blank 
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control group (p-values of 0.044 and 0.022, respectively). The other groups had a non-
significant reduction of tumour volume (Fig. 4). 
On day 14 no significant differences between the different treatments were detected, 
although treatment with Pac/RAME-β-CD formulation at 37 and 41 °C resulted in tumour 
reduction. Remarkably, the smallest tumour volume was observed for the HIPEC control 
group (69 ± 30 % )(Fig. 4).  
Despite the initial tumour reduction on day 9 after hyper- and normothermic Taxol® 
treatment the tumour volume had increased at day 14: 141 and 108 %, respectively. However, 
only for rats treated with Taxol® at hyperthermic conditions (41 °C) the increase of tumour 
volume at day 14 was significantly different (p = 0.018) compared to day 9. For both 
formulations no significant difference was detected in function of temperature (p-values of 1). 
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Fig.4: Tumour volume (%), measured via MRI scan, 2 (   ) and 7 (   ) days post treatment in 
rats without paclitaxel treatment (Blank, HIPEC) and in rats having different 
paclitaxel treatments: Taxol-37 °C, Taxol-41 °C, Pac/RAME-β-CD-37 °C and 
PAC/RAME-β-CD-41 °C) (n = 3). Blank = no treatment; HIPEC = hyperthermic 
perfusion with saline. 
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7.5. DISCUSSION 
 
Since this preliminary study was intended to determine the feasibility of a tumour 
growth delay study using PET and MRI as monitoring tools, a number of essential aspects 
were evaluated in this chapter: 
- Tolerance of rats with an implanted intraperitoneal tumour towards the surgical 
HIPEC procedure and administered paclitaxel dose. The indicators (mortality and 
recovery of weight) confirmed the tolerance of the rats for the HIPEC procedure. 
- Stability of paclitaxel solutions during HIPEC procedure. Since at the end of 
the HIPEC procedure a large fraction of the initial paclitaxel concentration was 
recovered in the perfusate, a consistent dose of paclitaxel will be intraperitoneally 
delivered to the rats. 
- Time points for PET and MRI analysis to monitor tumour growth. As 
autonecrosis of the peritoneal tumour was observed 21 days after implantation, 
evaluation of tumour growth was set at day 9 and 14 (i.e. 2 and 7 days after HIPEC). 
- Number of test subjects required per treatment group. Based on the variability 
of the data obtained during this preliminary study it is predicted that increasing the 
number of rats per group to 6 will provide sufficient power (> 80 %, Table 1) for 
statistical analysis (except for analysis of PET data at day 9 as one value obtained 
during this preliminary study is probably an outlier). This indicated that using PET 
and MRI as evaluation tools allowed to reduce the number of test animals during a 
TGD study since the same animal can be used to determine the TGD. 
- Resolution of MRI and PET scans. A sufficient resolution for accurate 
visualisation of the tumour was obtained using a wrist coil MRI designed for human 
applications. Tumour volume was determined using a human PET, which already 
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provided sufficient resolution. However, future experiments will be performed using a 
PET for small animals (µPET), enhancing the resolution. 
 
Power in function of the 
number of test subjects 
 
n = 3 n = 6 
PET at day 9 0.203 0.490 
PET at day 14 0.489 0.918 
MRI at day 9 0.821 0.998 
MRI at day 14 0.563 0.956 
 
Table 1:  Post hoc calculated (n=3) and estimated (n=6) (based on the same variation) power 
of ANOVA analysis in function of the number of animals per treatment group.  
 
Although only a limited number of significant differences were detected in this 
preliminary study due to the small number of test subjects and the large variability (resulting 
in a low power of the ANOVA, Table 1) some trends were emerging: 
- hyperthermic treatment with PBS (i.e. blank HIPEC procedure) reduced the 
tumour activity and volume which confirmed the well known cytotoxic activity of heat 
(Wust et al., 2002; Sugarbaker, 2007).  
- no synergism between the cytotoxicity of paclitaxel and hyperthermia was 
observed. This could not be statiscally confirmed due to the low power of this study, 
but is in accordance with previous results which showed that heat had no effect on the 
in vitro cytotoxicity of paclitaxel (Bouquet et al., 2009) nor on the bioavailability of 
paclitaxel after HIPEC using Taxol and Pac/RAME-β-CD complexes (Chapter 6). 
- Pac/RAME-β-CD inclusion complexes had a better efficiency compared to 
Taxol®. MRI scans indicated that Pac/RAME-β-CD was the only formulation which 
induced at both temperatures a significant decrease in tumour volume at day 9. In 
contrast to Taxol®, one week post treatment the tumour size was still below its initial 
size after Pac/RAME-β-CD treatment. PET images were less conclusive, but also 
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indicated a slightly better result for the Pac/RAME-β-CD formulation. The difference 
in efficiency between Pac/RAME-β-CD and Taxol® is probably linked to the different 
bioavailability of both formulations after HIPEC (Chapter 6).  
 
Extension of the TGD study to a larger number of animals will provide an answer to 
the question if sustained release of paclitaxel is beneficial for its tumoricidal activity. 
Sparreboom and co-workers (Sparreboom et al., 1999; Gelderblom et al., 2001; van Zuylen et 
al., 2001; Gelderblom et al., 2002) claimed that the Cremophor EL® fraction of Taxol® was 
responsible for a sustained release of paclitaxel and that this reduced the side-effects and 
provided long term exposure of the cancer to chemotherapy. However, a short treatment with 
a high paclitaxel dose might be more effective, especially in a PC setting where it is the 
intention to eradicate microscopic free-flowing or residual cancer cells to eliminate the 
recurrence of peritoneal spread.  
 
7.6. CONCLUSION 
 
This preliminary study has shown the feasibility of MRI and PET to evaluate tumour 
growth delay after HIPEC with paclitaxel solutions and allowed to establish the study 
protocol for a future in-depth TGD study after HIPEC in a rat model.  
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 GENERAL CONCLUSION 
 
 
 
The objective of this doctoral research project was to develop an alternative paclitaxel 
formulation suitable for HIPEC. Randomly-methylated-β-cyclodextrins (RAME-β-CD) were 
chosen as alternative excipients and produced a stable water soluble complex with paclitaxel. 
Dissolution of this complex was rapid and rendered a tensioactive- and co-solvent-free 
paclitaxel solution. Due to the addition of HPMC, this solution was sufficiently stable during 
HIPEC conditions. The activity of the cyclodextrin-based formulation was only based on 
paclitaxel, whereas the cytotoxicity of Taxol® was also due to Cremophor EL® (used as 
excipient to solubilise paclitaxel). This phenomenon was responsible for the observed activity 
of Taxol® against multidrug resistant (MDR) cells, while the P-gp efflux pumps in the MDR 
cells resulted in a concentration-independent response towards paclitaxel administered via a 
cyclodextrin inclusion complex. Addition of a novel PDMP analogue restored the 
cytotoxicactivity of the Pac/RAME-β-CD formulation.  
Following HIPEC the Pac/RAME-β-CD formulation had a similar maximum tolerated 
dose as Taxol®. Bioavailability data showed a larger drug penetration through the peritoneum 
in case of the Pac/RAME-β-CD formulation. A preliminary tumour growth delay study 
indicated that MRI and PET could be used to monitor the activity and volume of an 
intraperitoneal tumour in function of time. This research is part of a larger framework in the 
treatment of PC, which will only be successful thanks to further enhancements in surgical 
techniques, better screening and selection of patients, and improvement of the diagnostic tools 
8 
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(i.e. MRI, PET/CT,…). Only the combination of these fields will lead to an improvement of 
the management of patients with PC. 
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 FUTURE PERSPECTIVES 
 
 
 
A number of aspects have been investigated in this research project towards the 
successful treatment of peritoneal carcinomatosis via hyperthermic peritoneal chemotherapy 
using a water soluble paclitaxel formulation. Nevertheless, further research is essential to 
optimize this treatment strategy and to broaden its applications: 
- Evaluation of different paclitaxel formulations using the rat model for HIPEC as well 
as using PET and MRI to monitor tumor growth delay In recent years, several 
strategies have been explored to find safer paclitaxel formulations. Some of these new 
formulations (Abraxane®, Pacliex®, Xyotax®, Genexol PM®) and an O/W emulsion 
(formulated at the Laboratory of Pharmaceutical Technology) will be included in 
future studies to evaluate their toxicity, bioavailability and toxicity against peritoneal 
tumours.  
- Evaluation of drug penetration in tumour tissue using different formulations for 
HIPEC. To strengthen the body of scientific evidence regarding drug distribution in 
the peritoneal tissue, these data can be correlated with histology data to evaluate 
apoptosis. 
- Develop an animal model to evaluate the efficiency of the different paclitaxel 
formulations against peritoneal carcinomatosis following metastasis of an ovarian 
cancer. Extending the application of this HIPEC procedure to different types of 
peritoneal cancer would expand the clinical relevance of this research. 
9 
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-  Elucidating the mechanism of the stabilising effect of HPMC on drug/cyclodextrin 
complexes with NMR spectroscopy. This aspect is currently investigated in 
collaboration with the Laboratory of NMR and Structure analysis of Ghent University.  
SUMMARY________________________________________ 
 
 
 
Patients diagnosed with peritoneal carcinomatosis have a median survival of 5.2 to 
12.6 months. This limited survival has prompted a search for a more effective treatment of 
this type of cancer, which is a common event in the course of gastrointestinal and ovarian 
cancer. Recently, a combination of an aggressive surgical approach and hyperthermic 
intraperitoneal chemotherapy (HIPEC) has generated new hope for these patients, but 
significant research efforts are still needed to optimize this treatment strategy which is the 
focus of this research project.  
The current situation and overall objective of this research project are addressed in 
Chapter 1: development of a novel and safer paclitaxel (Pac) formulation, which is suitable 
for HIPEC, using β-cyclodextrins (β-CD) to solubilise paclitaxel. After an in-vitro 
characterisation of the Pac/β-CD formulation and evaluation of its activity against different 
colon cancer cell lines, its maximum tolerated dose, toxicity, bioavailability and tumour 
growth delay was evaluated in an animal model for HIPEC treatment of peritoneal cancer of 
colorectal origin.  
Chapter 2 gives an overview of the main topics of this research project i.e. paclitaxel, 
peritoneal carcinomatosis and cyclodextrins. After a brief description of the history, chemistry 
and metabolisation and the method of action of paclitaxel, the advantages and disadvantages 
of the different formulation types of paclitaxel are reviewed, including the currently dosage 
forms marketed and the alternative formulation approaches. Treatment of peritoneal 
carcinomatosis, which is currently limited to systemic chemotherapy, via the cytoreductive 
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surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) is highlighted and the 
rationale for HIPEC is also elucidated. In the final part of the introduction, a general overview 
of cyclodextrins and their pharmaceutical applications is presented as in this project the 
formation of inclusion complexes between cyclodextrins and paclitaxel was used as a strategy 
to design a novel water soluble paclitaxel formulation.  
Chapter 3 describes the study that was executed to design a cyclodextrin-based 
paclitaxel formulation. The complexation efficiency of chemically modified β-CDs with 
paclitaxel was investigated, randomly-methylated-β-cyclodextrin (RAME-β-CD) yielded the 
best results. After characterization of the inclusion complex, its aqueous stability (at room 
temperature as well as at normo- (37 °C) and hyperthermic (41 °C) conditions) was evaluated. 
The complex with a molar Pac/RAME-β-CD ratio of 1/40 showed the best stability. Addition 
of 0.1 % (w/v) hydroxypropylmethylcellulose (HPMC) to the aqueous medium significantly 
improved the stability and allowed to reduce the amount of RAME-β-CD to a 1/20 molar 
ratio.  
In Chapter 4, the in vitro efficiency of this new formulation was compared to the 
commercially available Taxol® formulation. Both formulations were equipotent (≤ 10 % 
difference in viability results) against a human (CaCo-2) and a rat (CC531s) cell line. The 
formulation excipients, however, showed significant differences in IC50 values: ≥3.5 mg/ml 
and 0.5 mg/ml for RAME-β-CD and Cremophor EL®, respectively. Hyperthermia (1 hr at 41 
°C) had no effect on the cytotoxic activity of both formulations. This study indicated that it 
was possible to reformulate paclitaxel in a less cytotoxic vehicle while maintaining the 
cytotoxic activity of the formulation.  
Using a different test setup (Chapter 5) (higher cell concentration and reduction of 
time between administration and detection) to evaluate the cytotoxicity of Taxol® and the 
Pac/RAME-β-CD formulation against the CC531s colon cancer cell line significant 
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differences were observed between Taxol® and Pac/RAME-β-CD, especially at higher 
concentrations (5 - 20 µg/ml) as the Cremophor® fraction also contributed to the cytotoxicity 
of Taxol®. In contrast, RAME-β-CD was not cytotoxic and Pac/RAME-β-CD showed a 
similar cytotoxicity as Pac dissolved in dimethyl sulphoxide (DMSO). The reduction in 
viability of CC531s cells was concentration-independent after administration of Pac/RAME-
β-CD due to the presence of P-glycoprotein (P-gp) efflux pumps, making the cells resistant to 
paclitaxel. The Pac/RAME-β-CD formulation was combined with HPPP, a glucosyl ceramide 
synthase (GCS) inhibitor, to improve the sensitivity of P-gp positive cells towards paclitaxel. 
At an added concentration of 5 µM this novel compound worked synergistically and restored 
the activity of Pac/RAME-β-CD against these multidrug resistant (MDR) cells. The action of 
HPPP was based on a non-selective inhibition of GCS.  
Chapter 6 describes the in vivo evaluation of the Pac/RAME-β-CD formulation 
following HIPEC. The maximum tolerated dose (MTD) of RAME-β-CD was 10 mg/ml; after 
addition of hydroxypropylmethycellulose (HPMC) to the medium the MTD increased to 15 
mg/ml. Pac/RAME-β-CD had an MTD of 0.24 mg paclitaxel/ml, which was similar to the 
MTD of Taxol®. The influence of HIPEC using both formulations on blood parameters (red 
blood cell (RBC) and white blood cell (WBC) count, creatinine, alanine aminotransferase 
(ALT) and γ-glutamyltransferase (GGT) levels) was monitored. Pac/RAME-β-CD reduced 
the RBC count to a larger extent than Taxol® and also resulted in an elevated neutrocyte 
count. Both observations can be linked to the inflammatory state of the animal. 
Bioavailability data, however, showed significant differences between both formulations: 
compared to Taxol®, Cmax and AUC of Pac/RAME-β-CD were 50- and 40-fold higher, 
respectively. Hyperthermia (41 °C) during the perfusion did not alter these observations.  
In Chapter 7 a tumour growth delay (TGD) study was performed to evaluate the 
feasibility of positron emission tomography (PET) and magnetic resonance imaging (MRI) 
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for monitoring the growth of an intraperitoneal tumour in function of time. This preliminary 
study using 3 animals per treatment group allowed to establish the study protocol that will be 
followed in a future TGD study using larger number of animals to accurately determine the 
effect of formulation and hyperthermia on the activity of paclitaxel formulations following 
HIPEC. 
  
SAMENVATTING__________________________________ 
 
 
 
Patiënten, bij wie peritoneale carcinomatose wordt vastgesteld, hebben gemiddeld nog 
5.2 à 12.6 maanden te leven. Deze beperkte overleving onderstreept de nood aan een 
zoektocht naar een nieuwe en meer effectieve behandeling van dit type kanker, die zeer 
frequent voorkomt bij patiënten met een gastro-intestinale kanker of een ovariumkanker. 
Recent heeft een combinatie van een agressieve cytoreductieve chirurgie en een hypertherme 
intraperitoneale chemotherapie (HIPEC) nieuwe hoop gegenereerd bij deze patiënten. Er is 
wel nog veel onderzoek nodig om deze therapie te optimaliseren; ook naar de selectie van 
patiënten toe.  
De situering en de doelstelling van deze studie wordt besproken in Hoofdstuk 1. Deze 
bestaat uit de ontwikkeling van een nieuwe en veiligere paclitaxel formulatie op basis van β-
cyclodextrines, die kan toegepast worden in een HIPEC. Na een in vitro karakterisatie van de 
Pac/RAME-β-CD formulatie en een evaluatie op verschillende coloncarcinoom cellijnen, is 
het finale doel om deze formulatie in vivo te onderzoeken op een HIPEC diermodel met 
peritoneale carcinomatose van colorectale oorsprong. Deze in vivo evaluatie bestudeert de 
maximum tolereerbare dosis, toxiciteit, biologische beschikbaarheid en tenslotte de tumor 
groei vertraging.  
Hoofdstuk 2 geeft een overzicht van de 3 belangrijkste onderwerpen van dit 
onderzoeksproject. Dit zijn paclitaxel, peritoneal carcinomatose en cyclodextrines. Na een 
korte beschrijving van de geschiedenis, werking, chemische eigenschappen en metabolisatie 
van paclitaxel, wordt er verder aandacht besteed aan de verschillende formulatietypes van 
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paclitaxel, zowel de huidige als de alternatieve formulaties. Iedere aanpak wordt besproken en 
geëvalueerd aan de hand van zijn voor- en nadelen. In het tweede deel van de introductie 
komen peritoneale carcinomatose en het peritoneum aan bod. De behandeling van dit type 
kanker, die voorlopig meestal beperkt is tot systemische chemotherapie, wordt samen met de 
cytoreductieve chirurgie en HIPEC besproken. De redenering/motivering achter deze nieuwe 
therapie wordt in dit stuk uit de doeken gedaan. In het derde deel van de introductie wordt een 
algemeen overzicht van de cyclodextrines en hun farmaceutisch toepassingen gegeven daar 
deze als alternatieve formulatie excipientia gekozen zijn voor dit onderzoek.  
Hoofdstuk 3 beschrijft de formulatiestudie die uitgevoerd werd om een paclitaxel 
formulatie op basis van cyclodextrines te vinden. Verschillende types van chemisch 
gemodificeerde β-cyclodextrines zijn getest geweest op hun complexatie efficiëntie met 
paclitaxel. Random-gemethyleerde-β-cyclodextrine (RAME-β-CD) leverde de beste 
complexatie resultaten op. Vervolgens, na de karakterisatie van het complex, werden de 
verschillende stabiliteiten (24 u. op kamertemperatuur en 2 u. in normo (37°)- en hypertherme 
(41 °C) omstandigheden), van deze nieuwe formulatie geëvalueerd. Het complex met een 
molaire ratio van 1/40 (Pac/RAME-β-CD) vertoonde de beste stabiliteit. Additie van 0.1 % 
(w/v) hydroxypropylmethylcellulose (HPMC) verhoogde significant de stabiliteit en liet toe 
om de hoeveelheid RAME-β-CD te reduceren tot een molaire ratio van 1/20.  
In Hoofdstuk 4 werd de in vitro efficiëntie van deze nieuwe formulatie vergeleken met 
de huidige formulatie, Taxol®. Beide formulaties waren equipotent (verschil in 
leefbaarheidsresultaten ≤ 10 %) voor twee coloncarcinoom cellijnen (CaCo-2 (humaan) en 
CC531s (rat)). De formulatie excipientia, daarentegen, vertoonden wel een significant verschil 
in cytotoxiciteit met IC50 waarden van ≥ 3.5 mg/ml en ± 0.5 mg/ml voor respectievelijk 
RAME-β-CD en Cremophor EL®. De additie van hyperthermie (1 uur op 41 °C) had geen 
effect op de cytotoxiciteit van beide formulaties. Deze studie gaf aan dat het mogelijk was om 
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paclitaxel te herformuleren in een minder toxisch vehiculum maar met behoud van de 
cytotoxische activiteit.  
Een verderzetting van dit in vitro onderzoek in Hoofdstuk 5 gebeurde aan de hand van 
een gewijzigde test set-up (hogere celconcentratie en een kleiner tijdsinterval tussen 
toediening en detectie). Deze nieuwe test set-up bracht significante verschillen in de 
leefbaarheidsresultaten van beide formulaties aan het licht, vooral in de hogere concentraties 
(5 - 20 µg/ml) daar waar de Cremophor EL® fractie bijdroeg tot de cytotoxiciteit van Taxol®. 
In tegenstelling hiermee was RAME-β-CD veel minder cytotoxisch en was de cytotoxiciteit 
van Pac/RAME-β-CD te vergelijken met Pac opgelost in dimethylsulphoxide (DMSO). Het 
uitblijven van een concentratie dependente daling voor zowel Pac/DMSO als Pac/RAME-β-
CD in levensvatbaarheid werd uiteindelijk verklaard door de aanwezigheid van P-
glycoproteïne (P-gp) efflux pompen, die verantwoordelijk zijn voor de resistentie bij 
kankercellen aan paclitaxel. Omdat de complexen een activiteit vertonen die enkel gebaseerd 
is op paclitaxel, werd deze formulatie gebruikt voor het uittesten van de additie van een 
glucosylceramide synthase (GCS) inhibitor, HPPP. Deze nieuwe molecule, een analoog van 
D-threo-(1R,2R)-1-phenyl-2-decanoylamino-3-morpholino-1-propanol (PDMP), werkte 
synergistisch (na de additie van 5 µM van HPPP) en herstelde de activiteit van Pac/RAME-β-
CD. Dit synergisme was gebaseerd op een niet-selectieve inhibitie van GCS. 
Hoofdstuk 6 beschrijft de in vivo evaluatie van Pac/RAME-β-CD. RAME-β-CD had 
een maximum tolereerbare dosis (MTD) van 10 mg/ml; additie van HPMC aan het 
oplosmedium verhoogde de MTD tot 15 mg/ml. Pac/RAME-β-CD en Taxol® hadden beiden 
een MTD van 0.24 mg paclitaxel/ml. In een volgende stap werd voor beide formulaties de 
invloed van een HIPEC behandeling op de bloedparameters (aantal rode en witte bloedcellen, 
creatinine, alanine aminotransferase (ALT) en γ-glutamyl transferase (GGT) concentratie) van 
de dieren gevolgd. Pac/RAME-β-CD veroorzaakte een iets sterkere daling in aantal rode 
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bloedcellen alsook een verhoogd niveau aan neutrocyten. Biologische beschikbaarheidsdata 
brachten veel grotere en significantere verschillen aan het licht tussen de 2 formulaties. De 
maximum concentratie (Cmax) en oppervlakte onder de curve (AUC) van de Pac/RAME-β-CD 
formulatie nam met een factor 50 en 40, respectievelijk, toe in vergelijking met Taxol®. Het 
verhogen van de temperatuur van het perfusaat van 37 naar 41 °C had geen invloed op de 
bekomen resultaten (voor beide formulaties). 
Tenslotte, in hoofdstuk 7, werd een preliminaire studie uitgevoerd om de 
uitvoerbaarheid van een tumor groei vertraging (TGD) studie met behulp van positron emissie 
tomografie (PET) en magnetische resonantie beeldvorming (MRI) te bestuderen. Aan de hand 
van deze preliminaire studie op 3 dieren per behandelingsgroep liet toe om een studie protocol 
vast te leggen. Deze studie heeft ook aangetoond dat een toename tot 6 dieren per groep 
voldoende moet zijn om statistisch significante conclusies te trekken.  
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